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Abstract 
There is a lack of stability data for in-use parenteral drugs. Manufacturers state a 
shelf-life of 24 hours for infusions based on microbiological contamination. The lack 
of data is of particular significance with protein-based drugs where action is 
determined by their complex structure. A range of techniques are required to assess 
stability, including biological assessment to support other data. There has been an 
increase in published data but often the few studies that address in-use stability are 
incomplete as they do not employ biological assessment to assess potency. 
 
Trastuzumab is an antibody-based drug used to treat cancers where the Epidermal 
Growth Factor Receptor 2 (HER2) is over expressed or over abundant on the cell 
surface. Trastuzumab infusions have been assigned by the manufacturer to be stable 
for 24 hours at temperatures not exceeding 30 oC. If stability is shown beyond this 
point it would enable extended storage and administration. To this end, methods were 
selected and developed with biological assessment central to the approach to assess 
clinically relevant infusion concentrations (0.5 mg/mL and 6.0 mg/mL) and a sub-
clinical infusion concentration (0.1 mg/mL). This may enhance instability and provide 
opportunity to study degradation. 
 
A Cell Counting Kit CCK8 (Sigma Aldrich) was ultimately adopted as a basis for a 
colorimetric assay to assess cell viability. Attenuated Total Reflectance Infra-Red 
Spectroscopy and Size Exclusion Chromatography methods were developed to 
evaluate secondary structure and aggregation respectively. These methods were 
applied to a shelf-life study (43 days) as a collaboration with Quality Control North 
West (NHS) and Clatterbridge Centre for Oncology NHS Foundation Trust, 
Clatterbridge Hospital. There was no evidence of degradation and no loss efficacy for 
clinically relevant infusions (0.5 mg/mL and 6.0 mg/mL) over 43 days, whilst the sub-
clinical infusions (0.1 mg/mL) developed particles after 7 days of storage between 2 
oC and 8 oC. Furthermore, evidence of stability at day 119 gave increased confidence 
for the data from earlier time points. This work assisted in the shelf-life being 
recommended to be extended to 28 days for Trastuzumab stored in polyolefin IV bags 
at concentrations between 0.5 mg/mL and 6.0 mg/mL with 0.9% saline between 2 oC 
and 8 oC. However, infusions with concentrations below 0.5 mg/mL were not 
recommended for storage. 
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CHAPTER 1 
 
1. GENERAL INTRODUCTION 
 
1.1 Rationale for study 
 
Stability studies by the manufacturer provide sufficient information for regulatory 
purposes of the manufactured product but may have limited relevance in practical use. 
Clinical requirements may be very different from those needed for licensing purposes. 
Indeed out of necessity practical use conflicts with the manufacturers specifications 
for use such as for patient-ready preparations (Bardin et al. 2011). Therefore there is a 
need to show drugs continue to be safe and efficacious in clinical practise.  
 
The determination of physicochemical stability for drugs based on relatively simple 
robust chemical compounds is a relatively straightforward and established process 
(Allwood & Wilkinson 2013). However, new drugs are increasingly based on proteins 
which are innately more susceptible to instability (Allwood & Wilkinson 2013). The 
complex variable structure of these molecules determines their clinical effect. 
Therefore changes in structure may decrease efficacy or initiate an inappropriate 
response by the immune system. Consequently the complex structure of these 
molecules requires a multifaceted approach to the assessment of stability. However, 
there has been a lack of consensus in the approach to this class of drugs (Bardin et al. 
2011). This state of affairs can be illustrated by the drug Herceptin® (Roche) which 
has been selected for this study. 
 
Herceptin® (Trastuzumab (international nonproprietary name (INN)) is an antibody-
based drug used to treat cancers where the Epidermal Growth Factor Receptor 2 
(HER2) is over expressed or over abundant on the cell surface. Trastuzumab typifies 
the expense of this class of drug. For example the drug cost alone for treatment of 
early breast cancer by Norfolk and Norwich University Hospital NHS UK Trust in 
2006 equated to £1.9 million for 75 patients (Barrett et al. 2006). If other expenditure 
associated with treatment are added, including pharmacy preparation, the cost 
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becomes £2.3 million (Barrett et al. 2006). Thus it is apparent that any improvements 
in efficiency of drug use would have significant financial benefit. 
 
It can be seen from the example that acceptable stability data beyond this time would 
enable an extension of the assigned shelf-life. This would aid a safer and cost 
effective compounding of the drug in practise. 
 
To measure the stability of protein-based drugs is complex and thus requires a range 
of techniques. Techniques selected must be stability indicating assay methods 
(SIAMs) to determine physicochemical stability and biological activity (Barnes 
2012). Analytical techniques are required to detect sub-visible aggregation as this may 
lead to particles. It has been suggested that particle formation will determine the shelf-
life of the product and therefore should be studied more methodically (Bardin et al. 
2011). The determination of biological activity has been largely ignored. This 
approach has been identified by the NHS UK, in their document A Standard Protocol 
for Deriving and Assessing Stability Part 2 Aseptic Preparations, as an essential part 
in determining the overall stability profile (Barnes 2012) and is therefore a focus in 
this study. 
 
An appropriate study design would entail applying these techniques at suitable time 
points to assess the integrity of the drug. The NHS recommends that a study has a 
minimum of four sampling points in addition to the baseline or time zero data (Barnes 
2012). Stored samples at each time point would be tested together with standards (day 
= 0) prepared on the same day. 
 
 
1.2 General Stability issues and existing guidelines 
 
1.2.1 Hospital Pharmacy Practice and In Use Drug Stability 
 
Hospital pharmacists are required to prepare safe and efficacious doses of parenteral 
drugs. Ready to administer preparations need to be prepared sufficiently in advance to 
meet patient needs and for efficient organisation of hospital resources; including staff 
workload management and reducing wastage of drug (Bardin et al. 2011). This may 
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entail advanced preparations for an individual treatment over several days, weekends 
and holiday periods or for dose banding (Bardin et al. 2011). This situation is 
particularly the case for cytotoxic drug infusions where a short shelf-life, typically 24 
hours, has been arbitrary or provisionally assigned on bacteriological grounds (Bardin 
et al. 2011). Furthermore, there is no documentary indication or data supporting 
evidence that physicochemical stability is compromised after 24 hours. A shelf-life of 
over 28 days would be appropriate for most clinical situations for efficient use of 
infusions (Bardin et al. 2011; Sewell et al. 2003). 
 
Hospitals observe Good Hospital Pharmacy Manufacturing Practise (GHPMP) which 
is complementary to Good Manufacturing Practise (GMP) observed in drug 
production. GHPMP ensures that drugs continue to be safe and efficacious within the 
clinical setting. This means drugs are of the correct dosage and possess appropriate 
microbiological stability. Therefore the remaining uncertainty resides in the 
physicochemical stability of the compounded drug. Physicochemical stability is 
unlikely to have been altered but this needs to be obviously confirmed with 
appropriate studies. This has been the case with conventional cytotoxic cancer drug 
infusions such as paclitaxel, a drug used to treat ovarian and breast cancer (Donyai & 
Sewell 2006). 
 
New cytotoxic cancer drugs are increasingly based on monoclonal antibody structures 
(Weinberg et al. 2005). These are protein-based drugs which are members of the 
biologic family of drugs which include hormone drugs. These newer monoclonal 
antibody-based biologics are more complex than previously approved biologics and 
conventional chemical drugs. Furthermore, due to their complex structure, 
monoclonal antibodies are more susceptible to change. Thus there is a need to assess 
infusions of these drugs under clinically relevant conditions. Conventional drug 
infusion stability has set the precedence for these new studies to increase shelf-life of 
this drug class (Kaiser & Kramer 2011; Paul et al. 2012 (a);  Paul et al. 2012 (b); Paul 
et al. 2013; Pabari et al. 2013). However, the methods employed may differ to reflect 
the distinct instability in this class of drug. In addition, methods will need to be 
selected on an individual drug basis and, due to the targeted mechanisms of these 
therapeutic molecules, should include evaluation of biological activity. Assessment of 
both physicochemical stability and biological activity may offer the best approach for 
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both safe and efficacious monoclonal antibody-based drugs and other biologics in 
practical clinical use. 
 
In-use stability studies of protein-based drugs are becoming even more relevant 
because this class of drug continues to grow in importance. Furthermore, the patents 
of established biologics are currently coming to the end of their lifetime (Cornes 
2012). Indeed, it has been reported Chemistry World (Royal Society of Chemistry)  
that the very first biosimilar monoclonal antibody-based drugs have been approved in 
Europe (Anon 2013). These are two biosimilars, manufactured by Celltrion South 
Korea (Remsima) and Hospira UK (Inflectra), of Johnson and Johnson’s Remicade 
(Infliximab) used to treat autoimmune diseases. It was reported that ‘these drugs are 
the most complex biosimilars yet to be approved in Europe’(Anon 2013). 
Additionally, it was reported that approval in the US has being delayed due to 
inadequate guidance for the approval of biosimilars from the Food and Drugs 
Administration (Anon 2013; Mukhopadhyay 2011).  Biosimilars have to show 
functional similarity to the parent drug (Weise et al. 2012; European Medicines 
Agency 2014). This is a complicated process and comparable for that of approval for 
an innovator drug (Mellstedt et al. 2008). In contrast to drugs based on relatively 
simple chemical structures the biosimilar version will not be identical to its parent 
drug (Weise et al. 2014). Furthermore, the manufacturing processes will be different 
to the original drug (European Medicines Agency 2014). Therefore the drug must be 
considered a new entity (Weise et al. 2012). Hence the term biosimilar is preferred to 
that of generic or biogeneric (European Medicines Agency 2014; Mellstedt et al. 
2008).  
 
Celltrion and Hospira had to complete human trials to ensure that their biosimilar 
Infliximab was safe and efficacious as Remicade (Anon 2013). Additionally, as with 
any biosimilar, a comprehensive stability profile should be established as the ‘generic’ 
version may behave differently to that of the parent drug. This is due to the inherent 
variation of structure of these complex molecules and in part to some biosimilars 
being an improved version of the parent drug. Consequently this has generated an 
additional need for stability data of these new drugs within a clinical context.  
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However, there needs to be guidance to ensure stability studies are fit for purpose so 
as to furnish appropriate data. The limited body of stability data published may only 
partly meet this need (Allwood & Wilkinson 2013). This is often due to unsuitable 
methodology and inadequate evaluation measures or unavailability of data from the 
manufacturer (Barnes 2012). This situation must change so that clinically pertinent 
stability data can be available. This can be achieved by building on the existing 
guidelines to produce a post-licensure approach to practical stability. This has been 
recognised by European hospital pharmacists and various NHS bodies (Allwood & 
Wilkinson 2013; Bardin et al. 2011; Barnes 2012). 
 
 
1.2.2 Guidelines for stability assessment 
 
Information on the stability of the diluted drug is limited as the available 
documentation, including the product insert, is focused on the marketing requirements 
of the drug rather than its deployment within a clinical setting. In these documents it 
is presumed the drug will be used immediately (European Agency for the Evaluation 
of Medicinal Products (EMEA) 2010) and consequently infusions are often 
designated a shelf-life of 24 hours for bacterial contamination reasons (European 
Agency for the Evaluation of Medicinal Products (EMEA) 2010). 
 
The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) publishes the ICH harmonised 
tripartite guidelines (ICH 2012). These documents generally refer to the requirements 
for licensing and offer only a limited guidance for biological products (European 
Medicines Agency 2006). ICH Q1A Stability Testing of New Drug Substance and 
Products is concerned with the information required for applications for new 
molecular entities and drug products (European Medicines Agency 2003). This parent 
guide refers to ICH Q5C Stability Testing of Biotechnological/Biological Products for 
further guidance concerning stability of biological-based products (European 
Medicines Agency 2006). These general guides are concerned with the manufacturing 
process and the drug as marketed. Nevertheless, the ICH Specifications guides such as 
ICH Q6B Specifications Test Procedures and acceptance criteria for 
biotechnological/biological Products, which are a list of tests, references to analytical 
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procedures, and proposed acceptance criteria, does provide a more explicit guidance 
(European Medicines Agency 1999). 
 
However, this official guidance is complementary to in use stability and provides a 
platform to create a more appropriate approach post-licensure. This has been 
recognised by a European consensus conference in 2010 sponsored by the French 
Society of Oncology (SFPO) to propose adapted rules based on the existing guidelines 
to facilitate an approach to anti-cancer drug practical stability (Bardin et al. 2011). 
The consensus conference identified the need to assign acceptance criteria with 
respect to degradation products on an individual case. In particular, there was a focus 
on biologically-based therapies. The acknowledgment of this area of therapeutics is 
important as there is no such framework in place at present for this class of drugs. It 
was identified that validated stability indicating assay methods (SIAMs) should be 
used (Bardin et al. 2011). Moreover consideration should be given that an accepted 
analytical procedure from a pharmacopoeia may not be sufficiently a SIAM. The 
method would have been originally developed for the determination of synthesis or 
process impurities rather than degradation products (DPs). Therefore it is important to 
show that a proposed procedure is able to distinguish DPs being formed in practical 
clinical use (Bardin et al. 2011).  
 
The NHS has also recognised the need for an approach to practical stability especially 
for use of biologically-based drugs. To meet this need the NHS Pharmaceutical 
Quality Assurance Committee, the NHS Pharmaceutical Production Committee and 
the NHS Pharmaceutical Aseptic Services Group have commissioned a protocol for 
deriving and assessing stability of biopharmaceuticals (Barnes 2012). The document 
was created by the NHS Pharmaceutical Research and Development Working Group. 
This has resulted in a standard protocol for aseptic preparation of licensed 
biopharmaceuticals (Barnes 2012). The focus of the protocol is on monoclonal 
antibodies although much will be relevant to other proteins. The document does not 
refer to cell-based therapies, vaccines or blood components and is intended only for 
aseptic manipulation post-licensure use.  
 
In conclusion it is apparent that the need of stability data for infusion-based drugs is 
in the process of being addressed. This is particularly important for innovator and 
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biosimilar monoclonal antibody drugs, where their structure makes them potentially 
more vulnerable to change. This fact combined with their high cost more than justifies 
the need for an extended shelf-life for efficient use and to reduce unnecessary 
wastage.  
  
 
1.3 Trastuzumab Case Study 
 
1.3.1 Trastuzumab and Cancer 
 
Trastuzumab belongs to the relatively new class of antibody-based drugs. Antibody-
based drugs are part of the biologic family of drugs (Goldenberg 1999). Biologics are 
manufactured using recombinant DNA technology and have been engineered to treat 
a variety of diseases including cancer. Trastuzumab is an anti-Human Epidermal 
Growth Factor Receptor 2 (HER2) humanized monoclonal immunoglobulin G1 
(IgG1) antibody (rhuMAb 4D5-8). 
 
Trastuzumab was generated by immunization of Balb/c mice with cells and 
membranes containing the HER2 protein. This was achieved by using an antibody 
producing hybrid cell-line (hybridoma). The resultant murine parent of Trastuzumab 
(muMAb 4D5) was humanized by genetic engineering (Carter et al. 1992). The 
humanized Trastuzumab (rhuMAb 4D5-8) retains only the HER2 recognition site of 
the original murine antibody and is produced in recombinant Chinese Hamster Ovary 
cells by hybridoma technology (European Agency for the Evaluation of Medicinal 
Products (EMEA) 2005b). 
 
Trastuzumab has been designed to bind with high affinity and specificity to the extra-
cellular domain of the HER2 receptor (Human Epidermal Growth Factor Receptor 2) 
(Carter et al. 1992). The binding of Trastuzumab to the HER2 receptor interrupts its 
role with other HER receptors in the intra-cellular signaling process and marks out the 
cell for destruction by antibody dependent cell cytotoxicity (ADCC) (Goldenberg 
1999). Trastuzumab is only indicated for cancers where the HER2 receptor number is 
found to be higher than normal (European Agency for the Evaluation of Medicinal 
Products (EMEA) 2010). The HER2 gene is amplified affording an increase in the 
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number of HER2 molecules at the surface of the cells. Tumours which show this are 
therefore termed as over-expressing HER2 or HER2 positive. Furthermore, the large 
difference between normal levels and over-expressed levels make the receptor a prime 
therapeutic target (Maple et al. 2004). HER2 over-expression is found in 30% of 
breast cancers as determined by Slamon et al. (1987) and cited by Nahta  (2012). 
 
HER2 over-expression is also found in other tumours besides breast such as ovarian, 
non-small-cell lung and bladder cancer (Scholl et al. 2001). Trastuzumab is indicated 
for the treatment of patients with the following cancers: metastatic breast cancer 
(MBC); early breast cancer (EBC) and metastatic gastric cancer (MGC) (European 
Agency for the Evaluation of Medicinal Products (EMEA) 2010).  HER2 positive 
cancer is linked with rapid tumour growth and increased ability of the disease to 
spread. Initially licensed for HER2 positive breast cancer, treatment with Herceptin 
has been extended to other HER2 positive cancers. 
 
 
1.3.1.1 HER2 and Cell Signalling 
 
HER2 is a trans-membrane protein and is a member of the Tyrosine Kinase Receptor 
family (TKR). These receptors are structurally related comprising of an ligand 
binding extra-cellular domain (ECD), a membrane spanning region and an intra-
cellular signalling region reviewed by Hynes and MacDonald (Hynes & MacDonald 
2009). The TKR group is involved in the control of cellular processes such as 
proliferation, differentiation, migration and apoptosis or cell death. Control is 
provided by the transduction of a chemical messenger or peptide ligand and 
interaction between one of the other receptor molecules. The HER2 receptor molecule 
has a key role due to being a preferred partner in this interaction (Gijsen et al. 2010). 
HER2 is always present in the activated conformation whilst the other receptor 
molecules need to be activated by ligand binding to allow interaction with HER2. 
 
The receptor family comprises of HER1 (commonly referred to as EGFR), HER2, 
HER3 and HER4. Ligand activation of the HER1, 3 and 4 causes dimerisation of 
these receptors with HER2. Figure 1 shows the HER2:HER3 dimerisation and the 
resultant phosphorylation of HER3 which initiates intra-cellular signalling. HER2 is 
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responsible for activating the mitogen associated protein kinase (MAPK) signalling 
pathway. A mitogen is a substance which causes nuclear and cell division. Increase in 
this process results in cell proliferation. Each possible combination initiates a different 
signalling pathway through the activated EGFR tyrosine kinase of the receptor. A 
protein kinase is an enzyme which adds a phosphate to a specific amino acid such as 
tyrosine. The activated EGFR tyrosine kinase undergoes autophosphorylation of its C-
terminus tyrosine residues (phosphotyrosine sites) within the cell. This allows 
numerous proteins (protein kinase) to bind to the phosphotyrosine sites on the 
cytoplasmic tail of the receptor, thus enabling the propagation of the intra-cellular 
signalling cascade (Busse et al. 2000). The regulation of the interaction of signalling 
pathways is intimately controlled by the presence and identity of the ligand, the 
heterodimer partners and the availability of proteins that can bind to the 
phosphotyrosine sites  (Kruser & Wheeler 2010). 
 
The HER2:HER3 heterodimer may be the most effective coupling for the generation 
and development of the tumour (Genentech 2015). This dimer activates cell 
proliferation and survival pathways. The HER3 dimer partner activates the 
phosphatidylinositol 3-kinase (PI3K) pathway. The HER3 receptor is the only HER 
member that can directly initiate the PI3K pathway. This kinase phosphorylates a 
membrane phospholipid on the insositol group at carbon 3 of its ring structure. This 
signal pathway leads to an increase in cell survival and resistance to programmed cell 
death (apoptosis). 
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Content removed for copyright reasons. 
Genentech, 2015. HER2 HER3 Dimerization | BioOncology. Available at: 
http://www.biooncology.com/research-education/her/dimer [Accessed January 9, 
2015]. 
 
 
 
 
 
 
 
Figure 1 Schematic representation of the HER2:HER3 heterodimer. HER2 
phosphorylates (transphosphorylation) the tyrosine kinase domain of HER3. This 
results in intra-cellular signalling leading to proliferation, increased cell survival and 
resistance to programmed cell death. Source: adapted from Genentech Reaction HER 
Pathways [online] (Updated 2009) (Genentech 2015).  
 
 
 
 
1.3.1.2  Mechanisms of Trastuzumab Action 
 
The mechanisms of action of Trastuzumab are not completely known. The action of 
Trastuzumab is thought to involve the binding of the Trastuzumab molecule to the 
HER2. This event prevents the dimerisation of HER2 with other HER molecules. The 
intra-cellular signalling is therefore interrupted, inhibiting cellular proliferation 
(Genentech 2015). The bound Trastuzumab may also stop the loss of the extracellular 
domain (ECD) of HER2 (Molina et al. 2001). The loss of the ECD is an activation 
mechanism of HER2 (Zabrecky et al. 1991). However, there is strong evidence that an 
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immune response is a major element of the action of Trastuzumab (Gijsen et al. 2010; 
Colombo et al. 2010). The summary of product characteristics states that 
‘Trastuzumab is a potent mediator of antibody-dependant cell-mediated cytotoxicity 
(ADCC)’(European Agency for the Evaluation of Medicinal Products (EMEA) 2010). 
This is consistent with the mode of action of antibodies in general. In this process the 
surface bound antibody molecules mark these cells out for destruction by the immune 
system (Elgert 2009; Collins et al. 2012). This process is mediated by the Fc region of 
the antibody with Fc receptors of the immune cells (Elgert 2009). In addition, 
Trastuzumab may cause the cell membrane to surround the HER2 receptor taking it 
within the cell (Valabrega et al. 2007). This process is called endocytosis and as a 
result down-regulates the HER2 expression and function. 
 
 
1.3.1.2.1 Inhibition of tumour cell proliferation  
 
Trastuzumab is an anti-HER2 antibody which means it will recognize and then bind 
specifically to the extra-cellular domain of the HER2 protein. This highly specific 
binding interaction is enabled through the fragment antigen binding (FAB) residing 
on the Trastuzumab molecule (Cho et al. 2003). Figure 2 shows the structure of the 
extra-cellular domain (ECD) of HER2 alone and in complex with the Herceptin FAB 
(Cho et al. 2003). Once bound to the HER 2, Trastuzumab prevents the formation of a 
dimer with HER3 (figure 2) or one of the other receptor molecules. Thus 
phosphorylation of the receptor is prevented and signalling cascade halted. This 
results in inhibition of cellular proliferation and cell growth (figure 3).   
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Content removed for copyright reasons. 
Cho, H.-S. Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. 
W., & Leahy, D. J., 2003. Structure of the extracellular region of HER2 alone 
and in complex with the Herceptin Fab PDB 1n8z. Nature, 421(6924), pp.756–60. 
 
 
 
 
 
 
 
Figure 2 X-ray crystal structure of (A) Trastuzumab Fab fragment (Fragment antigen 
binding) bound with (B) extra-cellular domain of HER2 (Cho et al. 2003). PDB 
access code 1n8z; resolution 2.5Å.  
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Content removed for copyright reasons. 
Genentech, 2015. HER2 HER3 Dimerization | BioOncology. Available at: 
http://www.biooncology.com/research-education/her/dimer [Accessed January 9, 
2015]. 
 
 
 
Figure 3 Bound Trastuzumab prevents the formation of the dimer with HER3. 
Phosphorylation of the receptor is prevented and signalling cascade halted. The result 
of this is inhibition of cellular proliferation and cell growth. Source: adapted from 
Genentech Reaction HER Pathways presentation [online] (Updated 2009) (Genentech 
2015). 
 
 
 
 
Recent research has shown that Trastuzumab does not decrease HER2 
phosphorylation (Gijsen et al. 2010). Furthermore, is has been reported that 
Trastuzumab given alone to HER2 positive cells can increase HER2 phosphorylation 
(Scaltriti et al. 2009; Junttila et al. 2009). This may be an important factor in acquired 
immunity when Trastuzumab is given as a monotherapy (Gijsen et al. 2010).  
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1.3.1.2.2 Antibody-dependant cell-mediated cytotoxicity (ADCC) 
 
ADCC is a process where the cell bound antibody marks the cell out for destruction 
by the immune system cells. The immune cells primary involved in this process are 
the natural killer (NK) cells (Strome et al. 2007). These are large granular 
lymphocytes which are white blood cells. The process is reliant on the antibodies Fc 
region γ heavy chain being recognised by the NK cells corresponding Fc gamma 
receptor (FcγR). ADCC is initiated when Fc binds to the lymphocyte FcγR.  
 
 
1.3.1.3  Formulation and practice aspects of drug compounding 
 
Herceptin® in Europe contains Trastuzumab (150 mg) and is formulated with the 
excipients α, α trehalose dehydrate (136.2 mg), L-histidine hydrochloride (3.36 mg), 
L-histidine (2.16 mg), and polysorbate 20 (0.6 mg) as a lyophilised powder. The 
powder is contained in a clear glass Type I borosilicate glass vial (15ml capacity) with 
butyl rubber stopper laminated with fluoro film resin (European Agency for the 
Evaluation of Medicinal Products (EMEA) 2010). 
 
Trastuzumab is reconstituted for administration with 7.2 mL of sterile water for 
injection (SWFI) in the original vial. This gives a single dose solution of Trastuzumab 
at a concentration of approximately 21 mg/mL and a volume of 7.4 mL representing a 
4% volume overage. The overage is provided to ensure that the full dose of 150 mg of 
Trastuzumab can be removed from the vial if necessary. The actual volume of 
solution removed relates to the dosage required which in turn depends on patients 
weight and the regimen followed. Calculations for a weekly and three-weekly 
regimens are adapted from the product information supplied in the summary of 
product characteristics (European Agency for the Evaluation of Medicinal Products 
(EMEA) 2010). The requisite volume is withdrawn from the vial and is always diluted 
for intra-venous infusion by addition to an infusion bag containing 250 ml of 0.9% 
saline solution.  
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1.4 Structure of Trastuzumab 
 
1.4.1 General Protein Structure  
 
The compact structure of a protein is determined by the interaction between the 
constituent amino acid groups and the water present. The hydrophilic polar side 
chains interact with the water solvent through hydrogen bonding. This aids the burial 
of hydrophobic non-polar groups within the protein, a thermodynamically favoured 
process (Stryer 1995). 
 
In contrast, hydrogen bonding between amino acid residues gives rise to the various 
structures found within proteins. The amino acid group can hydrogen bond through 
the main chain CO and NH groups. In addition, some of the side chain groups are able 
to form hydrogen bonds within the core. Therefore structure can be described in terms 
of amino acid sequence and the 3-dimensional structures that emerge. There are four 
levels of increasing complexity that describe protein structure: primary, secondary, 
tertiary and quaternary (Stryer 1995) (figure 4). 
 
 
1.4.1.1 Primary 
 
Primary structure is the sequence of amino acids and encodes the folding instructions 
for the protein. The peptide bond which forms the sequence is rigid. This pre-
determines the number of conformations available on rotation of the adjacent bonds. 
This may result in the polypeptide chain folding into distinct structures (Stryer 1995).  
 
 
1.4.1.2 Secondary (Stryer 1995) 
 
What is called secondary structure? This process is driven by the formation of 
hydrogen bonds between amino acid residues to give a repeating pattern or motif. 
These motifs are termed α-helix and β-sheet (figure 4). These are present within small 
regions of relatively disordered coils. The α-helix is a tightly coiled helix formed by 
the main chain CO and NH forming inter-molecular hydrogen bonds. The β-sheet is 
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formed from a series of β-strands. A β-strand is an almost fully extended polypeptide 
chain. Inter-molecular hydrogen bonds between individual β-strands stabilise the β-
sheet. The polypeptide chain may run in the same or opposite direction. The resulting 
structures are termed parallel and anti-parallel β-sheets respectively.  To conserve the 
compact structure of the protein a β-strand has to reverse its direction. This gives rise 
to the β-turn resulting in a β-sheet running in the opposite direction (figure 4). 
 
 
1.4.1.3 Tertiary 
 
Tertiary structure is the overall folded structure of a polypeptide. This consists of 
various secondary structural elements forming domains, regions of less ordered 
structure and distribution of disulphide bonds (Stryer 1995). 
 
 
1.4.1.4 Quaternary 
 
The final organisational level is the quaternary structure. This refers to the 
relationship of discrete polypeptide sub-units (Stryer 1995).  
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Content removed for copyright reasons. 
Egan, W.M., 2009. Analytical Techniques for Characterizing Follow-on Protein 
Products NDA and BLA Pathways for Biologics. PharmaNet Boston. 
 
Four levels of protein structure also described and illustrated in Stryer, L., 1995. 
Biochemistry. In Biochemistry. New York: W H Freeman, pp. 17–41. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Schematic of the four levels of protein structure. Primary structure: amino 
acid sequence. Secondary structure: folding of sequence into distinct structures such 
as α-helix (red) and β-strand (blue). Tertiary structure: overall folding of the 
polypeptide with interaction of secondary structures. β-strands form sheets with turns 
(A). Quaternary structure: relationship between polypeptide sub-units. Source: 
adapted from the presentation Analysing Techniques For Characterising Follow-on 
Protein Products (Egan 2009). 
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1.4.2  IgG Antibody Structure 
 
1.4.2.1 Antibody fragments 
 
The model of antibody structure and its terminology originates from work in the late 
1950’s and early 1960’s (Elgert 2009). Porter in 1959 selectively fragmented IgG 
using the enzyme papain (figure 5). Three fragments were produced each having a 
mass of 50 kiloDaltons (KD). Two of the fragments were able to bind antigens. These 
were termed fragment antigen binding (Fab). In contrast, the third fragment was 
unable to bind an antigen and crystallised on storage at low temperature. This part 
was the stem portion and called fragment crystalliable (Fc) (Elgert 2009).  
 
Corresponding studies by Alfred Nisonoff cited by Elgert (2009) investigated 
antibody structure with the enzyme pepsin. The site of hydrolysis by pepsin cleaves 
the molecule at a different site to papain (figure 5). In this case one large fragment 
was yielded and many very small fragments. The molecular weight of this large 
fragment was 100 KD, twice that of the Fab. This fragment was termed F(ab’)2.  
 
 
1.4.2.2 Chain Structure Heavy and light chains (Elgert 2009) 
 
In a different approach, Edelman used a reducing agent and solvent treatment to 
determine the polypeptide structure of the IgG. Dithiothreitol was used to reduce the 
disulphide bonds. An addition of iodoacetamide prevented disulphide bonds from 
reforming by alkylating the sulphur. A denaturant was used to disrupt non-covalent 
interactions. After a separation step two polypeptide sub-units of different mass were 
identified in equimolar ratio. The larger sub-unit was named heavy (H) and the 
smaller light (L). The molecular weights of the fragments were 50 KDa and 23 KDa 
respectively. Edelman concluded that the IgG comprised of two heavy and two light 
polypeptides. Additionally, it was concluded that these subunits are linked by a 
disulphide bridge and non-covalent interactions.  
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Figure 5 shows a representation of the IgG molecule indicating the positions of 
enzymatic cleavage by papain and pepsin. Fab and F(ab’)2 fragments are generated by 
pepsin and papain respectively.  
 
 
 
 
Content removed for copyright reasons. 
Elgert, K.D., 2009. Antibody structure and function. In Immunology: 
understanding the immune system. John Wiley and Sons, pp. 58–78. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Schematic representation of the IgG molecule: showing light and heavy 
chains with positions of enzymatic cleavage indicated. Cleavage with papain releases 
the individual Fab units. Cleavage with pepsin generates the F(ab’)2. L = light chain 
and H = heavy chain polypeptides. Based on figure 4-2 Antibody structure and 
function Chapter 4 (Elgert 2009). 
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The polypeptide is further arranged into domains. These are regions which fold into a 
compact structure. The domains are defined by disulphide bridges across one point of 
the chain to another point on the same polypeptide chain. In between the domains the 
peptide chain is less ordered.  
 
 
1.4.2.3  Glycosylation 
 
The carbohydrate content of an antibody is in the form of two nitrogen-linked 
oligosaccharides on the Fc heavy chains. The presence of these oligosaccharides and 
their structure is essential for ADCC. This aspect of action is important in the efficacy 
of therapeutic mAbs (Goswami et al. 2013). The composition of the carbohydrate 
includes variable amounts of fucose, galactose and sialic acid.  
 
 
1.4.3 Trastuzumab structure (Elgert 2009; Magdelaine-Beuzelin et al. 2007) 
 
The quaternary structure of a Trastuzumab IgG molecule consists of two identical 
polypeptide chains of 214 amino acids (light chain), two identical polypeptide chains 
of 446 amino acids (heavy chain) and 2-3% carbohydrate. Each chain is divided into 
domains of variable or constant primary structure. The light chains consist of a 
variable (V) and constant (C) domain. The heavy chains have one V and three C 
domains. The heavy chains pair and the light chains pair with the heavy chains. The 
chains and domains are linked by disulphide bonds and non-covalent interactions 
forming the characteristic Y shape. The N-terminal (amino terminal) of the 
polypeptide chains are on the arm tips whilst the C-terminal (carboxylic acid terminal) 
is at the opposite end. The arm tips of the Y are highly variable in amino acid 
sequence and vary between different antibodies.  
 
The variable regions are organised into three distinct hypervariable regions (HVRs). 
These are called complementarity determinant regions (CDRs) and are termed CDR1, 
CDR2 and CDR3. Between each HVR the amino acid sequences are of limited 
variability and define each separate CDR. The variable regions of the light and heavy 
chains fold to form a cleft. The CDRs are exposed on the cleft surface and are 
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important in determining its shape. The specific shape is essential in binding an 
antigenic determinant or site on an antigen. The distinctive shape of the cleft is 
responsible for the high specificity of Trastuzumab in binding to the HER2 protein 
(Elgert 2009).  
 
Trastuzumab is the result of the humanisation of its parental murine monoclonal 
antibody (mumAb 4D5) during the production process. This means only the CDRs are 
of mouse origin in Trastuzumab. The humanisation process resulted in a 3-fold 
increase in binding affinity (European Agency for the Evaluation of Medicinal 
Products (EMEA) 2005b). The primary structure determines the proteins 3-
dimensional structure. Therefore changes in amino acid sequence of the variable 
regions may modify the cleft shape, change specificity and binding affinity. The hinge 
region connects the arms of the molecule to the stem. This allows greater flexibility 
facilitating simultaneous binding of different sites (Magdelaine-Beuzelin et al. 2007).  
 
The stem portion of the heavy chains has a constant amino acid sequence. The heavy 
chains are identical within an antibody class or isotype. In the IgG1 isotype, which 
Trastuzumab belongs, they are called γ chains and determine its biological action or 
effector functions. The IgG1 stem region mediates the immune systems response. 
This arises when the antibody covers the cell, marking it for destruction, and the Fc 
binds to the immune cells. This process recruits various types of white blood cells, 
especially the natural killer (NK) cells, to kill the antibody-targeted cells. The process 
is called antibody dependent cell cytotoxicity (ADCC). Furthermore, the 
humanisation of  mumAb 4D5 maximise the immune response of Trastuzumab by 
incorporating the human IgG1 heavy chains (γ1) for the Fc (European Agency for the 
Evaluation of Medicinal Products (EMEA) 2005b). This ensures recognition and 
attack by the human immune system for which the Fc has a critical role (Liu et al. 
2008).  
 
Glycosylation and its structure are essential for this function. This aspect of action is 
important in the efficacy of therapeutic mAbs. The composition of the carbohydrate 
includes variable amounts of fucose, galactose and sialic acid. The carbohydrate 
content has been modified in therapeutic mAbs to improve affinity with the immune 
system (Carter 2006). This has enhanced anti-tumour activity (Liu et al. 2008). In 
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particular, the fucose content has an effect on ADDC effectiveness. The absence of 
fucose in the oligosaccharide has been shown to increase ADDC (Jefferis 2009). This 
was shown with Trastuzumab when produced in a mutant CHO cell-line (LEC 13). 
However, the cell-line was not suitable for production of the drug (Jefferis 2009). 
 
 
1.5 Protein stability  
 
Conventional drugs are based on relatively simple robust chemical entities. Their 
structure enables them to withstand processes such as tableting, encapsulation and 
packaging (Wang 1999). In contrast protein-based drugs have physical and chemical 
properties that make them more prone to structural change (European Medicines 
Agency 2006). These differences can be attributed to the types of chemical bonding 
which define the active structure (European Medicines Agency 2006). The 
biologically active protein structure, referred to as the native state, is the result of the 
highly specific organisation of the primary, secondary and tertiary structures (Stryer 
1995).  
 
Stability is classed and described in terms of physical or chemical processes. This 
classification is useful in providing a mechanistic understanding of the principal 
processes involved. In actuality, physical and chemical instabilities are linked 
(Manning et al. 2010). Changes in conformation may expose a chemically reactive 
site or conversely a chemical change at the primary level will influence structural 
changes at higher levels (Manning et al 2010.). This may lead to loss of efficacy or 
increased immunogenicity. A more complete understanding of these processes will 
aid the production of more stable formulations, effective monitoring and the 
assessment of protein drugs in-use. 
 
The understanding of protein-based drug stability is becoming increasingly important 
as new biologics are developed. More specifically, as patents are beginning to expire 
on current biologics, the field of biosimilar or biogeneric protein-based drugs is likely 
to expand. Manning et al (1989) wrote a review on protein stability which has been 
frequently cited (Manning et al. 1989). The review has been recently updated 
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(Manning et al. 2010) which reflects how knowledge has progressed with a 
corresponding increase in dominance of protein-based drugs. 
 
 
1.5.1 Physical Stability 
 
Physical stability refers to the ability of the protein to retain its 3-dimensional 
biologically active or native structure. The protein superstructure is only slightly 
stable and is in constant flux of different folded states. Unfolding of the protein 
molecule may make the protein drug product susceptible to degradation through the 
mechanisms of denaturation, adsorption, aggregation and precipitation (Manning et al. 
2010).  
 
 
1.5.1.1 Adsorption 
 
Surface induced instability of a protein molecule begins with adsorption of a native or 
partially unfolded  protein molecule (Manning et al. 2010). The adsorption of the 
IgG1 molecule is a particular favoured process due to its structural complexity and 
flexibility irrespective of surface charge or surface energy. Surface adsorption may 
result in a lowering of the bulk Trastuzumab concentration and thus reducing the 
administered effective dose or efficacy of the preparation. Additionally, adsorption 
may induce changes in conformation leading to denaturation and loss of efficacy of 
the Trastuzumab molecule. 
 
 
1.5.1.2 Conformational stability 
 
The native folded conformation is achieved by the combination of attractive forces 
and hydrophobic interactions. Attractive forces involved are electrostatic forces, Van 
der Waals forces and hydrogen bonds. The native folded state of the protein is not 
static and involves a distribution of many different states of folding or partial 
unfolding. The dynamic native structure is a balance between the stabilising 
interactions and tendency for entropy of the conformation to increase. Entropy is the 
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drive for the unfolding of the protein. The large and complex structure of the protein 
gives scope for disorder of the system to increase. This is manifest in the range of 
different folded states centered on the native conformation. 
 
The thermodynamic stability of the native structure of a protein is minimal (~21-84 kJ 
mol-1) under physiological conditions (Chi et al. 2003). To put this into context the 
staggered and eclipsed conformations of a hydrocarbon only differ by a 12 kJ mol-1. 
The rotation about the carbon-carbon single bond readily takes place at 25oC with 
frequency of approximately 1012s-1. In contrast, the thermodynamic stability of 
covalent and ionic bonds is considerably greater (~627kJ mol-1) (Chi et al. 2003). For 
example the bond energy of a C-C single bond energy in ethane is 347 kJ mol-1 and 
that of the C=C double bond in ethene is 598 kJ mol-1. 
 
 
1.5.1.3 Aggregation 
 
1.5.1.3.1 Low Order Aggregation (Dimers, trimers and other low order 
oligomers) 
 
The native monomer in solution has a tendency to form reversible native 
conformation aggregates which are the result of association and disassociation of the 
protein molecules (Philo & Arakawa 2009). The constituent monomers of these 
aggregates retain their original structure and biological activity. The reversible native 
conformation dimers are innate within the formulation and are present in protein 
solutions from the time of production to administration. The antibody molecule is 
inherently self-complementary and will have a tendency to naturally associate 
forming reversible oligomeric species such as dimers and trimers. These oligomers 
may become irreversible (non-native) over time by the formation of covalent bonds 
between the monomeric units. Further aggregate growth of these small oligomers by 
the addition of monomers is thermodynamically disfavored due to an energy barrier to 
assemble or nucleate (Chi et al. 2003). However, overtime may eventually lead to 
particulate formation and ultimately precipitation. 
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1.5.1.4 Denaturation 
 
1.5.1.4.1 High Order Aggregation (Precipitation) 
 
Non-native or irreversible aggregation is a process whereby the protein molecules 
associate. This process occurs via a partly unfolded intermediate which reveals the 
hydrophobic core. The core is normally bound and not accessible to the water solvent. 
Binding of this internal structure to another molecular core can lead to irreversible 
collapse of the protein structure and aggregation.  
 
Irreversible aggregation is a common way physical instability is demonstrated within 
a formulation (Chi et al. 2003). The aggregation process results in reduced activity 
and more significantly an increase in immunogenicity of the drug system. Aggregates 
can form in both liquid and solid forms under a variety of conditions experienced 
during processing, storage and use (Arakawa et al. 2006). Conditions which may 
promote aggregation include concentration, pH, temperature, lyophilisation, freeze-
thaw processing and mechanical stress. 
 
Mechanical stress is of particular interest as it is encountered at each step of 
production and use of the protein. Liquid formulations are stirred and pumped during 
the manufacturing process. In use, the drug will be administered by injection or 
infusion. Mechanical stress includes sheer forces induced by mixing (stirring and 
shaking) and injection. The large velocities of these processes have been described as 
capable of denaturing the structure of the protein leading to aggregation and cleavage 
of the amide backbone (Jaspe & Hagen 2006).  
 
Studies using Horse cytochrome c exposed to laminar flow high shear forces showed 
no change in structure (Jaspe & Hagen 2006). Horse cytochrome c is a small and 
compact globular protein of 104 amino acids and therefore may be more resistant to 
sheer forces. Conversely, the antibody molecule may be more susceptible to shear 
forces. This view is consistent with the fact that the antibody molecule is considerably 
larger, more complex and flexible than simpler globular proteins. A study of the 
rheological and syringeability properties of polyclonal antibodies were not affected by 
irreversible aggregation (Burckbuchler et al. 2010). 
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In considering these types of studies it is important to be sure other factors are not 
contributing to the observed effect. Shear forces are often applied over an extended 
period of time. This may give time for surface adsorption denaturation to contribute or 
affect the amount and type of aggregates (Jaspe & Hagen 2006; Kiese & 
Papppenberger 2008). In contrast to simple shear force models, shaking and stirring of 
IgG1 may generate aggregates (Kiese & Papppenberger 2008).  
 
Precipitation is the macroscopic result of molecular association whereby the aggregate 
size exceeds the limit for solubility. This is particularly important issue for long term 
storage. Precipitation may also occur by the concentration exceeding the solubility 
product.  
 
 
1.5.2 Chemical stability 
 
In contrast to physical instability, chemical instability within a protein molecule can 
be manifest in bond formation or disassociation generating a new chemical entity. 
Degradation may involve the following discrete chemical reactions; deamination 
(scheme 1), aspartic acid isomerisation (scheme 2), proteolysis (scheme 3), oxidation 
(scheme 4), disulphide exchange (scheme 5), Maillard reaction and para-glutamine 
residue (p-Glu) formation (scheme 6).  
 
 
1.5.2.1 Chemical Degradation 
 
1.5.2.1.1 Deamination to succinimide 
 
Deamination is a common degradation path for peptides and proteins (Manning et al. 
2010). Trastuzumab formula at pH 6 the mechanism will involve an acid catalyzed 
intra-molecular cyclization of the Asparagine (Asn or N) or glutamine (Gln or Q) 
residues with the back-bone amide nitrogen. The reaction of Asn residue is 
considerably faster than that for the Gln side chain amide and is probably due to the 
conformational stability of the succinimide 5-membered heterocyclic ring at pH6 
(scheme 1). 
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The scheme shows the reaction of the Asparaginyl forming a succinimide with 
concomitant irreversible loss of ammonia from the amide. The steps involved in the 
intra-molecular cyclization are described below. 
 
Step 1: Base abstraction of hydrogen from the back bone amide N generates a 
nitrogen nucleophile. This is stabilised by delocalisation of negative charge in a π-
allyl system over the back bone amide bond. Stabilisation of the anion intermediate 
can be further enhanced by conformation (Robinson & Robinson 2004) and effects 
such as hydrogen bonding.   
 
Step 2: Nucleophillic attack on the carbon of the side chain amide to give a cyclic 
intermediate. 
 
Step 3: Protonation of the amine group (regeneration of base) and its loss as ammonia 
to give the succinimide. 
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Robinson, N.E. & Robinson, A.B., 2004. Molecular Clocks – Deamidation of 
asparaginyl and glutaminyl residues in peptides and proteins, Cave Junction 
OR: Althouse Press. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 The succinimide reaction mechanism: showing the intra-molecular 
cyclization of the Asparaginyl residue with the amide back bone (Asparaginyl residue 
in green) (Robinson & Robinson 2004). 
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1.5.2.1.2 Hydrolysis of succinimide and isomerism of aspartic acid product 
 
The L-succinimide an identifiable degradation product in its own right, may be 
cleaved by hydrolysis at either side of the N atom of the heterocyclic moiety giving a 
mixture of aspartic and isoaspartic acid (scheme 2). Inter-conversion or isomerism is 
then made possible by imide ring intermediate shown in scheme 1 and 2. This process 
of isomerism has been reported to take place often in the recent literature for 
monoclonal antibodies (Manning 2010). 
 
 
 
 
Scheme 2 The scheme shows isomerism of aspartic acid side chain by the hydrolytic 
cleavage of succinimide to give aspartic acid and isoaspartic acid. Cleavage can take 
place either side of the ring nitrogen atom at position A or B. 
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1.5.2.1.3 Proteolysis 
 
Aspartyl (Asp or D) residues may induce hydrolysis of the peptide bond of the 
backbone at either N and C terminals or both (scheme 3). Peptide cleavage may lead 
to inactivation of protein (Manning et al. 1989). The Asp-Pro Proline (Pro or P) 
sequence is particularly prone to hydrolysis in the presence of ammonia. The 
mechanism involves an intra-molecular cyclization and as the deamination process 
discussed above is pH dependent. 
 
Degradation by hydrolysis not involving Asp occurs in the hinge region. This process 
is different to the enzymatic cleavage reactions usually used to prepare fragments of 
antibodies for study and characterization. Cleavage in the case of hydrolysis involves 
a residue sequence range within the hinge location and has been associated with the 
inherent flexibility of the protein in this location and instability of the fragment 
antigen binding Fab unit itself (Manning 2010). 
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Manning, M.C., Patel, K. & Borchardt, R.T., 1989. Stability of Protein 
Pharmaceuticals. Pharmaceutical research, 6 (11), p.903 818. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3 Aspartyl (Asp or D) residues may induce hydrolysis of the peptide bond of 
the backbone at either the N or C terminals. Aspartyl residues may form 6 and 5-
membered ring intermediates with N-peptide and C-peptide bond fission of the 
respective intermediates. Source: Stability of protein pharmaceuticals (Manning et al. 
1989). 
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1.5.2.1.4 Disulphide exchange 
 
Trastuzumab as with many protein molecules contain important sulphur bonds. These 
can be disrupted or scrambled leading to change in structure. Sulphur bonds are 
important in defining and stabilizing the globular structure of the protein and hence its 
ability to recognize and bind with other proteins. Therefore alteration or mismatching 
of sulphur bonds will lead to changes in 3-dimensional structure and loss of activity. 
The mechanism of disulphide exchange in neutral and alkaline media is shown in 
scheme 4.  
 
 
 
Contents remove for copyright reasons. 
Manning, M.C., Patel, K. & Borchardt, R.T., 1989. Stability of Protein 
Pharmaceuticals. Pharmaceutical research, 6(11), p.903 818. 
 
 
 
Scheme 4 The mechanism of disulphide exchange under neutral and alkaline 
conditions. Source: Stability of protein pharmaceuticals (Manning et al. 1989). 
 
 
 
 
During SDS-PAGE under reducing conditions the disulphide bonds of an antibody are 
broken apart to furnish the individual light and heavy chains of the protein. This 
contrasts with enzymatic treatment where the Fab and Fc fragments of an antibody 
molecule are generated instead. 
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1.5.2.1.5 Oxidation 
 
Another major protein degradation route is that of oxidation. A solution of protein 
drug will have a head space which increases after initial use and therefore on storage 
presents an increased opportunity for aerial oxidation. The residues that are most 
susceptible to oxidation are the sulphur containing Cysteine (Cys) and Methionine 
(Met) side chains. The sulphur containing side chains are hydrophobic and therefore 
buried within the core of the globular protein. Rate of reaction is dependent on 
oxygen solubility and diffusion.  Cys will form disulphides and radical species and in 
contrast Met will give sulphoxides. Oxidation of Met residues has been shown to 
occur in the constant region of monoclonal antibodies and may impact on the 
functionality of therapeutic antibodies (Manning 2010). The mechanism of Met with 
different oxidation agents is shown in scheme 5. 
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Scheme 5 Met oxidation mechanism under (a) mild condition: hydrogen peroxide and 
(B) strong condition: performic acid to give sulfoxide and sulfone respectively. 
Source: Stability of protein pharmaceuticals (Manning et al. 1989). 
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1.5.2.1.6 Maillard Reaction 
 
The Maillard reaction or non-enzymatic browning is the result of a reducing sugar 
reacting with the amino group on a lysine side chain. For this reason formulation of 
excipients avoids reducing sugars. However, sucrose present in excipient formulations 
may be hydrolysed to glucose and fructose.  Non-enzymatic browning is a result of 
the formation of a carbohydrate–protein adduct. The reaction may occur at all 
temperatures. The reaction mechanism is a complex series of reactions which involve 
the formation of a Schiff’s base as an intermediate (Kumar & Banker 1998).  
 
 
1.5.2.1.7 Para-glutamate formation 
 
Glutamate (Glu, E) can react to give para-glutamate (pGlu). This is a five membered 
N-terminal cyclised product. It is frequently seen in monoclonal antibodies due to the 
prevalence of Glu in the N-terminal light chain. In particular, it is seen during long 
term storage. The reaction involves a nucleophilic attack by the amine on the carbonyl 
of the N-terminal Glu side chain with concomitant loss of water (scheme 6) (Manning 
et al. 2010). 
 
 
 
 
 
Scheme 6 The para-glutamate (pGlu) formation. This stable product is formed by a 
nucleophilic attack by the amine on the carbonyl of the N-terminal Glu side chain of 
the light chain. 
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1.6 Generic Techniques for determining Stability  
 
1.6.1 Physical techniques 
 
Physicochemical studies of proteins using a selection of techniques enable the 
complexity of physical and chemical instability to be investigated. Techniques should 
be stability-indicating and complementary. The measurement of different parameters 
and chemical markers of instability can provide a more satisfactory stability profile. 
There are numerous techniques available for the study of protein stability. Many 
approaches initially characterise the protein in terms of its chromatographic and 
electrophoretic behaviour (Arakawa et al. 2001). Other techniques which may be 
useful for a specific protein become evident during initial characterisation (Arakawa 
et al. 2001).  A selection of techniques which are often applied to protein 
characterisation are reviewed. 
 
 
1.6.1.1 Size Exclusion Liquid Chromatography 
 
SE-LC is generally accepted as a very suitable method for determining protein size. It 
is used for both detection and quantitative determination of aggregates and fragments 
in biologic pharmaceuticals. Furthermore, it is virtually always a regulatory requisite 
for drug approval (Arakawa et al. 2001). 
 
Separation is achieved by the differential residing time of proteins within the silica-
based porous column packing. For example a monoclonal antibody (mAb) sample 
containing monomer, aggregates and fragments will elute in the order of size of 
species. Aggregates will elute first followed by the monomer or parent mAb and lastly 
fragments.  
 
Protein adsorption has been a problem as the technique requires separation to be 
based only on size. This has been largely addressed by manufacturer column design 
and method development (Bond et al. 2010). 
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1.6.1.2 Ion Exchange chromatography (IEX) 
 
This technique performs separation using a proteins net charge. The process is 
advantageously carried out under non-denaturing conditions. Electrostatic interactions 
mediated by the amino acid side chains and the charged surface of the ion exchange 
resin. The net charge of the protein has been used to explain retention. However, 
separation can be achieved when the net charge is zero. It is one of the commonly 
used methods for the detection of charge variants (Weinberg et al. 2005). Therefore 
this would be an appropriate way of following changes within a protein under non-
denaturing conditions. 
 
 
1.6.1.3 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
 
SDS-PAGE is used to separate proteins (Lord 2003). This involves first denaturing 
the protein in the sample with the detergent SDS and heated. This produces unfolded 
polypeptide strands which migrate under the influence of an electric field through a 
polyacrylamide gel. Due to the loss of tertiary structure the polypeptides are impeded 
through the gel network to the same degree. Therefore separation is achieved solely 
on a mass basis (Grabski & Burgess 2001). 
 
SDS-PAGE may detect fragments and aggregates (Arakawa et al. 2006). Fragments 
will travel further while aggregates will be impeded by their size. A variation of this 
technique is to perform it under reducing conditions. This entails adding a reducing 
agent at the denaturing step with the SDS detergent. Any disulphide bonds present 
will be will be broken producing single polypeptide chains. An antibody will be 
rendered into its Fab and Fc component polypeptides. A consequence of this process 
is that any disulphide bonded aggregates present will be separated under reducing 
conditions. 
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1.6.1.4 Attenuated Total Reflectance Fourier Transform Infra-Red Spectroscopy 
(ATR-FTIR) 
 
The infra-red (IR) spectroscopy depends on bonds in the protein having a dipole, and 
therefore able to absorb in the infra-red region (Barth & Zscherp 2002). The result is a 
vibrational spectrum. The amide I normal vibrational mode or region of the IR 
spectrum is usually used to study protein structure. This region originates mainly from 
the carbonyl stretching vibration and depends on the conformation of the polypeptide 
backbone. Therefore this can give information on secondary structure within the 
protein.  
 
However, when operating in normal transmission mode the IR travels through the 
protein solution. Water is a good absorber of IR and obscures protein absorption in 
the amide region even with a cell of small path length. Increasing concentration of the 
protein does not offset this because dispersive effects are introduced. This problem 
has been overcome by using attenuated total reflectance FTIR. The IR beam is guided 
through an IR transparent germanium crystal by total internal reflection and due to 
quantum effects the electromagnetic field penetrates into the crystal to the depth of 
about one micron. This vanishing or evanescent wave interacts with the surface 
protein which then contributes to the absorption without involvement from the bulk 
water.  
 
One approach is to quantitatively analyse the amide I region of the spectrum (figure 
6). The amide I region can be analysed in terms of the percentage component of 
secondary structure using band fitting.  If there are significant structural changes in 
the molecule these will be reflected in changes in secondary structural motifs. 
Monoclonal antibodies such as Trastuzumab have a mainly ordered beta sheet 
structure, some alpha-helix, with the remaining being random coil. Therefore an 
increase in random coil is expected to be seen at the expense of the more ordered beta 
sheet during degradation. This can be an effective tool to assess these changes on a 
molecular level.  
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Figure 6 Amide regions of the FTIR spectrum showing position of the amide I which 
originates form the carbonyl bond vibrations of the amide backbone. Source: IMB 
Jena Image Library (IMB 2014) 
 
 
 
An alternative approach (Barth & Zscherp 2002) is to look for differences in the 
whole spectrum and not specific signals from chromophores or infra-red active 
groups. The principle of analysis involves correlating the whole spectral signature (a 
multivariate response) with biological activity.  
 
 
1.6.1.5 Dynamic Light Scattering 
 
An important area of studying aggregation is the characterisation of particles which 
are not detectable by SEC-LC or visual examination. This can be effectively achieved 
by Dynamic Light Scattering (DLS) which determines particle size and distribution. 
This is achieved by measuring fluctuations in the intensity of scattered light 
originating from Brownian motion on laser illumination of the test solution. The 
fluctuations in scattering can be correlated to the diffusion coefficient. Therefore the 
hydrodynamic radius of the particle can be determined through the Stokes-Einstein 
equation:  
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D = k T / 6 π η RH Equation 1 
 
 
Solve for the hydrodynamic radius: 
 
 
RH = k T / 6 π η D Equation 2 
 
 
Where RH = radius, k = Boltzmann constant, T = absolute temperature, η = solvent 
viscosity and D = diffusion coefficient. 
 
 
Additionally, the experiment is not intrusive and therefore is a suitable method for 
monitoring the same sample over a period of time. Trace amounts of aggregates can 
be detected due to the scattering intensity being proportional to the square of the 
molecular weight of the protein. DLS has been shown to be a useful technique for 
monoclonal antibodies allowing their study under native conditions. In particular the 
study of the monomer-dimer equilibria is of interest (Nobbmann et al. 2007). 
 
 
1.6.1.6 Electrospray Mass Spectroscopy 
 
Electrospray Mass Spectroscopy can be used to probe changes in primary structure 
during degradation such as amino acid sequence and chemical modifications of the 
protein (Beck et al. 2005; Manning et al. 2010).  The Mass spectrometer consists of 
three basic units; ionizer, analyser and detector (Harris 2003). The ionization step 
utilized in this particular mass spectroscopy technique is electrospray. It is well suited 
to fragile protein molecules which have a tendency to fragment. The sample must first 
be dissolved in a polar volatile solvent and nebulized at high voltage. The resultant 
charged droplets decrease in size as the volatile solvent evaporates eventually 
releasing charged sample ions. The ionized sample enters the analyser which is under 
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high vacuum to allow the ions to travel unimpeded. The ions are separated according 
to their mass/charge ratios under the influence of a quadrupole magnetic field. The 
signals generated from the detector are stored and displayed as mass/charge ratios and 
their relative abundance as a spectrum. 
 
 
1.6.2 Biological Techniques 
 
There are three types of biological assays biochemical, cell-based and animal-based. 
An animal-based assay is unlikely to be used (Barnes 2012). Therefore the cell-based 
assay is the most direct way of evaluating how much drug is still intact and functional. 
This approach has been largely ignored and physicochemical methodology has been 
the sole strategy to assess stability of diluted protein-based drug infusions such as the 
Kaiser and Kramer (2011).  
 
A cellular approach which measures the biological response to the drug or efficacy is 
preferable to biochemical methods which only assess the binding of the antibody such 
as an enzyme-linked immunosorbent assay (ELISA). However, the biological 
response selected must reflect the clinical mechanism of drug action using an 
appropriate cell-line which expresses the receptor target for the disease, in the case of 
Trastuzumab a cell-line which overexpresses the HER2. 
 
 
1.6.2.1 ELISA 
 
The use of the ELISA provides information on the success of the binding interaction 
but does not report on biological effects (Crowther 2000; Barnes 2012). In the ELISA 
method for Trastuzumab Maple et al. (2004) used monoclonal antibodies which are 
Fab specific to the cytoplasmic domain of the HER2 receptor. These are absorbed 
onto the bottom of the micro-plate well surface. A full complement of HER2 protein 
is then added which is captured by the antibody surface. This system ensures the 
correct orientation of the protein enabling the extracellular domain (ECD) to be 
presented with a binding opportunity to the Trastuzumab FAB region during the 
assay. Trastuzumab that successfully binds to the ECD of HER2 will be detected by 
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an antihuman IgG-horse radish peroxidise (HRP) conjugate reporter and a (3, 3, 5’, 
5’)-tetramethylbenzidine (TMB) substrate which turns blue on reaction with 
peroxidase (figure 6). Absorbance can be measured at 652 nm and is proportional to 
the amount of Trastuzumab which is bound to the HER2. 
 
 
 
 
 
 
Contents removed for copyright reasons. 
Maple, L., Lathrop, R., Bozich, S., Harman, W., Tacey, R., Kelley, M., &, 2004. 
Development and validation of ELISA for herceptin detection in human serum. 
Journal of immunological methods, 295(1-2), pp.169–82. 
 
 
 
 
 
Figure 7 Schematic of the Trastuzumab-ELISA. 1. Mouse anti-C terminal part of 
HER2 antibody. 2. Trastuzumab. 3. Antihuman IgG conjugated with horse radish 
peroxidase (HRP) reporter. 4. TMB substrate turnover (Maple et al. 2004). 
 
Key steps in a general ELISA for Trastuzumab (Maple et al. 2004): 
1. Micro-plate coated with mouse anti-C terminal part of HER2 antibodies. 
2. HER2 receptor captured in cell lysate ensuring correct orientation with 
Trastuzumab binding to HER2 N-terminal part representing extra cellular 
domain (ECD). 
3. Antihuman IgG conjugated with horse radish peroxidase (HRP) reporter. 
4. TMB substrate turnover signals Trastuzumab binding. 
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1.6.2.2 Cellular Assay 
 
Biological activity can be determined by measuring viability or proliferation of the 
BT474 cells. These two parameters are subtlety but importantly different.  Cellular 
proliferation relates to the number of dividing cells and therefore the ability to form 
colonies whilst viability relates to the number of living cells within a sample.  Cellular 
proliferation may be determined  by performing a colony formation assay which tests 
each cell’s ability (Franken et al. 2006) to produce progeny and therefore to form 
colonies. The colonies are fixed and stained to aid examination. The size and number 
of colonies will be related to the inhibitory effect of a chemical or physical agent and 
therefore a gauge of reproductive capability. This approach is standard for biological 
assessment of cytotoxic agents such as chemical compounds. The colony formation 
assay is not biased towards any specific mechanism of death if the cytotoxic agent 
affects the cells’ ability to reproduce (Franken et al. 2006).  
 
Cell viability can be determined using a colorimetric reporter to indicate differences 
in absorbance and hence cell number. Colorimetric cell viability methods include the 
water soluble tetrazolium (WST) analogues, MTT, MTS and XTT (Serra et al. 2008; 
Budman et al. 2007; Nahta et al. 2004; Ozbay et al. 2010). These methods work on 
the principle of the conversion of a water soluble tetrazolium (WST) analogue to a 
formazan dye by living or viable cells. For example the WST-8 assay works by the 
conversion of a yellow tetrazolium salt, using an electron coupling agent, to form a 
soluble orange formazan dye by metabolically active cells and therefore only occurs 
in viable cells (figure 8). The formazan dye concentration is determined by 
absorbance between 450 nm and 500 nm using a spectrophotometer.  
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Contents removed for copyright reasons. 
Held, P., 2009. An Absorbance-based Cytotoxicity Assay using High 
Absorptivity, Water-Soluble Tetrazolium Salts. Available at: 
http://www.biotek.com/assets/tech_resources/An_Absorbance-based-
Cytotoxicity_App Note.pdf [Accessed August 14, 2014]. 
 
 
 
 
 
 
 
 
 
Figure 8 Mechanism of a WST-8 formazan dye assay. Schematic showing conversion 
of a water soluble tetrazolium (WST) analogue to a formazan dye by living or viable 
cells. Source : BioTek instruments (Held 2009). 
 
 
 
 
Cell viability can also be determined by colorimetric absorbance by stain release of 
cells. This method is appropriate because the colonies are fixed and stained for a 
colony formation assay. The stain can be easily released and re-stained if required. 
For a crystal violet stain absorbance is measured at 570 nm (Eichhorn et al. 2008).  
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1.7 Method Rationale 
 
1.7.1 Selection of Physical Techniques 
 
A common route to drug degradation when stored is aggregation (Philo & Arakawa 
2009). Aggregation is a process whereby the protein molecule self-associate 
reversibly or irreversibly and may lead to particulates or precipitation of the protein 
within the formulation (Philo & Arakawa 2009). Aggregation has been reported as a 
common concern during the storage and use of therapeutic proteins (Kiese & 
Papppenberger 2008; Manning et al. 2010; Arakawa et al. 2006; Chi et al. 2003). The 
aggregation process results in reduced activity by decreasing the concentration of the 
active drug and more significantly an increase in immunogenicity. Aggregates are 
antigenic and consequently recognised by the immune system which may lead to 
anaphylaxis. This is an instant reaction, produced by immunoglobulin E (IgE) of the 
immune system, which causes local or systemic attack. This immune reaction has 
been associated with increased patient morbidity and mortality (Manning et al. 2010). 
 
Accordingly aggregate detection and characterisation became a focus in the selection 
of the methodology (Bardin et al. 2011). There is an extensive range of physico-
chemical techniques which are suitable. Ideally a range of methods are needed for 
aggregate characterisation, but practicality requires a manageable number of 
techniques. The approach adopted in this study has used a small set of techniques. The 
selection is appropriate for the different ways instability is revealed within the drug. 
This is a practical approach rather than an exhaustive characterisation of the drug. 
This means differences in the drug will be monitored and not the determination of 
absolute structural change of the protein molecule. However, this will involve 
determining the stability indicating properties of the molecule such as shape 
(conformation), size (aggregation, particulates and fragmentation) and chemical 
modification.  
 
The various chromatography and spectroscopic techniques applied to protein 
secondary structure determination and aggregation have been assessed (Arakawa et al. 
2006; Brousseau 2008; Hawe et al. 2009; Nobbmann et al. 2007).  
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Size exclusion chromatography and infra-red spectroscopy have been identified as the 
most promising in terms of studying the changes in the protein and further developing 
the use of these techniques within Trastuzumab drug stability (Bond et al. 2010; Kong 
& Yu 2007). This combination of methods allows the opportunity to study the 
physico-chemical nature of instability in terms of aggregation and secondary 
structure.  
 
Size exclusion chromatography of protein based drugs (Arakawa et al. 2006) provides 
to assess the condition of the formulation in terms of aggregate size distribution and to 
aid the prediction of particle formation. The appearance and increase in multimeric 
species are of significance as they may be indicative of instability of the drug 
solution. Furthermore, these species may lead to higher order aggregates and 
subsequent precipitation. Particle formation has been identified as a limiting factor in 
shelf-life (Bardin et al. 2011).   
 
Infra-red spectroscopy (FTIR) has been a choice method for secondary structural 
determination and work has focused on the fundamental evaluation of spectral 
information of proteins in general. FT-IR has been applied to the assessment of 
stability of protein-based drugs during the lyophilisation process and upon 
reconstitution (Arakawa et al. 2001; Andya et al. 2003). Additionally, it has been 
utilised to study the effects of stress after reconstitution (Kiese & Papppenberger 
2008). Thus it is appropriate to extend the application of infra-red spectroscopy for 
stability studies of further diluted Trastuzumab during storage. 
 
 
1.7.2 Selection of Biological Assay 
 
A cell-based approach was selected as this models the mechanism of the disease. 
Knowing the HER2 is the target of Trastuzumab an appropriate cell-line can be 
chosen. There are several suitable cell-lines but BT474 was selected as this 
overexpresses HER2 and  is therefore Trastuzumab responsive (Neve et al. 2006; 
Holliday & Speirs 2011). Determination of biological activity using a cell-based 
approach enables the assessment of the activity of the drug with respect to its binding 
to a receptor and the subsequent effects on cellular processes which are detected and 
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measured. Proliferation and viability are usually assessed with various readouts of 
these cellular properties being employed. Both cell viability and cell proliferation 
approaches were selected. 
 
 
1.8 Quality Assurance and Quality Control 
 
1.8.1 Quality Assurance 
 
These are the measures to ensure that quality control activities related to Quality 
Control are implemented correctly. This is a management process that involves 
documentation of procedures which have relevance to the quality of the data, thus 
allowing those procedures to be monitored and therefore enabling quality to be 
maintained. 
 
Laboratory books and standard operating procedure documentation are a main part of 
ensuring quality of procedures and consequently data. Also log books documenting 
items such as cell stocks which aid traceability. 
 
Equipment calibration and maintenance should be on a regular basis and fully 
documented. General care of the laboratory is important for ensuring overall quality. 
 
These measures were employed in this study 
 
1.8.2 Quality Control 
 
Quality control can be achieved through the determination of accuracy and 
uncertainty of data which informs on the precision or closeness of a series of 
measurements. 
 
Accuracy is the closeness or agreement of measurement and a true or accepted 
reference value. Accuracy may be inferred once precision, linearity and specificity are 
determined (ICH 2005). Uncertainty or error of data may originate systematically or 
randomly in an experiment (Harris 2003). Linearity of an analytical method is its 
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ability to obtain a test result, within a given range, which is directly proportional to 
the amount of analyte (ICH 2005). The range is the upper and lower limit of analyte 
amount that shows suitable precision, accuracy and linearity. Specificity is the ability 
to assess the analyte in the presence of other components such as excipients or 
degradants (ICH 2005) 
 
These validation characteristics are regarded as the most important for assay 
validation and are the characteristics normally evaluated (ICH 2005) 
 
 
 
1.9 Aim and objectives 
 
Aim: 
 
To provide experimental evidence to support an extended shelf-life of Trastuzumab 
infusions under clinical in-use conditions. 
 
The objectives of this study are to: 
 
 Develop and validate a cell-based analytical method to detect and measure 
changes in activity in Trastuzumab (Herceptin) after reconstitution and 
dilution; 
 
 Select, develop and validate physico-chemical methods to characterise 
Trastuzumab (Herceptin). This includes development of FTIR to monitor 
changes at the secondary structural level and Size Exclusion Chromatography 
to monitor dimers leading to aggregation,   
 
 Evaluate the stability-indicating capability of the biological and 
physicochemical methods, 
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 Apply these methods to evaluate the stability of Trastuzumab (Herceptin) after 
reconstitution and dilution in infusion solutions during extended storage and 
administration. 
 
 
1.10 Hypothesis 
 
Trastuzumab is sufficiently robust to remain unaltered following reconstitution or 
dilution to clinically relevant concentrations when stored in appropriate containers 
under controlled normal conditions of storage. 
 
Note: When diluted to high dilution, below clinically relevant concentrations, at 
0.1mg/ml or lower increased interactions between protein and container become 
important in limiting shelf-life than at lower dilution. 
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CHAPTER 2 
 
 
2. METHOD DEVELOPMENT OF PHYSIOCHEMICAL CORE 
TECHNIQUES FOR STABILITY ASSESSMENTS 
 
 
2.1 INTRODUCTION  
 
Particulate formation is an important indicator of injection solution quality. In use it is 
essential to assess particulates in injections as in parenteral administration the drug is 
introduced directly into the body, typically into the blood stream. The presence of 
particles, which may be product related or a contaminant, will present a serious risk 
for patient safety. Protein-based drug products have the additional properties of drug 
aggregation and increased immunogenicity. Furthermore, the degree of 
immunogenicity increases with aggregate size with dimers and trimers being 
inefficient at initiating immune reaction (Rosenberg 2006). Therefore aggregate 
characterisation has been identified as an important indicator of particle formation and 
consequently the safety of the Trastuzumab formulation. This has informed the 
selection of the core techniques identified and discussed in Chapter 1 General 
Introduction (Section 1.7 Method rationale). The nature and extent (size) of 
aggregation can be assessed using the selected core techniques of infra-red 
spectroscopy and size exclusion chromatography, respectively.  
 
Aggregates may be native, i.e. where folding of the protein structure remains 
unaltered, or non-native, i.e. when unfolding results in abnormal secondary and 
irregular higher order structure within the aggregate (Manning et al. 2010). The 
detection of aggregates and changes in their size distribution may aid prediction of 
instability. An increase in higher order aggregates or aggregate growth, i.e. greater 
than dimeric or trimeric species, should rationally precede particle formation of the 
protein (Manning et al. 2010). Particulate formation has been identified as a restrictive 
factor in determining a shelf-life for protein-based drugs (Bardin et al. 2011). 
Therefore the ability to monitor the aggregate profile of the reconstituted and diluted 
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Trastuzumab formulation was the main objective of physicochemical assessment 
method development.   
 
 
2.2 METHODS AND MATERIALS 
 
2.2.1 Preparation of Trastuzumab (Herceptin® Roche) 
 
Trastuzumab (150 mg) previously reconstituted with water for injection (WFI) (7.2 
mL) in single dose vials (triplicate vials clear glass type I vial was supplied for use by 
BUPA home healthcare UK). The vials were fitted with butyl rubber stoppers coated 
with a fluoro film resin, batches HO636 with expiry date 07/13) and H3144 with 
expiry date 07/15. These vials were supplied and used within a few days following 
reconstitution for the early preliminary work only. Fresh Trastuzumab solution was 
used in the remainder of the work. 
 
Two batches of lyophilised Trastuzumab were used (batches H4008 and H3144 with 
expiry date 2015). 
 
Trastuzumab was reconstituted under aseptic conditions for reference and test 
purposes by weighing accurately using a four place analytical balance approximately 
20 mg of drug and adding 1 ml nominal volume of sterile water for injection (SWFI). 
The actual volume of SWFI was adjusted to give 21 mg/mL of Trastuzumab and 
corresponds to the approximate vial concentration.  
 
 
2.2.2 Size exclusion liquid chromatography (SEC-LC) 
 
2.2.2.1 Instrumentation 
 
Size exclusion liquid chromatography was performed using a Dionex MAb Pac 
SEC1TM (Dionex; a Fisher Scientific company) size exclusion column with a packing 
particle size of 5 μm with a 300 Angstrom (0.03 μm) pore size. Instrumentation 
comprised of Gynkotek Gina 50 HPLC system with quaternary pump and vacuum 
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degasser (Gina 50). Gynkotek ultraviolet UV340S Diode array detector (Type: UVD 
340S). Kontron Instruments 422 HPLC Pump operated under by Opus software under 
a Chromeleon operating system. A Shimadzu LC-10 system was also used operated 
by Lab Solutions Chromatography system under Windows XP environment 
performed the analysis.  
 
 
2.2.2.2 Conditions for chromatographic separation 
 
The mobile phase was 300 mM sodium chloride and 50 mM disodium hydrogen 
phosphate solution adjusted to pH 6.8. The elution rate was 0.2 mL/minute with dual 
wave length UV detection at 280 nm and 220 nm. 
 
 
2.2.2.3 Chromatogram processing and analysis 
 
Chromatographic data was converted and exported for further processing in Microsoft 
EXCEL (2003). This enabled the comparison of chromatograms at UV detection of 
280 nm and 220 nm. 
 
 
2.2.3 Development of Attenuated Total Reflectance Fourier Transform Infra-
red (ATR-FT-IR) Spectroscopy for the analysis of Trastuzumab 
 
2.2.3.1 Instrumentation 
 
Infra-red spectra were acquired using Fourier Transform Infra-red (ATR-FT-IR) 
Spectroscopy (Spectrum One spectrophotometer Perkin-Elmer) with a fast recovery 
deuterated triglycine sulphate (FR-DTGS) detector operated by Spectrum 1 software 
(Spectrum version 5.0.1), under Windows XP environment. Attenuated total 
reflectance infra-red spectra were acquired using a germanium crystal ATR accessory 
with liquid sample recess (Specac Silver Gate™ Evolution) mounted on the ATR base 
plate (Specac Benchmark™ base plate). 
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Optical performance: range 7,800 to 350 cm-1, resolution 0.5 to 64 cm-1 and accuracy 
0.1 cm-1 at 1,600 cm-1 within the Amide I region. 
 
 
2.2.3.2 ATR plate installation, set-up and optimisation of  throughput signal 
 
The transmission base plate and cell holder was removed and replaced with the ATR 
base plate (Specac Benchmark™ base plate). The optical unit with the ATR crystal 
top plate in position (Specac Silver Gate™ Evolution) was mounted on the base plate 
and secured by a screw into the front column of the base plate support. The optical 
path was finely aligned to optimise throughput energy. This was achieved by 
adjusting the mirror screws and monitoring the resultant energy (detector current) 
until a maximum level was obtained.  
 
 
2.2.3.3 Spectra acquisition 
 
Final acquisition parameters were as follows; 256 continuous scans for each spectrum 
at a resolution of 4 cm-1 and scan range of 4,000 cm-1 to 1,000 cm-1 wave numbers.  
 
The sample (20 μL) was introduced into the recess within which the germanium 
crystal is housed ensuring full surface coverage of crystal. The crystal was cleaned 
between samples with deionised water (ten times) followed by acetonitrile (three 
times) (HPLC grade Fisher Scientific).  
 
 
2.2.3.4 Spectra processing and analysis 
 
Water vapour background subtraction and ATR correction were carried out by the 
Spectrum One software (Spectrum version 5.0.1). The ATR correction function 
transforms the spectrum to a form comparable to that of transmission spectroscopy 
where the infra-red beam passes through the sample. The spectral peaks resulting 
from attenuation of the infra-red beam are broadened due to the variation of 
penetration depth with frequency or wave number. 
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Spectra were converted and exported as ASCII (American Standard Code for 
Information Interchange) files for further processing in Microsoft EXCEL (2003). 
The corresponding blank spectra were subtracted from the sample spectra and the 
resultant spectrum normalised to 1,850 cm-1; the baseline wave number adjacent to 
the amide I envelope and graphed as Microsoft EXCEL (2003) charts. This enabled 
the direct comparison of the Amide I region by spectrum overlay of all sample 
spectra. 
 
 
2.3 Quality Assurance and Quality Control 
 
2.3.1 Trastuzumab 
 
Two independent batches of lyophilised Trastuzumab, within the expiration date, 
were used. Trastuzumab concentrate was accurately prepared under aseptic conditions 
as described in section 2.2.1. 
 
 
2.3.2 Size exclusion liquid chromatography (SE-LC) 
 
Trastuzumab (21 mg/mL) was diluted accurately with water for injection WFI to the 
desired concentration. The chromatographic separation was performed in triplicate. 
Calibration of instrument response to Trastuzumab concentration was performed to 
confirm satisfactory linearity, accuracy and precision. Specificity of the method to the 
analysis of the monomer was shown in the presence of degradation products and 
excipients. Absence of analyte carry-over was assured by blank column runs 
following Trastuzumab analysis. Table 1 shows the retention time of Trastuzumab 
with reference to co-eluted molecular weight marker proteins. 
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Trastuzumab
29kDa443kD a
11.5443Apoferritin
14.829Carbonic 
anhydrase
12.6148Trastuzumab
Retention Time 
(min)
MW (kDa)Sample
MAbPac™ SEC-1 column (Dionex) molecular weight marker data at 220nm. Elution 
was with a mobile phase comprising 0.3M sodium chloride, 0.05M sodium 
phosphate, pH 6.8 (0.2ml/min).
 
 
Table 1 Trastuzumab retention time compared to co-eluted molecular weight markers 
 
 
2.3.3 Attenuated Total Reflectance Fourier Transform Infra-Red (ATR-FT-IR) 
Spectroscopy 
 
The accuracy specification of the FT-IR instrument is 0.1 cm-1 at 1,600 cm-1. 
Furthermore, the accuracy specification resides within the Amide I region and 
therefore should enable small but significant changes in absorbance and hence 
secondary structure to be detected.  
 
After optimisation of instrument throughput signal, a spectrum of the ATR crystal in 
air was obtained to confirm 100% transmission for the germanium crystal, i.e. without 
sample. Signal to noise ratio was improved by increasing scan number from 128 to 
256 continuous scans. Signal to noise was assessed by subtracting two spectra 
obtained in air to see residual instrument noise level. 
 
Blank background (air) spectra were collected before and after sample analysis. A 
blank spectrum with a 100% transmission line, i.e. zero absorbance, with no spectral 
features showed that the crystal was clean prior to further samples being analysed. 
 
A representative sub-sample of the heat stressed Trastuzumab solution was obtained 
from the original sample used for SE-LC. This assured that stressed Trastuzumab had 
been sampled. 
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2.4 Results and Discussion 
 
2.4.1 Size exclusion chromatography (SE-LC) of reconstituted Trastuzumab 
with ultraviolet (UV) detection at 220 nm and 280 nm 
 
After commissioning and conditioning the column an acceptable resolution with 
repeatability was observed for the Trastuzumab monomer appearing at 12.3 minutes 
and the dimer at 11.3 minutes (figure 1 and 2). Species elute in order of decreasing 
size. The excipient buffer peak is free of the peaks associated with Trastuzumab 
monomeric and multimeric peak system. This gives a sufficient retention window for 
peaks associated with fragmentation to be seen. 
 
The selection of a dual wavelength approach to improve sensitivity of aggregate 
characterisation has been cited in the literature (Bond et al. 2010). This approach 
allows the monomer peak to be on scale at 280 nm (figure 2) and the smaller 
aggregate and fragment peaks detected with greater sensitivity at 220 nm (figure 1). 
At 280 nm the aggregate and fragment peaks are very small and give inaccurate 
indication of their quantity. The use of dual ultraviolet wavelength detection SE-LC 
with the system has confirmed that this mode of analyte detection gives an improved 
analytical procedure in terms of the accurate and sensitive determination of 
percentage purity of the monomer. Calibrations of reconstituted Trastuzumab over a 
range of concentrations prepared from a stock of 21 mg/mL were performed. The 
resulting calibrations of instrument response (peak area) as a function of Trastuzumab 
concentration were linear with a correlation coefficients approaching unity. A 
characteristic calibration with a correlation coefficient of 0.9997 is shown in figure 3. 
The SE-LC data and statistical analysis for this calibration are presented in table 2. 
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Figure 1 Representative SE-LC chromatogram of Trastuzumab with UV detection at 
220 nm showing peaks for monomer (off scale), dimer and excipient buffer. Dionex 
(Fisher Scientific) MAbPacTM SEC-1 size exclusion column with a column packing 
particle size of 5 μm with a 300 Angstrom (0.03 μm) pore size. The mobile phase was 
300 mM sodium chloride in a 50 mM disodium hydrogen phosphate adjusted to pH 
6.8 with an injection volume of 10 μL. The elution rate was 0.2 mL/minute with dual 
wave length UV detection at 280 nm and 220 nm. 
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Figure 2 Representative SE-LC chromatogram of Trastuzumab with UV detection at 
280 nm showing peaks for monomer (on scale). Conditions for analysis as in figure 1. 
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Trastuzumab 
concentration 
mg/ml 
 
Area 
injection 
1 
 
Area 
injection 
2 
 
Area 
injection 
3 
 
Mean 
Area 
 
Standard 
Error 
 
Standard 
Deviation 
 
Variance 
4.20 - 180.63 184.12 182.38 1.75 2.47 6.09 
2.10 88.70 87.13 89.77 88.53 0.77 1.33 1.76 
1.05 42.19 42.69 42.44 42.44 0.14 0.25 0.06 
0.53 20.73 20.91 20.89 20.84 0.06 0.10 0.01 
0.26 9.99 9.88 9.85 9.91 0.04 0.07 0.01 
0.13 4.58 4.60 4.57 4.58 0.01 0.02 0.00 
0.07 2.10 2.10 2.10 2.10 0.00 0.00 0.00 
 
 
Table 2 SE-LC calibration data of instrument response (peak area) using UV 
detection at 280 nm for Trastuzumab showing integration of peaks and statistical 
analysis for each standard concentration of drug. 
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Figure 3 SE-LC calibration of instrument response (UV detection at 280 nm) to 
Trastuzumab for a range of concentrations. Standard error of replicate analysis is 
shown with inferential error bars (injections per concentration n = 3 for all 
concentrations except for the 4.2 mg/mL sample n = 2). Conditions as previously 
stated.  
 
 
2.4.1.1 Assessment of forced degradation (aggregate induction) of reconstituted 
and diluted Trastuzumab using Size exclusion chromatography (SE-LC) 
with ultraviolet (UV) detection at 220 nm and 280 nm 
To assess the stability indicating ability of SE-LC in terms of detecting aggregate 
formation a Trastuzumab sample was heated to 75 oC for 5 minutes. The rationale for 
this was that a temperature of 75 oC approximates the melting temperature (Tm) of the 
Trastuzumab molecule (Matheus, et al. 2006; Pabari et al. 2013). At this temperature 
the protein molecule population is in equilibrium between native and denatured (loss 
of native secondary structure) states (Arakawa et al. 2001(b); Manning et al. 2010). 
Aggregation may occur below this temperature, as the sample heats, via partial 
unfolding of the protein molecule (Chi et al. 2003) and retain native secondary 
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structure (Pabari et al. 2011). As the sample temperature approaches the Tm the extent 
of unfolding increases with associated aggregation probability and rate increasing 
(Vermeer & Norde 2000).  
Therefore the adopted method was to perturb the system for a sufficiently short time 
to initiate aggregation whilst not to induce complete denaturation or chemical 
degradation. Furthermore, aggregates formed by a relatively mild perturbation are 
likely to be representative of the species formed under the conditions of this study 
(Barnes 2012).  This approach is in contrast with the standard method of thermal 
degradation used for conventional drugs (Blessy et al. 2014). This entails application 
of a thermal stress for prolonged periods which would result in an unrepresentative 
decomposition mechanism and products (Barnes 2012). This method may have some 
relevance to drugs based on more robust chemical compounds but is completely 
inappropriate with protein-based drugs (Allwood & Wilkinson 2013).  
Mechanical stress was considered as a means to induce aggregation but is a less 
defined stress mechanism involving a complex combination of shear and interfacial 
effects (Jaspe & Hagen 2006). Additionally, mechanical stress would be appropriate 
for stability studies pertaining to the manufacturing process (Kiese & Papppenberger 
2008; Pabari et al. 2011). 
Figure 4 and 5 shows a chromatogram overlay with UV detection at 220 nm of a heat 
treated sample of Trastuzumab (0.1 mg/mL) which had been heated in a water bath at 
75 oC for 5 minutes and an untreated standard drug chromatogram at full scale (figure 
4) and reduced scale (figure 5). The degraded sample has a peak area of ~90% of that 
of the untreated Trastuzumab sample (figure 4). On the reduced scale (figure 5) an 
increase in multimeric species is apparent. There is an increase in the size of the peak 
assigned to the dimer and an appearance of a broad peak system extending from the 
shoulder of the dimer peak. This is indicative of aggregate growth and consistent with 
the formation of trimers and other higher order multimeric species (Bond et al. 2010). 
Also, there is a new peak system between the monomer and excipient peak (figure 5). 
This region corresponds to large species but smaller than the monomer, i.e. 
fragmentation of the Trastuzumab antibody molecule possibly by the loss of a sub-
unit (Bond et al. 2010; Vlasak & Ionescu 2011). This infers that the forced 
degradation experiment was not completely successful. However, peaks indicating 
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smaller fragments indicating additional unrepresentative degradation were absent 
(Bond et al. 2010). This type of fragmentation ought to be found at retention times 
greater than that for the excipient buffer peak. Indeed, in thermal stressing 
experiments discussed in the Chapter 5 (forced degradation studies of Trastuzumab) 
these peaks appear at retention time greater than the excipient peak. 
 
 
Figure 4 SE-LC chromatogram with UV detection at 220 nm (showing peaks for 
monomer on scale) of Trastuzumab (0.1 mg/mL) after heating in a water bath at 75 oC 
for 5 minutes compared with an overlaid chromatogram of an untreated Trastuzumab 
(0.1 mg/mL) reference. The heat treated sample has a monomer peak area of ~90% of 
that of the untreated reference sample. Chromatographic conditions as previously 
stated. 
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Figure 5 SE-LC chromatogram with UV detection at 280 nm (showing peaks for 
monomer off scale) of Trastuzumab (0.1 mg/mL) after heating in a water bath at 75 
oC for 5 minutes compared with an overlaid chromatogram of an untreated 
Trastuzumab (0.1 mg/mL) reference. The heat treated sample shows an increase in 
peak system assigned to the dimer and appearance of a peak system attributed to 
aggregate growth. Fragmentation of the monomer is indicated by the peak system 
between the monomer and excipient peaks. Chromatographic conditions as previously 
stated. 
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2.4.2 Attenuated Total Reflectance Fourier Transform Infra-red (ATR-FT-IR) 
Spectroscopy for the analysis of Trastuzumab 
 
2.4.2.1 System optimisation 
 
Signal to noise was assessed by subtracting two spectra obtained in air to see residual 
instrument noise level. The noise is randomly or normally distributed around zero 
absorbance. Signal to noise ratio was improved by increasing scan number from 128 
to 256 continuous scans. Figure 6 shows spectrum of the ATR germanium crystal in 
air within a wavenumber range of 2,000 cm-1 to 1,000 cm-1. 
 
 
 
Figure 6 ATR-FT-IR spectrum from 2,000 cm-1 to 1,000 cm-1 of germanium crystal 
ATR in air i.e. no sample. Scan range of 4,000 cm-1 to 450 cm-1 wave numbers 256 
continuous scans at a resolution of 4 cm-1 and with an accuracy of +/- 0.1 cm-1 at 
1,600 cm-1. Spectrum normalised to wavenumber 1,850 cm-1 and background, water 
vapour and ATR corrected. 
  
65 
 
 
A greater number of scans didn’t produce any observable improvements and 
significantly increased analysis time. Multiple scans and precise replication of wave 
numbers during each scan enables the instrument to average the signals from each 
scan (Harris 2003). This improvement assists in the identification of slight differences 
in spectra (Harris 2003).  Averaging 256 scans produces an improved signal to noise 
ratio by a factor of 16, i.e. the square root of the scan number (Harris 2003). The 
improved signal and inherent instrument accuracy of 0.1 cm-1 at 1,600 cm-1 (Perkin 
Elmer Life and Analytical Sciences 2004) within the Amide I region provided 
acceptable conditions to acquire and compare spectra of Trastuzumab.  
 
 
2.4.2.2 Acquisition of Trastuzumab spectra 
 
It is important that the spectra acquired originate from the sample alone and that 
Trastuzumab does not change during sample manipulation. This was ensured as no 
preparation, including dilution, of the sample was required. The original sample was 
introduced to the recess in the top plate which houses the crystal and may be 
recovered and reserved for further testing if required. However, it is imperative the 
sample recess was thoroughly cleaned to avoid absorbance artefacts from sample 
carry over. This was particularly important as the antibody molecule was expected to 
adsorb to an extent onto the crystal surface (Philo & Arakawa 2009). Complete 
removal of protein from a previous sample was shown by acquiring a blank spectrum 
of the cleaned and dried crystal.  
 
Figure 7 shows the complete spectrum (4,000 cm-1 to 1,000 cm-1 wave numbers) and 
figure 8 shows the Amide I region (1,800 cm-1 to 1,500 cm-1 wave numbers) for two 
different vial samples of 21 mg/mL Trastuzumab. The Amide I region, originating 
mainly from carbonyl stretching vibration, is the most commonly selected reporter of 
secondary structure conformation due to its almost sole dependence on the orientation 
of the polypeptide backbone (Barth & Zscherp 2002). Therefore the Amide I band has 
been selected as a marker of conformational change. If there are significant functional 
changes of Trastuzumab, i.e. loss of efficacy, these may be related to the structural 
change within the molecule and reflected in the spectrum in this region. 
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Figure 7 ATR-FT-IR spectrum of reconstituted Trastuzumab 21 mg/mL from two 
vials (red and blue plots). Scan range of 4,000 cm-1 to 1,000 cm-1 wave numbers 256 
continuous scans at a resolution of 4 cm-1 and with an accuracy of +/- 0.1 cm-1 at 
1,600 cm-1. Spectrum normalised to wavenumber 1,850 cm-1 and background, water 
vapour and ATR corrected. 
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Figure 8 ATR-FT-IR representative spectra of reconstituted Trastuzumab 21 mg/mL 
from two vials (red and blue plots) showing Amide I region (1,800 cm-1 to 1,500 cm-1 
wave numbers). Scan range of 4,000 cm-1 to 1,000 cm-1 wave numbers, 256 
continuous scans at a resolution of 4 cm-1 with an accuracy of +/- 0.1 cm-1 at 1,600 
cm-1. Spectrum normalised to wavenumber 1,850 cm-1 and background, water vapour 
and ATR corrected. 
 
 
 
2.4.2.3 Interpretation and analysis of Trastuzumab spectra 
 
Trastuzumab has a mainly ordered β-sheet structure with the remaining being random 
coil. Therefore an increase in random coil is expected to be seen at the expense of the 
more ordered β-sheet during degradation. Furthermore, it has been stated previously 
that aggregate species may develop non-native structures (Chi et al. 2003) which 
often contain intermolecular β-sheet structures in high levels irrespective of the initial 
secondary structure (Carpenter et al. 1998; Chi et al. 2003). Therefore it is likely that 
if there is any difference in the structure of whole or part of the molecular population 
this will manifest itself as a change in the shape of the Amide I envelope or shift in 
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wave number of the peak profile (Barth & Zscherp 2002). A method to enhance any 
differences in the spectra is to calculate the second derivative of the Amide I spectrum 
(Barth & Zscherp 2002). This method does not distort the spectrum and preserves the 
original spectral information (Dong et al. 1995).  
 
The change in peak profile can be followed over time to give information on the 
secondary structure of the stored reconstituted and diluted Trastuzumab. This may be 
achieved by overlaying spectra or generating difference spectra; i.e., spectrum at time 
point n minus spectrum at time point 0 = difference spectrum. The new difference 
spectrum may show small, complex and difficult to detect global changes between the 
two spectra in the Amide I profile or complete spectrum and hence changes within the 
formulation (Grdadolnik 2002).  
 
An additional approach available to monitor changes in the protein is to assign 
structural motifs to their corresponding regions in the Amide I envelope and calculate 
their relative quantities hidden there in (Barth & Zscherp 2002). This entails using an 
iterative band fitting approach of the Amide I envelope (Jackson & Mantsch 1995). 
The structural elements are hidden within the broad Amide I envelope and can be 
thought of as being separate peaks of combined area equal to the Amide I area (Barth 
& Zscherp 2002). Thus knowing that the initial state of the antibody molecule has β-
sheet (60-70%) at 1,642cm-1 and 1,624cm-1, β-turn (~30%) at 168 cm1, 1,680cm-1, 
1,672 cm-1 and 1,666 cm-1 and random coil at 1,648cm-1 (Kong & Yu 2007), 
percentile changes of secondary structure may be determined. 
 
A great disadvantage of band fitting is its inherent subjectivity (Jackson & Mantsch 
1995; Carpenter et al. 1998). Furthermore, reorganization of the molecular structure 
may result in a significant change in peak shape although band fitting may show no 
change in the relative proportions of secondary structure (Carpenter et al. 1998). This 
behaviour has been observed in lyophilised-induced stress studies (Carpenter et al. 
1998). Dehydrated α-chymotrypsinogen was found to have an extremely disturbed 
structure although the whole relative secondary structure was unaffected (Carpenter et 
al. 1998). The authors indicate that quantitative analysis using band fitting is normally 
not required, may lead to increased subjectivity in data analysis and misleading 
(Carpenter et al. 1998). However, quantitative analysis may be useful for determining 
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percentage of intermolecular β-sheet which may form between aggregated monomers 
or increase in random coil (Vonhoff et al. 2010; Carpenter et al. 1998). 
 
 
2.4.2.4 Assessment of forced degradation (aggregate induction) of reconstituted 
and diluted Trastuzumab using Attenuated Total Reflectance Fourier 
Transform Infra-red (ATR-FT-IR) Spectroscopy 
 
ATR-FT-IR assessment of the heat treated Trastuzumab showed no difference in the 
spectral signature compared to that of an unstressed Trastuzumab. Generating a 
difference spectrum, which would enhances any change, did not reveal new spectral 
structures (figure 9).  This observation was consistent with the interpretation that the 
secondary structure had not changed significantly. 
 
 
 
 
 
 
Figure 9 ATR-FT-IR difference spectrum of reconstituted Trastuzumab (heat-stressed 
and not heat-stressed) at 0.1 mg/mL concentration. Showing region 2,000 cm-1 to 
1,000 cm-1 wave numbers. Scan range of 4,000 cm-1 to 1,000 cm-1 wave numbers, 256 
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continuous scans at a resolution of 4 cm-1 with an accuracy of +/- 0.1 cm-1 at 1,600 
cm1. Spectrum background, water vapour and ATR corrected.  
 
SE-LC confirmed that Trastuzumab monomer aggregation had increased after 
application of thermal stress (figure 5). This inferred that the aggregates generated 
have retained their secondary structure whilst increasing in size from the dimeric 
species inherently present in the reconstituted and diluted formulation. The retention 
of native structure has been found in shear-stressing experiments (Kiese & 
Papppenberger 2008). Furthermore, shear force is more stressful than heating and has 
been found to be more effective in generating insoluble aggregates (Xenopoulos 
2013). 
 
It is possible changes in secondary structure were not detected due to a limit in 
instrument sensitivity. Yet the FTIR spectrometer instrument has an accuracy 
specification of 0.1 cm-1 at 1,600 cm-1 (Perkin Elmer Life and Analytical Sciences 
2004).  
 
Alternatively, the aliquot used for the ATR-FTIR measurement may not be 
representative of the stressed bulk sample. However, the stressed protein solution 
used for analysis was a representative sample. 
 
An additional possibility is that the aliquot was not fully sensed or probed and 
consequentially changes are undetected in the bulk solution (Goldberg & Chaffotte 
2005). This view is consistent with the short-lived wave (Hsu 1997) only being able 
to penetrate to the depth of protein adsorbed on the crystal surface or crystal-solution 
interface and thus not sensing the bulk protein (Goldberg & Chaffotte 2005). 
Consequently, changes in bulk concentration were not detected when spectra were 
acquired for a series of concentrations (figure 10). None proportionality of absorbance 
was observed at each concentration with identical absorbance (figure 10). Providing 
that the crystal surface-associated protein molecules were representative of that of the 
bulk Trastuzumab solution assessment of the sample in terms of structure should be 
possible (Goldberg & Chaffotte 2005). This appeared to be the case due to the 
observed spread of sample over the crystal surface enabling efficient sampling of the 
ATR recess contents (Hsu 1997). 
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Figure 10 ATR-FT-IR spectra of reconstituted Trastuzumab at 0.1 mg/mL, 0.5 
mg/mL, 15 mg/mL and 21 mg/mL showing Amide I region (1,800 cm-1 to 1,500 cm-1 
wave numbers). Scan range of 4,000 cm-1 to 1,000 cm-1 wave numbers, 256 
continuous scans at a resolution of 4 cm-1 with an accuracy of +/- 0.1 cm-1 at 1,600 
cm-1. Spectrum normalised to wavenumber 1,850 cm-1 and background, water vapour 
and ATR corrected. Coincidental plots indicate concentration independence of infra-
red absorbance. 
 
 
 
2.5 Conclusions 
 
Dual ultra-violet wavelength detection size exclusion chromatography (SE-LC) 
enabled the detection of both monomer and dimer at retention times of 12.3 minutes 
and 11.3 minutes respectively (figure 1 and 2). Accurate determination of monomer 
was shown (table 1 and figure 3). 
The stability indicating ability of the method was shown by a decrease in monomer 
peak after application of thermal stress (figure 4). Loss of monomer peak was 
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accompanied by an increase in dimer peak (figure 5) and appearance of an adjacent 
new peak system (figure 5). The appearance of a further peak system between the 
monomer and excipient peaks is consistent with fragmentation of the antibody 
molecule (figure 5). 
 
ATR-FTIR spectroscopy showed acceptable residual instrument noise after 
subtraction of spectra obtained in air with 256 continuous scans (figure 6). Spectra 
can be acquired of Trastuzumab samples (figure 7) and comparisons made over the 
Amide I region (figure 8). 
 
ATR-FTIR assessment did not reveal any significant change after forced degradation 
of Trastuzumab as shown in the difference spectrum (figure 9). Additionally it was 
found that the absorbance was insensitive to Trastuzumab concentration (figure 10). 
 
 
 
 
 
  
73 
 
CHAPTER 3 
 
 
3. USE OF PHYSICOCHEMICAL TECHNIQUES TO DETERMINE 
TRASTUZUMAB STABILITY 
 
 
3.1 INTRODUCTION 
 
Physicochemical testing is the standard approach in assessing stability of drug 
substance and drug product. Assessment of physical and chemical stability is 
obligatory for regulatory purposes. The importance of physical and chemical stability 
is reflected in the quality of medicines guidelines published by the European 
Medicines agency: the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) (ICH 2012). 
However these comprehensive guidelines and the pharmacopoeial texts of the ICH 
regions European (Ph. Eur.), United States (USP) and (Japan (JP)) are specific to the 
manufacturing process and the drug as marketed. Nevertheless, this guidance for 
chemical product stability can be used as a basis to develop an approach to in-use 
stability. More specifically aid the selection of standard techniques which can be 
employed to characterise properties which are stability indicating. In the case of in-
use parenteral infusions and injections assessment of visual appearance, sub-visible 
particles and pH are of particular importance in determining acceptable drug quality. 
 
Visual appearance 
Colour, turbidity and visible particle levels should be assessed. The presence of 
visible particles is an important indicator of instability and quality of parenteral 
infusions and injectables. The requirement for these products is that the infusion 
should be “essentially free from visible particulates” according to the harmonised 
pharmacopoeial text (USP 2009). This statement has caused some confusion within 
the pharma community and requires clarification on definition with additional 
guidance on lot sampling and inspection (FDA Visual Inspection of Parenterals 
Advisory Panel Meeting, Purpose of Visual Inspection) (Madsen et al. 2009; Madsen 
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2010). Particulate contamination can be assessed using a standard method such as 
European Pharmacopoeia standard 2.9.20. (Ph. Eur. 2.9.20) (Ph. Eur 2000) and 
equivalent standards of USP and JP. However, other validated methods may be used.  
The test for assessing visible particles described in Ph. Eur. 2.9.20. (Ph. Eur 2000) 
entails examination using none glare white and black background with white-light 
illumination.  
 
Sub-visible particle 
Parenteral infusions must be assessed for sub-visible particles not including bubbles 
or dissolvable material. Light obscuration liquid particle count test can detect particles 
of 10 µm and 25 µm in size but requires large samples (25mL) (USP 788) (USP 
2006). Acceptance criteria are “the average number of particles present in the units 
tested does not exceed 6000 per container equal to or greater than 10 µm and does not 
exceed 600 per container equal to or greater than 25 µm” (USP 2006). The USP 788 
specifies the light obscuration particle count test and the microscopic particle test. The 
former is preferred for assessment of parental infusions but may be used in 
conjunction with the microscopic particle test to reach a conclusion on conformance 
USP 788 (USP 2006). The USP 788 is equivalent to the European Pharmacopoeia 
standard 2.9.19. (Ph. Eur. 2.9.19.) (Ph. Eur 2000). Sub-visible particles may also be 
detected using size exclusion chromatography or dynamic light scattering. 
 
pH 
The pH should be monitored as changes in value may indicate instability. The 
solution will have a pH influenced by the drug substance, product-related substances 
and product-related impurities. Chemical degradation may be influenced by the pH.  
The tendency of the drug product to undergo hydrolysis will vary over a pH range and 
therefore should be assessed (Allen 2011 (a); Allen 2011 (b); European Medicines 
Agency 2003). 
 
The assessment of the aforementioned characteristics may be applied to an in-use 
parenteral injections or infusions with little or no alteration. However, with protein-
based drugs the approach and methodology used must be adapted to reflect their 
specific nature. The International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) provides 
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general guidance for protein-based drugs with Q5 and Q6 documents (European 
Medicines Agency 1995; European Medicines Agency 1999). These documents are 
specific to the manufacturing process and the drug as marketed but do provide 
guidance for stability studies and test procedures respectively.  
 
Particles are of specific importance as they are indicative of quality and safety of the 
parenteral infusion. Proteins inherently form aggregates including dimers and higher 
order aggregates. In the case of protein-based infusions aggregation of protein 
molecules will lead to sub-visible and visible particles. Particulates will impact on 
safety and efficacy and must be thoroughly evaluated and a focus of a stability study.  
The USP General Chapter Injections <1> (USP 2009) states the following, “the 
Pharmacopoeial definitions for sterile preparations for parenteral use generally do not 
apply in the case of the biologics because of their special nature and licensing 
requirements.” 
 
Moreover, the USP Visual Inspection of Parenterals Advisory Panel Meeting, Purpose 
of Visual Inspection History and revision of General Chapter Injections <1> (USP 
2009) does not address assessment of protein particulates (USP 2009; Madsen et al. 
2009). A panel member commented in their presentation that, “protein products can 
contain visible proteinaceous particles due to high concentrations or simply the nature 
of the protein. These particles are shown not to impact safety or efficacy during 
development” (Madsen 2010). However, this is not compatible with clinical 
requirements where intrinsic protein particles are of prime concern due to patient 
safety.  
 
The absence of specific guidance for biologic or protein-based drug sterile 
preparations and more specifically for in-use clinical applications has been addressed 
by the NHS UK Pharmaceutical Research and Development Working Group with the 
document A Stability Protocol for Deriving and Assessment of Stability Part 2 – 
Aseptic Preparations (Biopharmaceuticals) (Barnes 2012). 
 
One important aspect highlighted by this document is the use of an appropriate 
container in a stability study. This must reflect what is used within the clinical setting, 
such as a polyolefin, because the interaction of the protein may change with a 
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different container material and consequently affect the stability profile (Barnes 
2012). Moreover, materials such as polyvinyl chloride (PVC) contain plasticisers 
which pose a health risk of leaching out di-(2-ethylhexyl) phthalate (DEHP) (US Food 
and Drug Administration 2001) into the infusion and may interact with the protein 
(Bee et al. 2011). 
 
Interaction of Trastuzumab with the hydrophobic surface of the plastic material of the 
infusion bag would likely involve adsorption to some extent (Manning et al. 2010). It 
is well known that hydrophobic interactions between the surface and hydrophobic 
patches on a protein initiate adsorption (Pinholt et al. 2011).  Surface activity of an 
antibody (mouse IgG1) molecule has been shown to be accompanied by partial 
unfolding on a hydrophobic Teflon surface (Vermeer et al. 1998). This process may 
involve unfolding of the fab fragment whilst conserving the native-fold of the Fc 
(Vermeer et al. 2001). Whilst the contribution of surface activity of proteins, with 
regard to instability has been established to a degree, applicable pH and excipient 
surfactant effects have not been fully investigated (Couston et al. 2012).  Studies have 
been generally confined to model monoclonal antibodies and surfaces which represent 
those encountered after preparation of the drug (Couston et al. 2012; Kapp et al. 
2015). Couston et al. ( 2012) showed that a human monoclonal antibody (identified as 
Mab 1) adsorbed on hydrophobic octadecyl-coated silica surfaces as a thin irregular 
monolayer using total internal reflectance fluorescence measurements. This is 
consistent with  minimum interaction of the antibody with the surface; when the 
hydrophobic core remains buried in the native form (Couston et al. 2012). 
 
Interaction may be further decreased by end-on orientation of the antibody molecule 
(Kapp et al. 2015) and also by the presence of the polysorbate excipient competing for 
adsorption sites (Garidel et al. 2009). Additionally, the limited contact point of the 
antibody may make displacement by the polysorbate more facile (Kapp et al. 2015). 
The effect of an hydrophobic surface on the extent of  adsorption can be illustrated by 
the following example from Couston et al. (2012). Their study found that the surface 
loading of the Mab was highest on silica at a value of ~5.5 mg/m2 and lowest on 
hydrophobic octadecyl-coated silica with a loading of ~2 mg/m2 at a solution 
concentration of 0.01 mg/mL and pH 5.4. Furthermore, the authors showed that the 
affinity for the hydrophobic surface does not markedly increase with an increase of 
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bulk concentration, thus retaining a monolayer structure. These results are consistent 
with the view that at clinically relevant concentrations the dose will not be 
compromised due to the low level of adsorption (Kapp et al. 2015). 
 
Another factor to consider is the effect of prolonged or inadvertent exposure to light 
of the Trastuzumab solution and clear polyolefin bag under in-use conditions, such as 
during infusion (Qi et al. 2009; Barnes 2012). Specifically this will mean exposure to 
UV-A and cool white light within the visible region (European Medicines Agency 
1998; Kerwin & Remmele 2007). Photo-induced damage of proteins has been widely 
documented and has been reviewed by Pattison et al. (2012). However, there has been 
a limited number of studies relating to protein-based drugs (Kerwin & Remmele 
2007) and have not included marketed drugs until a recent study by Hernández-
Jiménez et al. (2016). This study examined the photo-induced forced degradation of 
Bevacizumab, Cetuximab, Infliximab, Rituximab and Trastuzumab infusions at 
therapeutic relevant concentrations (2 mg/mL and 5 mg/mL). Aggregation  was 
assessed as dimer content by SEC-LC after exposure to simulated in-use light 
conditions (European Medicines Agency 1998) between a wavelength range of 320-
800 nm with an irradiance of 250 W/m2 (Hernández-Jiménez et al. 2016). The authors 
reported that light exposure caused aggregation in all drugs and was monitored each 
day until turbidity was observed. Trastuzumab infusions showed the greatest 
resistance to aggregation as dimer percentage was highest before the onset of turbidity 
after 17 hours of continuous light exposure (Hernández-Jiménez et al. 2016). 
 
The interaction of UV with the protein will be via the absorption of radiation by the 
amide backbone and specific amino acid residues (Schmid 2001)  The major UV 
absorbing amino acids are tryptophan (Trp), tyrosine (Tyr), phenylalanine (Phe), 
histidine (His), methionine (Met), cysteine (Cys) and disulphide bonds (Pattison et al. 
2012). Absorption is greatest for UV-B (280-320 nm) and to a lesser degree with UV-
A (320-400 nm) (Pattison et al. 2012). . Most other amino acids only weakly absorb 
UV at wavelengths >230 nm (Davies 2003). Trp is the predominate amino acid that 
absorbs UV (Creed 1984a). Trp and Tyr are mainly responsible for the observed 
absorbance maxima of proteins with a small contribution to the absorbance from the 
disulphide bond (Schmid 2001). Therefore the photophysics and photochemistry of 
these amino acids have been extensively reviewed and continue to be of interest due 
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to their role in protein analysis and degradation (Creed 1984a; Creed 1984b; Creed 
1984c; Pattison et al. 2012).   
 
Absorption of UV-A may result in direct photo-oxidation of these specific amino 
acids via the generation of excited states and radical-cations (Davies & Truscott 
2001). Additionally there can be secondary oxidation reactions involving peroxy 
radicals and singlet oxygen with the other amino acids (Laustriat & Hasselmann 1975; 
Kerwin & Remmele 2007; Gracanin et al. 2009). These processes are limited due to 
the relatively weak absorption, in the UV-A region (>290 nm) (Davies 2003), that 
they are normally exposed to in the absence of sensitisers (Kerwin & Remmele 2007). 
However, oxidation products of the amino acid side-chain, notably Trp, are more 
efficient at generating triplet oxygen (Davies 2003).  
 
Susceptibility of Trp has been recognised in recombinant monoclonal antibodies 
(Nowak et al. 2016). If the amino acid sequence of a recombinant antibody such as 
Trastuzumab is examined it is evident that  there are two Trp on each light chain and 
nine Trp on each heavy chain (Drug Bank 2016). This further implicates this amino 
acid residue’s potential role in degradation of Trastuzumab. On absorption of UV Trp 
will be excited and may relax to the singlet state followed by fluorescence, convert to 
the first triplet state by the non-radiative process of intersystem crossover or eject an 
electron (Kerwin & Remmele 2007). Furthermore, Phe and Tyr can transfer their 
excitation energy to Trp (Creed 1984b; Kerwin & Remmele 2007). Electron transfer 
is facile from the triplet state Trp to a thiyl anion giving a disulphide radical anion  
(Davies & Truscott 2001). The Trp radical-cation deprotonates to a neutral Tryp 
indolyl radical (Kerwin & Remmele 2007; Pattison et al. 2012). The neutral Trp 
indolyl radical may abstract a hydrogen from a Tyr to give a Tyr phenoxyl radical, 
form a peroxyl radical by reacting with oxygen or react with other amino acids 
(Kerwin & Remmele 2007). The reaction of the peroxyl radical may further react with 
oxygen to give N-formylkyneurenine and kyneurenine (Creed 1984a; Kerwin & 
Remmele 2007). These photo-products absorb at longer wavelength compared to Trp 
and therefore act as sensitisers, thus increasing damage (Kerwin & Remmele 2007). 
Alternatively the Trp radical cation may oxidise a nearby Tyr residue to the Tyr 
phenoxyl radical, thus reducing back to Trp (Creed 1984a).  
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Trastuzumab has one adjacent Trp and Tyr on each heavy and light chains (Drug 
Bank 2016). This observation suggests a possible intramolecular path of electron 
transfer for sensitisation of Tyr by the formation of the Tyr phenoxyl radical (Creed 
1984a; Aubert et al. 1999). The Tyr radical is particularly stable and therefore may 
combine with another Tyr radical giving a dityrosine (Creed 1984b; Malencik & 
Anderson 2003). This radical termination reaction may result in either intramolecular 
or intermolecular crosslinking (Balasubramanian & Kanwar 2002; Malencik & 
Anderson 2003). Other crosslinking reactions include thiyl cross coupling to give a 
disulphide (Creed 1984c; Roy et al. 2009) and reactions of histidine (His) and lysine 
(Lys) with singlet oxygen via an endoperoxide intermediate  generating His-His or 
His-Lys crosslinking (Davies & Truscott 2001). Intermolecular crosslinking has been 
identified as an important mechanism for photo-induced aggregation (Kerwin & 
Remmele 2007; Qi et al. 2009; Wang et al. 2010; Hernández-Jiménez et al. 2016).  
 
This physicochemical stability study was a collaboration with Quality Control 
Northwest (QCNW) (Liverpool NHS Primary Care Trust). This association has 
enabled an approach to obtain stability data which can be used in clinical practise.  
 
The approach to physicochemical assessment of Trastuzumab infusion stability 
employed some techniques not associated with general chemical stability. These were 
Electrophoresis (SDS-PAGE) and Infra-Red Spectroscopy (FTIR). These techniques 
are specific to the protein nature of Trastuzumab where determination of aggregate 
levels and secondary structure allow assessment of these indicators of stability. 
 
 
3.2 Materials and Methods 
 
3.2.1 Materials 
 
Trastuzumab (150 mg in a single dose vial clear glass type I vial) fitted with butyl 
rubber stopper laminated with fluoro-film resin, batch H4008 with expiry date 2015. 
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Trastuzumab was reconstituted as described in Chapter 2 Method Development of 
Physicochemical Core Techniques for Stability Assessments, Methods and Materials 
page 51. 
 
Two intravenous (IV) polyolefin bag types, with a volume of 50 mL, were used for 
the Trastuzumab infusions: Viaflo (Baxter no. FE1306, lot 11614663 with an expiry 
date of 09/2012) and Freeflex® (Fresenius Kabi no. B248941, lot 13EIS025 with an 
expiry date of 08/2013). 
 
Viaflo (Baxter) IV bag Trastuzumab infusions 
These infusions comprised of two bags at a Trastuzumab concentration of 6 mg/mL 
(batch numbers ML1103024 and ML1103027) and two bags at a concentration of 0.5 
mg/mL (batch numbers ML1103020 and ML1103018). The expiry date of the 
infusions was 05/11/2011.  
 
Freeflex® IV bag Trastuzumab Infusions 
The Freeflex® IV bag infusions consisted of two bags (batches) of Trastuzumab at a 
concentration of 0.1 mg/mL (batch numbers ML1103042 and ML1103002) with an 
expiry date of 05/11/2011. 
 
Trastuzumab infusion IV bags with 0.9% sodium chloride were aseptically prepared 
by Clatterbridge Centre for Oncology (pharmacy code CCOCH634JY and IMS 
number 18612) according to Summary of Product Characteristics (SPC).  
 
 
 
Sampling and testing 
 
All infusion bags were stored in a refrigerator between 2 oC and 8 oC to reproduce 
conditions encountered during in-use storage. Physicochemical testing of samples was 
carried out at 0, 7, 14, 28, 35, 43 days. Physiochemical testing comprised of 
assessment of appearance, pH and Trastuzumab monomer and dimer determination by 
SE-LC.  
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Techniques more specific to the protein nature of Trastuzumab were also employed to 
assess aggregate levels and secondary structure. These were Electrophoresis (SDS-
PAGE) and Infra-Red Spectroscopy (Attenuated Total Reflectance Fourier Transform 
Infra-red Spectroscopy (ATR-FTIR) respectively.  
 
After day 43 of the study QCNW subjected their infusions to further testing for 
stability at room temperature. The conditions used were 24 hours at room temperature 
in dark and light conditions and mechanical agitation in light for 6 hours. Tests 
carried out were pH, SDS-PAGE and SE-LC monomer assay. The remaining samples 
were stored for long term stability assessment for over 119 days. 
 
 
3.2.2 Methods 
 
3.2.2.1 pH 
 
Measurements of pH performed by QCNW. 
 
A combination electrode glass probe (Mettler Toledo InLab 413SG IP67) and pH 
meter (Mettler Toledo SevenMulti™ pH meter) was used to record sample pH at each 
time point (QCNW). 
 
 
3.2.2.2 Visual Appearance 
 
The infusions stored in the IV bags were examined for visible particles, clarity and 
colour with a magnifier using white light illumination and both a black and white 
background according to standard method (Pharmacopoeia Europaea Ph.Eur 2.9.20.) 
(Ph. Eur 2000). The acceptance criteria are that the infusion remained free of none 
dissolvable particles or precipitation and retains colour and clarity of initial infusion 
examination (day 0).  
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3.2.2.3 Sub-visible Particle Analysis and Trastuzumab Assay 
 
Due to the sampling burden determination of sub-visible particles by light obscuration 
was impractical. However, sub-visible particles may be detected by Size Exclusion 
liquid chromatography (SE-LC). SE-LC also allows monomer assay which provides 
information on the integrity of the Trastuzumab molecule and aggregate analysis. 
 
The two SE-LC methods employed had a different focus. Method 1 (University of 
Derby) had the aim of providing information on higher aggregates, whilst method 2 
(NHS (UK) QCNW) was concerned solely with quantitative assay. 
 
 
3.2.2.3.1 Size Exclusion Chromatography (SE-LC) method 1 
 
SE-LC method was performed as described in chapter 2 Method Development of 
Physicochemical Core Techniques for Stability Assessments, Methods and Materials.  
 
The chromatographic separation was performed in triplicate at 20 oC. Standards were 
prepared from a freshly reconstituted Trastuzumab solution (21 mg/mL) by dilution 
with 0.9% saline solution to the desired concentrations of 15, 10.5, 5.3, 2.6 and 1.3 
mg/mL. Trastuzumab infusion samples were injected undiluted.  
 
 
3.2.2.4 Size Exclusion Chromatography (SE-LC) method 2 
 
3.2.2.4.1 Instrumentation 
 
Size exclusion liquid chromatography was performed using a Tosoh TSKgel 
G3000SWXL size exclusion column (Hichrom). Instrumentation comprised of 
gradient pump (Kontron 325), auto sampler (Kontron 360) and UV detector (Kontron 
332). 
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3.2.2.4.2 Conditions for chromatographic separation 
 
The mobile phase was 100 mM sodium chloride, 50 mM potassium dihydrogen 
phosphate and 50 mM dipotassium hydrogen phosphate solution adjusted to pH 6.0 
with orthophosphoric acid. The elution rate was 1.0 mL/minute with UV detection at 
220 nm and injection volume of 20 µL. The chromatographic separation was 
performed at 20 oC. Standards were prepared from a freshly reconstituted 
Trastuzumab solution (21 mg/mL) by dilution with 0.9% saline solution to give 
concentrations of 0.08, 0.12, and 0.15 mg/mL.  
 
 
 
3.2.2.4.3 Chromatogram processing and analysis 
 
Data collection and analysis was performed using EZChrom Version 2.6.1. software. 
 
 
3.2.2.5 Attenuated Total Reflectance Fourier Transform Infra-red (ATR-FT-IR) 
Spectroscopy 
 
ATR-FT-IR was performed as described in chapter 2 Method Development of 
Physicochemical Core Techniques for Stability Assessments, Methods and Materials. 
 
 
 
3.2.2.6 Electrophoresis: SDS-Page (Sodium Dodecyl Sulphate Poly Acrylamide 
Gel Electrophoresis) 
 
SDS-PAGE analysis of test samples and reference sample at each time point was 
performed by QCNW.  Electrophoresis with 9% resolving gel under both non-
reducing and reducing conditions (2-mercaptoethanol) at 200 volts. Molecular weight 
markers (ColorBurst™) were resolved with test samples. Visualisation of protein 
bands using Coomassie Blue (Fisher). Gels stained for 2 hours and de-stained in water 
overnight. 
  
84 
 
 
Acceptance criteria are that the band pattern or distribution under none reduced and 
reduced electrophoresis conditions coincided with those obtained for the reference 
Trastuzumab. 
 
 
 
3.3 Results and Discussion 
 
3.3.1 Results for clinically relevant infusions 
 
Results are presented and discussed including statement of compliance to acceptance 
criteria for the clinically relevant samples: 0.5 mg/mL and 6 mg/mL infusions. It is 
difficult to assign acceptance limits for biologics. The NHS Pharmaceutical Research 
and Development Working Group suggest size exclusion chromatography (SE-LC) 
acceptance limit should be a maximum of 5% loss in active protein and a maximum 
of 2% relative loss in degradant peak. Physical appearance should not change and 
there should be no significant change in pH (Barnes 2012).  
 
 
3.3.2 pH 
 
The initial pH of the 0.5 mg/mL and 6 mg/ml infusion samples were 6.04 and 6.23 pH 
units respectively (table 1). These values were consistent with the pH of Trastuzumab 
being reported as approximately 6 pH units (European Agency for the Evaluation of 
Medicinal Products (EMEA) 2010). Furthermore, the pH of Trastuzumab may vary 
between 5.4 and 6.6 pH units for reconstituted Trastuzumab at the 21 mg/mL vial 
concentration as stated in the Roche safety data sheet for Trastuzumab (Roche 2006). 
Additionally, dilution with 0.9% saline solution of the Trastuzumab and excipient 
concentrate in the infusion may be expected to have an effect on pH (Pabari et al. 
2013). Indeed the 0.5 mg/mL infusion was 0.19 pH units lower than that for the 6 
mg/mL infusion sample at the initial measurement on day 0 (table 1). The difference 
in pH profile between 0.5 mg/mL and 6 mg/mL infusions was shown to be significant 
(p = 0.0001) by using a t-Student test with a significance threshold of < 0.0500. 
  
85 
 
 
The pH of all infusion samples remained within specification of the concentrate value 
within the study period (table 1). However, a small statistically non-significant 
decrease in pH was observed compared to the initial pH readings for both 
concentrations of infusion samples at day 14. This behaviour was almost mirrored in 
the pH differences between the two infusion concentrations approaching a maxim 
after day 14 (table 1). The pH data for both 0.5 mg/mL and 6 mg/mL infusions gave a 
mean and standard deviation of 5.94 +/- 0.06 and 6.24 +/- 0.03 pH units respectively. 
 
 
 
Day 
pH at 5 oC  
0.5 mg/mL 
infusion 
6 mg/mL 
 infusion 
Difference in pH  between 
infusion concentrations 
0 6.04 6.23 0.19 
7 5.99 6.21 0.22 
14 5.88 6.19 0.31 
28 5.90 6.25 0.35 
35 5.91 6.24 0.33 
43 5.94 6.29 0.35 
 
Table 1 pH at 5 oC reported for each time-point of study for the of 6 mg/mL and 0.5 
mg/mL infusion bag samples. Performed by NHS QCNW. 
 
 
The pH of biological-based pharmaceuticals is critical to their stability and 
consequently symptomatic of adverse conditions and instability (Barnes 2012). 
Accordingly pH measurements should be performed as part of an assessment of 
stability. 
 
The pH during storage remained consistent with the value being reported as 
approximately a value of pH 6 (European Agency for the Evaluation of Medicinal 
Products (EMEA) 2005b). Specifically, the pH of Trastuzumab may vary between 5.4 
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and 6.6 pH units for reconstituted Trastuzumab at the 21mg/mL vial concentration as 
stated by the manufacturer (Roche 2006). The pH values of the infusions ranged from 
6.0 to 5.9 and 6.2 to 6.3 over the storage period for 0.5 mg/mL and 6.0 mg/mL 
concentrations respectively. 
 
Pabari et al. (2013) and Kaiser and Kramer (2011) also found the pH remained within 
the acceptance limit. Whereas the measurement of pH was not included in the study 
by Paul et al. (2013). 
 
The assessment of pH fundamentally supports that these infusions stored within their 
containers are stable. Although judgement on stability must of course include the 
examination of data from other tests. An illustration of this is that of the 0.1 mg/mL 
infusions where pH remained within specification but developed particles. 
 
 
3.3.3 Appearance 
 
All infusions at clinically relevant concentrations, i.e. 6 mg/mL and 0.5 mg/mL 
infusions, remained clear and colourless after 43 days (table 2).  Other studies with 
visual assessment showed similar findings for stored Trastuzumab infusions (Kaiser 
& Kramer 2011; Pabari et al. 2013). These studies showed that the appearance of 
Trastuzumab infusions, at concentrations of 0.4 mg/mL and 4 mg/mL, did not change 
over a 28 day storage period (Kaiser & Kramer 2011; Pabari et al. 2013).  
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Day 
Visual appearance Pass/Fail 
0.5 mg/mL infusion 6 mg/mL infusion 
0 Pass Pass 
7 Pass Pass 
14 Pass Pass 
28 Pass Pass 
35 Pass Pass 
43 Pass Pass 
 
Table 2 Visual appearance reported for 6 mg/mL and 0.5 mg/mL infusions over the 
43 day study period.  
 
 
 
Assessment of visual appearance is a requirement common to both small molecule 
and biologic infusions (USP 2009). Changes in colour, clarity and appearance of 
particulates are indicative of changes in the quality of the infusion and accordingly 
their assessment should be part of a minimum testing protocol. Indeed in clinical 
practise an infusion will be routinely inspected visually before use. If the infusion is 
free of particulates or precipitates and shows no colour change it will be administered 
to the patient. 
 
The USP document does not include visual assessment as it is concerned with 
reference procedures and their validation which are specific to the characterisation of 
Trastuzumab. However, this assessment should be included in a stability study design 
that sets out to increase the shelf-life of a drug infusion. The acceptance criteria in this 
context are that the infusion must remain free visible particles or precipitation and 
retain colour and clarity of initial infusion examination (day 0) (USP 2009). 
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In this study there were no noticeable changes in appearance for all infusion bags at 
concentrations of clinical relevance (6.0 mg/mL and 0.5 mg/mL) over 43 day’s 
storage. In contrast the Trastuzumab infusions at the concentration of 0.1 mg/mL 
developed visible particles with the solution remaining clear and colourless. This 
could be observed with the naked eye in all 0.1 mg/mL bags after 14 days. This 
suggests that the appearance of particulate matter may be a result of the Trastuzumab 
and excipients being highly diluted at this infusion concentration.  
 
Subsequent studies by other authors showed that Trastuzumab infusions remained 
unchanged during storage with respect to their visual appearance (Kaiser & Kramer 
2011; Pabari et al. 2013). Although the method details are not stated and therefore it is 
not known if a compendia method was employed as in this study. All these studies, 
having various storage periods, used a range of concentrations which appropriately 
included therapeutic high and low concentrations of Trastuzumab. Kaiser and Kramer 
(2011) used 0.4 mg/mL and 4 mg/mL with a 28 day storage period. Whilst Pabari et 
al. (2013) used the same concentrations with the addition of a 1.0 mg/mL infusion 
with a 28 day test period. The final study to be compared is a long-term stability study 
of Trastuzumab infusions (Paul et al. 2013). Paul et al. (2013) stored Trastuzumab 
infusions at the concentrations of 0.8 mg/mL and 2.4 mg/mL for 6 months but did not 
include or reported on visual examination as part of the study design. 
 
The consensus conclusion of the published work, where visual examination was 
included, and with this study is that the visual appearance of the stored Trastuzumab 
infusions did not change over a period of 28 days. Furthermore, in this study it was 
shown that the appearance remained clear and colourless with no precipitate beyond 
the study period of 43 days. 
 
 
 
3.3.4 Sub-visible particle analysis 
Sub-visible particles as soluble aggregates, Trastuzumab monomer concentration and 
degradation were assessed using size exclusion liquid chromatography (SE-LC). 
Trastuzumab dimer is presented as a percentage of the initial Trastuzumab monomer 
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concentration (table 3), thus allowing the monomer purity to be determined. 
Aggregate content did not increase over time during the study. This is indicative of 
the Trastuzumab infusions retaining stability in terms of a relatively stable dimer 
concentration and absence of larger aggregates. This behaviour is consistent with the 
dimer being in dynamic equilibrium with the monomer which will be concentration 
dependent (Cromwell et al. 2006). This is shown in table 3 where the dimer content is 
greater at the higher concentration of 6 mg/mL. The larger aggregate species may 
become precursors of macroscopic sub-visible particles as the latter must grow from 
smaller aggregates such as the dimer via higher order or intermediate aggregates 
(Philo & Arakawa 2009). Thus it may be expected that if the aggregate levels remain 
unchanged the probability of visible particles forming should remain low. However, 
visible particles were observed early in the study after 7 days with the sub clinical 
infusion at the concentration of 0.1 mg/mL. This concentration is discussed separately 
in section 3.4.1 page 100. 
 
 
Day 
Percentage Trastuzumab Aggregate (dimer)/ % 
0.5 mg/mL infusion 6 mg/mL infusion 
0 0.1 0.27 
7 0.2 0.29 
14 0.2 0.29 
28 0.0 0.22 
35 0.0 0.30 
43 0.2 0.28 
119 0.1 0.30 
 
Table 3 Percentage aggregate dimer at each time point for 6 mg/mL and 0.5 mg/mL 
infusions over the 43 day study period. 
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The results of the quantitative assay of the Trastuzumab monomer is shown in table 4. 
It can be seen that there is no evidence of degradation of the stored samples had 
occurred. On the contrary monomer content appeared to have increased. This may 
indicate that the Trastuzumab aggregates have dissociated over time during storage. 
After dilution these aggregates would be expected to dissociate or re-dissolve over 
time due to their none-covalent nature. Furthermore, the extent of dissociation or 
dimer content would be expected to be dependent on concentration or dilution of 
Trastuzumab as stated previously.  This is supported by the difference in aggregate 
content between the 6 mg/mL and 0.5 mg/mL infusions (table 3 and figure 1). The 
difference in dimer content between these infusions was significant (p = 0.007, using 
a t-Student test with a significance threshold of < 0.050). However, the apparent 
increase in Trastuzumab monomer was not accompanied by a decrease in percentage 
aggregate content (table 3). A non-significant positive correlation was found with 
both concentrations between monomer and dimer content (Pearson’s correlation 
coefficient (r) was 0.19 and 0.35 for 0.5 mg/mL and 6 mg/mL infusions respectively). 
This is illustrated by the correlation graphs for each infusion which show no 
relationship between monomer and dimer content (figures 2 and 3). 
 
These observations may indicate that other aggregate species are present in the freshly 
prepared infusions which are too large to be detected by SE-LC. Indirectly this infers 
the presence of sub-visible particles which may dissolve and increase monomer 
content. This seems a reasonable assumption as the freshly reconstituted Trastuzumab 
will likely contain aggregates originating from the lyophilised solid form and may 
form new aggregates during reconstitution at the vial concentration (21 mg/mL) 
(Webb et al. 2002; Daugherty & Mrsny 2006). Furthermore, due to the reliance on 
self-mixing full dissolution of particulates may take some time. 
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Figure 1 Percentage dimer at each time point for 0.5 mg/mL and 6 mg/mL infusions. 
Standard error is shown with inferential error bars. 
 
 
 
 
 
Figure 2 Correlation graph of dimer content with monomer content for the 0.5 
mg/mL infusion. Standard error bars shown 
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Figure 3 Correlation graph of dimer content with monomer content for the 6 mg/mL 
infusion with standard error bars. 
 
 
 
Table 4 SE-LC determination of Trastuzumab monomer as percentage of initial 
Trastuzumab assay (relative standard deviation for 3 injections each for two infusion 
bags) at each time point for 6 mg/mL and 0.5 mg/mL infusions over the 43 day study 
period.  
Day 
 
Percentage Trastuzumab (monomer)  / % 
 
0.5 mg/mL 6 mg/mL 
 
0 
Method 1 
100.0 
Method 2 
100.0  
Method 1 
100.0 
Method 2 
100.0 
7 96.7 (3.1) 100.4 (0.6) 94.8 (0.5) 102.3 (1.2) 
14 97.9 (3.4) 100.6 (0.3) 96.1 (0.9) 101.1 (1.9) 
28 95.6 (3.6) 99.8 (0.7) 95.1 (0.4) 100.9 (1.2) 
35 100.0 (3.6) 100.4 (0.2) 100.1 (1.1) 101.6 (1.1) 
43 101.9 (8.0) 101.2 (0.4) 96.6 (1.0) 101.9 (1.1) 
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Size exclusion chromatography is employed as one of the reference procedures in the 
proposed USP summary validation report for Trastuzumab (USP 2013). The role of 
SE-LC in the USP document is to detect product related impurities, referred to as 
species with a higher molecular mass than that of Trastuzumab, in freshly 
reconstituted Trastuzumab. These impurities correspond to the aggregate species 
which may dissociate or form and increase in size when in-use and in storage. 
Therefore these species should be monitored to aid the assessment of the condition of 
the stored Trastuzumab infusions.  
 
The size exclusion chromatography methods employed showed that there was no 
evidence of degradation of Trastuzumab infusions at therapeutic concentrations 
during storage.  There was no significant loss in Trastuzumab monomer concentration 
or increase in aggregation and an absence of fragmentation peaks in all these 
infusions.  
 
In fact an increase in Trastuzumab monomer concentration was apparent during the 
study. The increase in monomer content was observed after day 7 with method 2 
(QCNW) and day 35 with method 1 for both 0.5 mg/mL and 6.0 mg/mL infusions. 
This behaviour may be due to the differences in sample preparation between the two 
methods. 
 
In method 2 the test solutions were highly diluted before chromatographic separation. 
This treatment may increase dissolution rate of aggregates which occurs over time. 
Furthermore, this view may be supported by the delayed increase in monomer content 
found by method 1. This behaviour may in some part be reflected in and consistent 
with the measured variance and relative standard deviation differences between the 
methods. 
 
The monomer assay for the 6.0 mg/mL infusion, using method 1, gave a variance of 
5.7 % and relative standard deviation of 2.2 % with initial measurement set at 100 %. 
Whereas analysis of the 6.0 mg/mL infusion by method 2 gave a variance of 0.6 % 
and relative standard deviation of 0.7 %. The 0.5 mg/mL infusion showed a similar 
difference between the variance and relative standard deviation for the two methods. 
Method 1 gave 4.6 % and 2.2 % for variance and relative standard deviation 
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respectively. Whilst method 2 had a variance and relative standard deviation of 0.2 % 
and 0.4% respectively. 
 
The other studies which have been compared to this study also show no evidence of 
degradation with SEC-LC under controlled in-use storage conditions between 2 oC 
and 8 oC (Kaiser & Kramer 2011; Pabari et al. 2013; Paul et al. 2013). Furthermore, 
Paul et al. (2013) state that no significant changes in the chromatogram, with 
detection at 280 nm, occur when stored at 20 oC under light protection for 6 months. 
However,  SE-LC with detection at 280 nm is not sensitive to aggregation (Bond et al. 
2010). 
 
 
 
3.3.5 Attenuated Total Reflectance Infra-Red Spectroscopy (ATR-FT-IR): 
Assessment of changes in Trastuzumab secondary structure 
 
The Amide I spectrum remained unchanged for all stored samples. This may indicate 
that no significant secondary changes had occurred. This was consistent with the view 
that aggregation resulted in aggregates that retained secondary structure. This was 
supported by the results of the monomer assay and aggregate SE-LC analysis showing 
reversibility of the dimer. However, very small changes may have occurred within the 
infusion and are undetectable. Therefore a difference spectrum method was applied 
which can reveal very small changes between spectra. 
 
The difference spectrum is the result of subtracting two spectra of two different states. 
If there are no changes the resultant spectrum will be featureless and centred on the 
zero datum. In this case a spectrum from time point 0 was subtracted from the 
spectrum acquired at different time points for day 7, 42 and 119. Small changes are 
revealed and can become manifest as positive or negative spectral features. For 
example, increase or appearance of new structure will be revealed by a positive 
spectral signature. Conversely loss of structure will result in a negative spectral 
features. 
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The difference spectrum for the samples resulted in the appearance of new spectral 
features at day 7. These were predominantly two peaks in the Amide A and Amide I 
regions. A control difference spectrum of two different 0.1 mg/mL infusion bags 
spectra acquired for day 0 showed no new spectral features. This confirmed that the 
new spectral features had appeared during the first week of storage. 
 
The amide peak at ~1,640 cm-1 is within the intramolecular β-sheet region (Vonhoff et 
al. 2010). This indicates β-sheet content has increased. This implies that the 
Trastuzumab molecule has undergone conformational rearrangement and increased in 
order (Sethuraman & Belfort 2005). The amide A band originates exclusively from 
NH stretching and is isolated from the polypeptide back bone and therefore indifferent 
to conformation (Barth & Zscherp 2002).  
 
There was no discernible relationship between the extent of these peaks, which varied 
in intensity, and the concentration. Figure 1 shows difference spectra relative to day 0 
for a 0.1 mg/mL infusion for spectra acquired at day 7, 43 and 119. For this series of 
spectra the amide peak disappeared after 7 days (figure 4). In figure 5 for a 6 mg/mL 
infusion sample the amide I peak has been retained for all time point samples. For 
another 6 mg/mL infusion bag there was no discernible peak at 1,640 cm-1. The amide 
A peak was prominent and showed a time dependency increase for each day. In one of 
the two 0.5 mg/mL infusion bags there was a small loss in structure, evident by the 
small negative peak in the amide I region. A similar observation was also apparent in 
one of the four 0.1 mg/mL infusions. This may be related to the lower concentration 
and is discussed in section 3.3.1. 
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Figure 4 ATR-FT-IR difference spectra of 0.1 mg/mL infusion. Spectrum from time 
point 0 was subtracted from the spectrum acquired at different time points for day 7 
(black), 42 (red) and 119 (green). Spectra shows amide A (1) and amide I (2) peaks. 
Amide I peak has diminished for day 42 and 119. 
 
 
 
1   2 
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Figure 5 ATR-FT-IR difference spectra of 6.0 mg/mL infusion sample. Spectrum 
from time point 0 was subtracted from the spectrum acquired at different time points 
for day 7 (black), 42 (red) and 119 (green). Spectra shows amide A (1) and amide I 
(2) peaks. Amide I peak has stayed constant for day 7, 42 and 119. 
 
 
 
 
Although not stability indicating the ATR-FTR-IR results do indicate that 
Trastuzumab has changed in structure to a varying degree on dilution within an 
infusion solution. Furthermore, these changes are generally indicative of increased 
order within the molecule. 
 
ATR-FT-IR spectroscopy was used to assess the secondary structure of the stored 
infusions. This entailed examination of the conformation sensitive Amide I region 
(1600 cm-1 - 1700 cm-1).  
 
The ATR-FT-IR spectra for both reference spectra acquired using freshly prepared 
Trastuzumab solutions and from samples from each time-point were superimposable. 
1   2 
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When difference spectra were generated new spectral features after day 7 were 
observed. These were in the Amide A and Amide I regions. The amide peak at 
~1640cm-1 is within the intramolecular β-sheet region (Vonhoff et al. 2010).  
Although there was no apparent trend with respect to peak size of these features with 
concentration this may indicate a minor change in structure. This may have resulted 
from internal reorganisation of the Trastuzumab molecule following dilution and 
hydration. This view is consistent with the appearance of the Amide A band in the 
difference spectrum. This peak originates from the NH stretch doublet, which is 
insensitive to conformation, but sensitive to hydration and thus obscured by the OH 
stretching band from H2O molecules in the resultant difference spectrum. 
 
Paul et al. (2013) also found reference and sample spectra superimposable during 
their study. Although Pabari et al. (2013) did not perform FTIR in their study they did 
assess the secondary structure using circular dichroism (CD). Pabari et al. (2013)  
found that the CD spectra did not change and this result is consistent with native 
structure being maintained throughout the 28 day storage period. The CD spectral 
signature also originates from the amide but is in the far-UV region (190 – 250 nm). 
The CD signal is determined by the amide group being in an ordered molecular 
environment and therefore reports on secondary structure (Barnes 2012).  
 
These studies provide convincing evidence that the secondary structure of 
Trastuzumab infusions stored between 2 oC and 8 oC have remained unchanged. 
Furthermore, the results of these studies are consistent with the apparent 
conformational stability at 20 oC reported by Paul et al. (2013). 
 
 
 
3.3.6 Electrophoresis SDS-PAGE: Trastuzumab degradation (fragmentation 
and aggregation) 
 
Electrophoresis under both none reducing and reducing conditions of 0.5 mg/mL and 
6 mg/mL infusion samples at each time point showed no change in band distribution 
compared to reference Trastuzumab. This indicates no observable levels (within 
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sensitivity range of 5 to 50 ng) of Trastuzumab degradation products, such as higher 
aggregation or fragmentation, were present in the samples from the infusion bags. 
 
 
 
 
Day 
Visual appearance of gel plate Pass/Fail 
0.5 mg/mL infusion 6 mg/mL infusion 
0 Pass Pass 
7 Pass Pass 
14 Pass Pass 
28 Pass Pass 
35 Pass Pass 
43 Pass Pass 
 
Table 5 Visual appearance of gel plate reported as Pass/Fail with reference to 
acceptance criteria for the 6.0 mg/mL and 0.5 mg/mL infusions over the 43 day study 
period.  
 
 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis may detect degradation 
by the appearance of band smearing but is often qualitative in its interpretation 
(Barnes 2012). 
 
SDS-PAGE was performed under both none-reducing and reducing conditions to 
assess the infusion samples at each time point. The resultant gels showed no change in 
band distribution or presence of band smearing and were equivalent to those of the 
freshly prepared reference Trastuzumab gels within sensitivity range of 5 to 50 ng. 
Under none-reducing conditions a single band at ~150 KD was observed which is 
consistent with the molecular weight of the intact Trastuzumab molecule. In contrast, 
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under reducing conditions the Trastuzumab molecule degrades into the component 
light and heavy chains as anticipated. This results in two bands corresponding to the 
light and heavy chains at 25 KD and 50 KD respectively. 
 
This result was also shown in the studies by Pabari et al. (2013) and Kaiser and 
Kramer (2011). The use of SDS-PAGE in all these studies, including this study, may 
provide evidence that Trastuzumab remains intact as commented by Kaiser and 
Kramer (2011). However, it is questionable that small changes in glycan content 
could be detected using this technique (Nebija et al. 2014). This is an important issue 
as the glycan profile is known to be influential on the functionality of the 
Trastuzumab molecule (Barnes 2012). 
 
 
 
3.4 Stability of sub-clinically relevant infusion (0.1 mg/mL) and original vial 
concentrate (21 mg/mL) 
 
3.4.1 Stability of sub clinically relevant infusion (0.1 mg/mL) 
 
The 0.1 mg/mL showed instability early in the study. Visible particles were observed 
in all bags within 14 days of the study and increased as the study progressed. This was 
accompanied by loss of Trastuzumab monomer and a decrease in pH (table 6). 
However, the pH values remained in the specification range of 5.4 to 6.6 pH units for 
reconstituted Trastuzumab at 21 mg/mL vial concentration (Roche 2006) (table 6). In 
contrast both reducing and none reducing electrophoresis (SDS PAGE) showed no 
evidence of degradation (table 6). This is consistent with aggregate disassociation 
which may occur during the considerable sample manipulation with this technique  
(Philo 2006; Das 2012). Furthermore, particles must be solubilised in the SDS 
detergent for any changes to the protein to be detectable (Das 2012).  
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0.1 mg/mL infusion 
Day 
Visual 
appearance 
Pass/Fail 
Percentage 
Trastuzumab 
(monomer) / 
% 
pH 
SDS PAGE 
Visual 
appearance of 
gel plate 
0 Pass 100.0 6.11 Pass 
7 Fail 98.8 (1.1) 5.73 Pass 
14 Fail 97.3 (0.7) 5.71 Pass 
28 Fail 95.5 (0.7) 5.66 Pass 
35 Fail 95.2 (1.2) 5.70 Pass 
43 Fail 94.2 (0.7) 5.87 Pass 
 
Table 6 Percentage monomer with relative standard deviation for 3 injections and pH 
at each time-point for 0.1 mg/mL Trastuzumab infusion.  
 
 
 
The decrease in pH on day 7 is maintained until a recovery on day 43. The pH data 
gave a mean and standard deviation of 5.80 +/- 0.17, thus presenting a significant 
change in pH greater than measurement scatter. The loss of monomer with time was 
highly linearly correlated (Pearson’s correlation coefficient (r) = -0.99). In addition 
the correlation of monomer loss with pH was strong (Pearson’s correlation coefficient 
(r) = 0.78) up to day 35 and decreased to moderate (r = 0.51) with inclusion of pH at 
day 43. These results are consistent with decreased stability at lower concentration. 
This may be due to the further dilution of excipients decreasing buffering capacity 
and the protection of polysorbate (Garidel et al. 2009; Bee et al. 2011). 
 
Evidence of degradation was also shown by the percentage monomer and dimer by 
relative peak area (table 7). The data gives a strong negative correlation of monomer 
content over time (Pearson’s correlation coefficient (r) = -0.69). The converse is 
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shown for the dimer content due to the relative relationship between monomer and 
dimer. 
 
 
 
 
Percentage monomer and dimer for 0.1 mg/mL 
Trastuzumab infusion 
Day  Monomer / % Dimer / % 
0 99.98 0.02 
7 99.96 0.04 
14 99.89 0.11 
28 99.98 0.02 
35 99.99 0.01 
43 99.61 0.39 
119 99.67 0.33 
 
Table 7 Percentage monomer and dimer by relative peak area for the 0.1 mg/mL 
Trastuzumab infusion. 
 
 
 
In contrast no significant changes in the secondary structure was shown by ATR-FT-
IR. However, difference spectra revealed a small negative change in spectral feature, 
in the amide I region, in one of the four 0.1 mg/mL Trastuzumab infusions (figure 
6A). This was also found with a 0.5 mg/mL infusion shown in figure 6B for 
comparison.  
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Figure 6 Difference spectra of A 0.1 and B 0.5 mg/mL infusions for day 7 (black), 42 
(red) and 119 (green).  
 
 
 
These features were accompanied by a relatively large negative change in the amide 
A region. This may indicate a decrease in hydration (Barth & Zscherp 2002). The 
A 0.1 mg/mL infusion 
B 0.5 mg/mL infusion 
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remainder of the 0.1 mg/mL infusions showed positive changes (figures 7, 8 and 9) 
similar to the 6 mg/mL infusions (figure 2). 
 
 
 
 
 
 
Figure 7 Difference Spectra for 0.1 mg/mL infusion (bag 1). 
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Figure 8 Difference spectra for 0.1 mg/mL infusion (bag 2). 
 
 
 
 
Figure 9 Difference spectra for 0.1 mg/mL infusion (bag 4). 
 
  
106 
 
3.4.2 Percentage dimer content of original vial concentrate (21 mg/mL) 
 
The percentage dimer content by SE-LC remained constant during the study period of 
43 days (table 8). Furthermore there was no change in dimer content during long term 
storage after 119 days under conditions of refrigeration (table 8). 
 
 
Day Percentage Trastuzumab (dimer) / % 
0 0.1 
7 0.3 
14 0.4 
28 0.3 
35 - 
43 0.3 
119 0.3 
 
Table 8 Percentage dimer for the original vial concentrate (21 mg/mL) over the study 
period. 
 
 
 
3.5 Stability of clinically relevant infusions at room temperature 
 
The NHS QCNW infusions showed satisfactory stability at room temperature with 
light and agitation. The pH remained within specification (table 9). The initial pH at 
the beginning of the study is shown for comparison (table 9). The pH after stress 
generally remains in the range found during the study (5.88 to 6.04 for the 0.5 mg/mL 
infusion and 6.21 to 6.29 for the 6 mg/mL infusion). However, the 0.5 mg/mL 
infusion showed an increase in pH for the light exposure test compared to the light 
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protected result at room temperature. This gave two approximate standard deviations 
higher from the mean (5.94+/-0.06) for the 6.07 result. Although a relatively small 
difference, this may reflect the dilution of excipients. This view is reasonable as the 
pH for the 6 mg/mL infusions with light protection and light exposure was very 
similar, although showing a small decrease for light exposure. Agitation showed little 
effect on pH.   
 
 
 
 
Table 9 Stability of clinically relevant infusions. The pH at room temperature (RT): 
after exposure to light (24 hours), without light (24 hours) and agitation with exposure 
to light for 6 hours. 
 
 
Conditions 
 
pH of Trastuzumab infusions 
 
0.5 mg/mL 6 mg/mL 
Initial 6.04 6.23 
 Day 43 5.94 6.29 
Exposed to 
light for 24 
hours at RT 
6.07 6.21 
Light 
protected 
for 24 hours 
at RT 
5.98 6.23 
Exposed to 
light with 
agitation for 
6 hours at 
RT 
5.95 6.20 
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The SDS-PAGE showed no differences between stressed and control plates (table 10).  
 
 
 
Conditions 
 
SDS PAGE analysis of Trastuzumab infusions 
Visual appearance of gel plate Pass/Fail 
0.5 mg/mL 6 mg/mL 
Exposed to 
light for 24 
hours at RT 
Pass Pass 
Light 
protected for 
24 hours at 
RT 
Pass Pass 
Exposed to 
light with 
agitation for 6 
hours at RT 
Pass Pass 
 
Table 10 Aggregate and fragmentation analysis of clinically relevant infusions. 
Electrophoresis of samples taken from infusion bags after being subjected to stress 
conditions at room temperature (RT). 
 
 
 
SEC-LC did not show evidence of degradation (table 11) compared to the variation of 
monomer content during the study period (table 4). This was reported as percentage 
loss of monomer (table 11). The percentage decrease of monomer was within the 
acceptance limit of 5% (Barnes 2012). 
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Conditions 
 
Percentage loss of Trastuzumab monomer / % 
 
0.5 mg/mL 6 mg/mL 
Exposed to light 
for 24 hours at 
RT 
1.0 1.2 
Light protected 
for 24 hours at 
RT 
1.7 1.1 
Exposed to light 
with agitation 
for 6 hours at 
RT 
1.5 0.5 
 
Table 11 Percentage loss of monomer as determined by SEC-LC after further stability 
testing of infusions. 
 
 
 
3.6 Conclusions 
 
The clinically relevant concentration infusions, 0.5 mg/mL and 6 mg/mL, remained 
free of visible particles (table 2). Furthermore, the clarity and colour observed at day 0 
was retained (table 2). Sub-visible particles as soluble aggregates, as determined by 
SE-LC, did not increase during the study (table 3). Additionally, there was no 
indication of monomer loss (table 4). SDS-PAGE did not show evidence of 
aggregation or fragmentation (table 5). The pH of the clinically relevant infusions was 
relatively constant during storage (table 1), with the 0.5 mg/mL infusion giving a 
slightly lower pH over the study period (table 1).  
 
The sub-clinically relevant 0.1 mg/mL concentration infusions developed particles 
from day 7 (table 6). Whilst SDS-PAGE did not detect aggregation or fragmentation 
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(table 6). Particulate formation was accompanied by a decrease in monomer (table 6) 
and increase in dimer content during storage (table 7). In contrast, the original vial 
concentrate showed no change in dimer content during the study period of 43 days 
and long term storage after 119 days (table 8). 
 
All infusions showed very small positive (figures 4, 5, 7, 8 and 9) or negative changes 
(figures 6A and 6B) in their difference spectra. 
 
The NHS QCNW infusions showed satisfactory stability at room temperature with 
light and agitation in terms of pH, aggregation levels and loss of monomer (tables 9, 
10 and 11). 
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CHAPTER 4 
 
 
4. DEVELOPMENT OF CELLULAR ASSAY 
 
4.1 INTRODUCTION 
 
The aim of this study was the development of a cellular assay that is appropriate to 
measure changes in potency of Trastuzumab. It is essential to consider the mechanism 
of action of Trastuzumab with an appropriate cell line to select the most suitable end 
reporter assay. 
 
Trastuzumab binds to the HER2 receptor on the cell surface inhibiting dimerisation 
and is targeted towards cells that over-express this cellular receptor (Goldenberg 
1999; Nahta 2012). Dimerisation is the key step in the cell signalling pathways which 
stimulate cell reproduction (Sundaresan et al. 1999; Genentech 2015). Therefore in 
assay design cellular growth (viability and proliferation) was selected as an end 
reporter of effective binding and action of Trastuzumab. There are other processes 
subsequent to Trastuzumab binding to the HER2 receptor. These processes involve 
the immune system in vivo and are not detected by the cellular assay used in this 
study. 
 
The selection of the level of dose for an assay can prove demanding (Barnes 2012), 
whilst referring to the equilibrium dissociation constant (kD) may aid this process. The 
equilibrium dissociation constant kD for Trastuzumab is 5 nM (De Lorenzo et al. 
2004). This means a concentration of 5 nM gives a 50% binding of the HER2 
receptors. Thus this gives some idea of what may be a clinical and sub-clinical dose. 
 
Another factor in designing the assay was the selection of an appropriate read-out to 
assess cellular growth. There are different types of assay read-out which include 
colony counting (Franken et al. 2006) or measurement of the enzymatic turnover of a 
substrate to a coloured product  (Riss et al. 2004). 
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In the case of Trastuzumab a number of cell-lines could be used (Subik et al. 2010). 
The BT474 cell line which over-expresses the HER2 receptor (Sundaresan et al. 1999; 
Subik et al. 2010) was selected. This receptor is the therapeutic target for the drug 
(European Agency for the Evaluation of Medicinal Products (EMEA) 2005b; Reichert 
2012). Following the cell line selection the type of assay has to be selected with 
careful consideration. Cell proliferation was originally selected as a reporter of drug 
potency for the BT474 cell line. Following initial work this was later changed to 
viability. It should be noted that preliminary work was performed using the MCF7 
cell line. MCF7 is an example of an adherent breast cancer cell line. Although this 
cell line does not over-express the HER2 receptor and is therefore unsuitable, it 
enabled the development of cell culture techniques and also methodology of the 
proliferation assay. Due to significant differences in growth characteristics between 
MCF7 and BT474 the early work had ultimately little relevance to the work with 
BT474. 
 
In a proliferation assay the ability of an individual cell to form colonies is assessed, 
i.e. the number of cells that are dividing to form colonies. These colonies will increase 
in size at a rate determined by the ability of the cell to divide. After an incubation or 
growth period colonies will vary in size depending on their individual capability for 
cellular division. If a lower limit of colony size is defined a count of colonies above 
this size threshold will be a measure of the number of actively dividing cells within 
the cellular population. 
 
Figure 1 shows colony counting in practise from this study. In this example colonies 
are counted using an inverted light microscope using phase contrast. The micrograph 
shows fixed and stained BT474 colonies at x100 magnification after a 14 day 
incubation or growth period within a 6-well micro-plate. Wells were filled with a cell 
suspension in media to give 100,000 cells per well. This process is termed seeding. 
The 50 µm diameter circles defines the size of a colony that may be included in a 
colony count. The circles numbered 1 and 2 are colonies that are below the size 
threshold. The circles numbered 3 and 4 would be included in a count.  
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Figure 1 Micrograph of fixed and stained BT474 colonies at x100 magnification after 
a 14 day incubation or growth period within a 6-well micro-plate. Wells were seeded 
with a cell density of 100,000 cells per well. The 50 µm diameter circles defines the 
size of a colony that may be included in a colony count. The circles numbered 1 and 2 
are colonies that are below the size threshold. The circles numbered 3 and 4 would be 
included in a count. Colonies were imaged using an inverted microscope and imaging 
system (Nikon Eclipse T100 binocular phase contrast microscope fitted with Digital 
Sight DS Fi1 imaging system). 
 
 
 
 
In contrast cellular viability was reported from a measure of the number of live or 
metabolising cells following incubation with and without the presence of 
Trastuzumab (Kawa et al. 2009). Changes in the biological potency of Trastuzumab 
can be described in terms of the effect on cellular viability. With fully active 
Trastuzumab, freshly prepared, cell proliferation and viability will be affected by the 
greatest extent. Any degradation of drug during storage could result in a decreased 
effect on cell proliferation and viability. 
1 
2 
3 
4 
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The ability of detecting a change in proliferation and viability is dependent on the 
sensitivity of the methods employed and the magnitude of change. In this study a 
colorimetric reporter read-out was used to assess cellular viability. The reporter 
chemistry selected was a commercial kit supplied by Sigma Aldrich (CCK8) which 
has high sensitivity in terms of read-out and is a variant of the much published MTT 
assay (Lin et al. 2005; Brescia & Banks 2009; Budman et al. 2007; Barnes 2012). 
Sensitivity will be affected by both repeatability in precision of the number of cells 
used in replicate experiments and the intrinsic sensitivity of the readout method 
employed. With the colorimetric readout approach adopted in this study the variability 
in the optical density measurement between successive readings of the same well 
provides an indication of the uncertainty in measurement. This uncertainty will limit 
the sensitivity of measurement. 
 
A significant amount of time was devoted to developing a robust cell delivery 
technique to ensure consistency in seeding cells within the 96-well plates used for the 
cellular assays. The cell seeding consistency was evaluated by using the same CCK8 
cell counting kit (Sigma Aldrich) and a Haemocytometer to measure the numbers of 
cells in each well of a 96-well plate. The approach that was developed in the study 
allowed characterisation of cell growth and provided a means to quantify viability 
using repeatable calibration curves over range of cell densities. This enabled both 
qualitative and quantitative assessment of cell growth. The strategy taken forward in 
this study included both cell viability and cell proliferation approaches were initially 
developed and cell viability selected for the final study.  
 
 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Preparation of Trastuzumab (Herceptin®) 
 
 
Trastuzumab was reconstituted as described in Chapter 2 section 2.2.1 page 51. 
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4.2.2 Cell lines  
 
The MCF7 breast cancer cell line was a kind gift from Dimitra Dafou (University 
College London). This cell line originates from the Massachusetts Cancer Foundation 
(MCF7) and was selected because the cells express the HER2 receptor which is the 
therapeutic target of Trastuzumab and this cell line is often used and cited in breast 
cancer literature (Holliday & Speirs 2011). The MCF7 cells exhibited rapid cell 
growth which was a desirable feature as this aided the development phase when 
establishing the cell culture methods.  
 
The BT474 breast tumour (human ductal tissue (epithelial) carcinoma) cell line from 
ATTC (HTB-20; lot: 58471910) was selected as the actual cell line for performing the 
potency testing of Trastuzumab. This cell line is superior to the MCF7 cell line for 
testing because BT474 cancer cells over-express the HER2 surface cell receptor 
which is the therapeutic target for Trastuzumab (anti-HER2 antibody) (Sundaresan et 
al. 1999; Subik et al. 2010).  
 
 
4.2.2.1  Reviving cells from cryogenic storage 
 
The selected vial was retrieved from cryostasis and warmed in a water bath (37 °C) 
for a few minutes until contents had liquefied. The submerging of the vial was 
avoided to reduce risk of contamination. Once the vial contents were completely 
thawed, the contents (~1 ml) were removed and diluted into a cell culture flask, 
containing pre-warmed (37 °C) media. The cells were incubated overnight to allow 
attachment of cells and the media exchanged (6 ml). Both cell lines were further 
passaged as and when required. Passaging is the process where the adherent cells are 
released and/or transferred between flasks when the growth area is beginning to 
merge or become confluent. The cells were passaged at approximately 60% 
confluence or coverage of the area available for growth described in section 4.2.2.4 
page 116. 
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4.2.2.2 Maintenance of BT474 Cells 
 
The BT474 cells were cultured in RPMI 1640 base growth media with stable 
glutamine and phenol red pH indicator (PAA Labs; E15-885: E88510-3009) 
supplemented with 10% foetal bovine serum FBS Gold (PAA Labs FBS; A11-151; 
lot: A15111-2028)  and 1% Penicillin/streptomycin (PAA Labs; P11-010; lot: 
P01009-2794). BT474 cells were incubated at 37 °C in a humidified 5% carbon 
dioxide incubator (Sanyo NC0-19AIC (UV)). The cells were grown and maintained in 
75 cm2 (growth area) tissue culture flasks (SPL Life Sciences; PAA 430641) until 
60% confluence and then passaged (released to give a cell suspension). The 
suspension was then transferred and distributed within two or three 75 cm2 tissue 
culture flasks (SPL Life Sciences; PAA 430641) or used in an assay. 
 
 
4.2.2.3 Maintenance of MCF7 Cells 
 
The MCF7 cells were cultured under the same conditions as the BT474 cell line 
(section 4.2.2.2 page 116) 
 
 
4.2.2.4 Cell Passage and Seeding of BT474 cells 
 
The BT474 cell growth media was removed by aspiration using a glass Pasteur pipette 
attached to plastic tubing and connected to plastic waste reservoir which was 
connected to a pump (Progen: article number 31200005 serial number 0638002367). 
The BT474 cells were then washed once with phosphate buffered saline (5 mL) (PBS, 
Dulbecco H00211-0079) delivered using a sterile disposable serological pipette or 
Strippete® (Corning Costar® Blue 4051 5 mL). Washing the BT474 cells removes any 
residual media which would otherwise inhibit the action of the trypsin.  The BT474 
cells were then released from the flask growth surface using an  addition of 0.05% 
trypsin in 0.02% ethylene diamine tetra-acetic acid/phosphate buffered saline 
(EDTA/PBS) solution (2 mL) (PAA Labs; L11-004; lot: L00410-2467). The cells 
were incubated at 37 °C for 5 minutes to assist release and then the trypsin was 
neutralised using an addition of growth media (20 mL) to the BT474 cell suspension. 
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The serum present in the media inhibits trypsin activity. The BT474 cellular 
suspension was gently agitated by the action of a rocking motion of the flask 
combined with the careful use of a sterile disposable serological pipette or Strippete® 
(Corning Costar® Red 4251 25 mL) to repeatedly withdraw and expel the suspension 
to ensure separation of cells to give a single cell suspension.  The resultant BT474 cell 
suspension is either distributed between a numbers of flasks depending on the degree 
of splitting required or diluted to required concentration and used for seeding plates.  
 
A uniform BT474 cell suspension is required for accurate cell counting and consistent 
seeding. The cell density or number of cells per unit volume was then determined 
using a Bright-Line Haemocytometer (20 µL loading capacity, Sigma Aldrich; 
product code Z359629) and standard counting protocol (Sigma Aldrich, 2012). The 
BT474 cell suspension was then serially diluted to a concentration of 50,000 cells/mL. 
The BT474 cell suspension was continually agitated during this process, as described 
above, to ensure a uniform distribution of cells and hence the target cell density or cell 
number would be achieved. For the final protocol a 0.2 mL aliquot of the same cell 
suspension was added to each of the 96 wells of a micro well plate (NunclonΔ Tissue 
Culture 96F; 167008; batch: 075127) using an 8-channel multi-pipette (Biohit, 30-300 
µL serial no: 725140 Cat No: 6545280) giving 10,000 cells per well. The 96 well 
plates were incubated for 24 hours to give time for the cells to attach or adhere on the 
growth surface and adopt normal cellular activity. The wells were inspected to assess 
the quality of seeding and health of cells using an inverted microscope (Nikon Eclipse 
T100 binocular phase contrast microscope fitted with Digital Sight DS Fi1 imaging 
system).  
 
 
4.2.2.5 Fixing and staining colonies of BT474 cells (Eichhorn et al. 2008) 
 
Media was aspirated or removed from the wells and the cells were washed twice with 
a phosphate buffered saline (PBS) to remove traces of media. The colonies were fixed 
with acetic acid and methanol solution (1:3) and stained with aqueous 0.5% crystal 
violet (Fisher Scientific) 25% methanol (Fisher Scientific). The wells were then filled 
with acetic acid/methanol (1:3) fixative solution and the BT474 cells plus 
acid/methanol (1:3) fixative solution incubated on the bench for 5 minutes. After this 
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time the fixative solution was removed and the stain solution was applied using a 
multi-pipette to each well (60 µL). The micro- well plates containing the staining 
solution were left undisturbed for 15 minutes to allow the staining process to take 
effect, then washed with copious amounts of water (tap water) to remove excess stain, 
rinsed with distilled deionised water (DI) and then drained and allowed to air dry 
partially inverted on a draining board. The fixing and staining process allows colonies 
to be preserved and aids visualisation for the colony formation assay (Eichhorn et al. 
2008). 
 
 
4.2.2.6 Method of stain release of crystal violet from BT474 cells and absorbance 
measurements of crystal violet at 540 nm as a measure of cell 
number/viability to calibrate instrument response for comparison to 
CCK8 reporter chemistry data  
 
The BT474 cells that were stained with crystal violet solution were treated with 
aqueous acetic acid (10%) to release the stain into solution and the released stain 
measured using a Biotek micro well plate reader (Biotek Epoch, operating Gen 5 
Software, version 1.10.8 under windows XP environment, service pack 2) at 540 nm. 
The method followed was that of a published method by Eichhorn et al (2008). The 
absorbance data was collected and then analysed using Microsoft Excel from 
Microsoft Office 2003. Re-staining of BT474 cellular colonies was performed when 
required using the same process as given above (Eichhorn et al. 2008).  
 
 
4.2.2.7 BT474 cell line colony formation assay 
 
The BT474 cell line was seeded in to a 6 well micro-plate format at cell densities 
ranging from 1000 to 500,000 cells per well. This level of seeding density proved 
optimal for colony counting purposes in the assay for the BT474 cell line. 
 
BT474 colonies (>0.1 mm) were counted using an inverted microscope (Nikon 
Eclipse T100 binocular phase contrast microscope fitted with Digital Sight DS Fi1 
imaging system) in ten random user defined fields (~1 mm) at x10 magnification (Wu 
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et al. 2002a; Hermanto et al. 2001) in addition to efforts to count colonies on the 
whole well surface. 
 
 
4.2.2.8  MCF7 cell line Colony formation assay 
 
The MCF7 cell line was seeded in to a 6 well microplate format at cell densities 
ranging from 50 to 600 cells per well. A seeding density 300 cells per well proved 
optimal for colony counting purposes in the assay for the MCF7 cell line. Seeding and 
passage procedure as for BT474 cell line. 
 
 
4.2.2.9 Method for assessing potency of an inhibitor of the MCF7 cell line for the 
development of colony formation assay protocols 
 
The MCF7 cell line was seeded at 300 cells per well in a 6 well-plate format. 
Resultant colonies were counted using either all of the surface area available on the 
micro well plate or using a user defined area and a low powered light microscope 
(Nikon Eclipse T100 binocular phase contrast microscope fitted with Digital Sight DS 
Fi1 imaging system) to aid counting. For the initial development work methanol was 
used as a known inhibitor of cell growth for the MCF7 cell line and was used at 
concentrations of 0%, 1.5% and 2.0% which were added to test micro wells within the 
6 well-plate to limit cellular growth in those wells. In this way it proved possible to 
establish a protocol for assessment of different chemical inhibitors of the cell line 
MCF7 and development of the assay protocols for use with the BT474 cell line. 
 
 
4.2.3 Method of cell counting using a commercial cell counting kit (Sigma 
Aldrich, CCK8) assay 
 
The BT474 cell line growth media was exchanged for either fresh media (200 μL) for 
the zero drug control (negative control) or seeding (calibration experiments) i.e. cells 
and media, reference Trastuzumab (positive control) which was freshly reconstituted 
in sterile water for injection (SWFI) and diluted in BT474 cell line growth media (200 
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μL) or test Trastuzumab solutions which following re-constitution in sterile water for 
injection were diluted in BT474 cell line growth media (200 μL). 
 
The micro well-plates were then aspirated to remove the media before the test 
samples were added using the glass Pasteur pipette aspirator system described in 
section 4.2.2.4 page 96. The micro well-plate was inclined vertically as possible and 
the media withdrawn from the side of the well to avoid contact with cells. The drug 
solution was added in tissue culture media (0.2 mL addition) at the appropriate 
concentration. The micro-plates were then returned to the humidified incubator at 37 
oC, 5% CO2 (Sanyo NC0-19AIC (UV)). The cells were incubated for 4 days to allow 
for growth of BT474 colonies or tested immediately. The plates were removed from 
the incubator and the cellular reporter substrate CCK8 (increased from 10 μl to 30 μl) 
(Sigma Aldrich CCK8 cell counting kit instruction leaflet) was added to each well 
using an 8-channel micro-pipette (Biohit, serial no: 725140 Cat No: 6545280) and 
incubated at 37 oC, 5% CO2 (Sanyo NC0-19AIC (UV)) for 1, 2, 4 and 20 hours. The 
absorbance was then read at 450nm according to the manufacturer’s instructions using 
a Biotek micro-plate reader (Biotek Epoch, operating on Gen 5 Software, version 
1.10.8).  
 
 
4.2.4 Optimisation of a commercial cell counting kit (Sigma Aldrich, CCK8) 
assay  method  
 
Seeding experiments using a range of cell densities were performed to assess the 
effect of an extended test period on the resultant absorbance measurements following 
addition of CCK8 reagent. This entailed testing immediately after seeding or after a 
growth period of 4 days. Absorbance was monitored at 1, 2, 4 and 20 hours after 
addition of CCK8 to monitor signal build-up and determine a working range of 
response.  
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4.2.5 Stability indicating capability of using a commercial cell counting kit 
(Sigma Aldrich, CCK8) to distinguish between differences in viability 
induced by changes in active Trastuzumab concentrations by thermal 
degradation 
 
The BT474 cell line growth media was exchanged for either fresh media (200 μL) for 
the zero drug control (negative control) or seeding (calibration experiments) i.e. cells 
and media, reference Trastuzumab (positive control) which was freshly reconstituted 
in sterile water for injection (SWFI) and diluted in BT474 cell line growth media (200 
μL) or test Trastuzumab (0.1 mg/mL) solutions which following re-constitution in 
sterile water for injection had been thermally degraded and then diluted in BT474 cell 
line growth media (200 μL) to determine the level of change in biological activity 
which may be observable. Trastuzumab was thermally stressed by heating in a water 
bath at 75 oC for a range of times (5, 10, 15 and 20 minutes) 
 
A colony formation assay using a seeding density of 10,000 cells/well, identical to the 
CCK8 assay, was performed to assess changes in proliferation and to identify the 
optimum drug concentration and stressing time for subsequent CCK8 proliferation 
assay. 
 
Samples were serially diluted in the complete cell culture media, which was used to 
maintain the cells prior to the assay, to a nominal concentration of 1 µM before serial 
dilution to the appropriate concentration range used in the stability indicating assay. 
The stressed sample and unstressed control were diluted in the range of 0.5, 1, 2 and 
100 nM. The reference Trastuzumab was diluted in tissue culture media in an 
equivalent manner to the samples.  
 
The micro well-plates were then aspirated to remove the media before adding the test 
samples as described in section 4.2.2.4 page 96. The micro well-plate was inclined 
vertically as possible and the media withdrawn from the side of the well to avoid 
contact with cells. The drug solution was added in tissue culture media (0.2 mL 
addition) at the appropriate concentration. Each sample of drug in media was added 
using replicate (n = 24) stressed drug wells to the 96 well micro-plate including 
reference standards (n = 24) and controls (no drug) (n = 32) for each plate. The micro-
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plates were then returned to the humidified incubator at 37 oC, 5% CO2 (Sanyo NC0-
19AIC (UV)). The cells were incubated for 4 days to allow for growth of BT474 
colonies. The plates were removed from the incubator and the cellular reporter 
substrate CCK8 (increased from 10 μL to 30 μL) (Sigma Aldrich CCK8 cell counting 
kit instruction leaflet) was added to each well using an 8-channel micro-pipette 
(Biohit, serial no: 725140 Cat No: 6545280) and incubated at 37 oC, 5% CO2 (Sanyo 
NC0-19AIC (UV)) for up to 4 hours. The absorbance was then read at 450 nm 
according to the manufacturer’s instructions using a Biotek micro-plate reader (Biotek 
Epoch, operating on Gen 5 Software, version 1.10.8). 
 
A seeding calibration was performed for each stability indicating assay in duplicate 
with replicate wells (n = 16) for each seeding density. The purpose of this was to 
determine the relationship between cell density and absorbance after the 4 day test 
period. The final projected cell densities (0 to 320,000 cells per well) of the 
calibration encompass the cell density range at the assay end-point to enable the 
determination of relative cell numbers within the wells which had a drug addition or 
none. The data from the assay and calibration was exported using Microsoft Excel 
2003 for further analysis. 
 
 
 
4.3 QUALITY ASSURANCE AND QUALITY CONTROL 
 
The BT474 cell line obtained had been thoroughly tested and authenticated by ATCC. 
In-house training and webinars ensured competence in cell culture knowledge and 
techniques. Documentation was kept and included SOPs, pipette calibration, details of 
feeding, frozen stock and passage number. A frozen stock from an early passage 
provided assurance of a homogeneous cell supply. Microscopic examination of cells 
on feeding, passaging and seeding provided assurance of culture health.  
 
The seeding operation was followed by cell counting, with a haemocytometer, gave 
assurance of an acceptable precision of seeding within a 6-well plate format. 
However, the absolute number of cells within the wells will be unknown. The 
colorimetric method of the CCK8 assay improves assessment of accuracy and 
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precision of seeding experiments. Linearity was assessed by calculating vertical 
deviation of data and plotted against cell number. 
 
  
4.4 STUDY LIMITATIONS 
 
The processes of Trastuzumab action which involve the immune system in vivo are 
not assessed in the cell-based assay. The processes assessed in this study induce 
apoptosis or normal cell death. Apoptosis shows variability between cells. This is 
shown even with genetically identical cells under the same growth conditions (Raj & 
van Oudenaarden 2008). 
 
The cost of Trastuzumab was a major limitation for this study putting constraints on 
repeating work outside of the main study and use of hospital compounding facility. 
 
 
4.5 RESULTS AND DISCUSION 
 
4.5.1 MCF7 and BT474 propagation and proliferation assessment 
 
4.5.1.1 MCF7 seeding and colony growth characteristics 
 
The MCF7 cell line has a rapid and evenly distributed growth characteristic allowing 
the implementation of numerous tests to aid development of test methodology.  The 
MCF7 cell line was seeded at 50 - 600 cells per well in a 6 well micro-plate format to 
find the optimal level of cell density to facilitate the counting of colonies. To aid 
singular and even distribution of the cells during seeding agitation of cell suspension 
was employed. Resultant colonies were distributed with varying success. There was a 
tendency for cells to preferentially form around the edge leaving the centre devoid of 
colonies or to gather in the centre. Delivering the cells with no agitation or a 
controlled figure of eight movement of the plate to aid distribution did not appear to 
correlate with the resultant cell or colony distribution. After many attempts some 
wells did appear to have an even distribution of diffuse and large colonies. The best 
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seeding was achieved at a density of 300 cells per well which gave a relatively even 
spread of colonies (figure 2). 
 
 
 
 
 
Figure 2 MCF7 colonies resulting from an initial seeding density of 300 cells per 
well. The photograph shows a top view of a well of a 6 well-plate with a 34.8 mm 
diameter and approximate growth area of 9.5 cm2. Cells were fixed with acetic 
acid/methanol (1:3) and stained with aqueous 0.5% crystal violet (CV) 25% methanol 
solution. 
 
 
 
4.5.1.2 BT474 seeding and colony growth characteristics 
 
The growth characteristics of this cell type were very different to that of the MCF7 
cell line. The initial revival of BT474 from cryostat stocks showed low viability and 
34.8mm diameter  
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slow growth as confluence or coverage was not achieved after several days’ 
propagation. On subsequent propagation viability and growth rate had improved 
possibly due to recovery from the revival procedure. Cellular growth produced 
inconsistent areas of stacked or layered of cells which were very unlike the behaviour 
of the MCF7 cell line. BT474 cells were seeded at densities ranging from a 1000 to 
500,000 cells per well in a 6 well microplate format. The resultant colonies were very 
small but well defined (figure 3). This was in contrast to the morphology of that found 
with the MCF7 colonies (figure 2). 
 
 
 
 
 
Figure 3 BT474 colonies resulting from an initial seeding density of 14,000 cells per 
well. The photograph shows a base view of a well of a 6 well-plate with a 34.8 mm 
diameter and approximate growth area of 9.5 cm2. Cells were fixed with acetic 
acid/methanol (1:3) and stained with aqueous 0.5% crystal violet (CV) 25% methanol 
solution. 
 
34.8mm diameter  
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The point-like appearance of the colonies was consistent with the tendency of the 
BT474 cells to stack or layer upon each other rather than spread over the flask growth 
surface during propagation. 
 
 
4.5.2 Development of MCF7 and BT474 colony formation assays 
 
4.5.2.1  MCF7 cell-line colony counting with and without methanol inhibitor 
 
Colony counting of the whole well surface was attempted but the diffuse colonies and 
overlap made the task of identifying individual colonies difficult which gave a highly 
variable and non-reproducible count. Colony counts resulting from a 300 cells per 
well seeding may vary, for example, between 113 and 154 units. Figure 4 shows the 
colonies resulting from a 300 cells per well seeding using methanol as a test inhibitor.   
 
 
 
Figure 4 MCF7 colonies resulting from an initial seeding density of 300 cells per 
well. The photograph shows a top view of a 6 well-plate in the process of colony 
counting aided by pen marking. The wells have a 34.8 mm diameter and approximate 
growth area of 9.5 cm2. Cells were fixed with acetic acid/methanol (1:3) and stained 
with aqueous 0.5% crystal violet (CV) 25% methanol solution. Well 1: 1.5% 
methanol, well 2: 2.0% methanol, well 3: 2.0% methanol, well 4: 2.0% methanol, well 
5: no methanol and well 6: no methanol.  
1 2 3 
4 5 6 
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The selection of a pre-defined randomised count area was also investigated but proved 
ineffective due to many wells having an uneven distribution of colonies. Nevertheless, 
the development of the colony formation work was continued by progressing to the 
BT474 cell-line. 
 
 
4.5.2.2 BT474 cell-line colony counting following exposure to Trastuzumab and 
placebo respectively 
 
BT474 is the target cell line which will allow the testing of Trastuzumab. Initially 
seeding experiments were carried out to determine if consistency of cell number could 
be achieved. This stage is essential before progressing to experiments assessing the 
action of inhibitors. Success of seeding was determined both quantitatively and 
qualitatively by releasing and counting cells using a haemocytometer and examining 
the resultant fixed and stained colonies respectively. The fixing and staining process 
allows unsatisfactory seeded wells to be rejected before attempting to count colonies 
or further analysis. Additionally a qualitative correlation of the degree of final colony 
growth with the level of initial seeding can be observed. Typical repeated cell counts 
for a single well were 199x104, 200x104, 180x104, and 197x104 cells per 20 μl 
volume for one seeding experiment (mean count 194 and standard deviation 8). In 
another experiment using a different flask the count was 209x104, 207x104, 198x104, 
207x104 and 151x104 cells per 20 μl volume (mean count 194 and standard deviation 
22). The last count was low due to intentionally allowing settling to show the 
importance of mixing to the procedure. Both experiments were at a 100,000 seeding 
and counted after 14 days growth. Generally cell counting with the aid of a 
haemocytometer was acceptable for assessing development of seeding technique but 
would be impracticable for the determination of viability for the shelf-life study. 
 
Colony counting of the whole well surface was attempted for seeding experiments and 
experiments using Trastuzumab and methanol as inhibitors but was found to be 
impracticable due to the large numbers involved and overlapping of colonies. The use 
of user-defined random count areas was also investigated (Wu et al. 2002; Hermanto 
et al. 2001). This was unsuccessful showing high variability. A variation of this 
method involved counting in a field of view defined by a microscopic image 
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(representing an area of ~1 mm area) of the well surface but showed limited success. 
This method was applied to the assessment of the activity of Trastuzumab (figure 5). 
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Figure 5 Colony formation assay bar chart showing action of Trastuzumab on colony 
count as a function of well drug concentrations in a 6 well-plate format. Control (12) 
and inhibitor (12) wells distributed over 4 plates. Standard error of replicate analysis 
of random count areas is shown with inferential error bars (replicate control (no drug) 
random area counts = 120 and replicate drug addition random area counts = 30 for 
each well drug concentration).  
 
 
 
Difference between drug and no drug was shown to be highly significant (p < 0.001) 
by using a t-Student test with a significance threshold of p < 0.05, although control 
data showed variability giving a mean and standard deviation of 13 +/- 5 respectively. 
However, there is no distinction between concentrations of drug. The colony count 
data for the 1 nM, 10 nM, 25 nM and 50 nM concentrations gave a mean and standard 
deviation of 5 +/- 4, 4 +/- 2, 4 +/- 3 and 6 +/-3 respectively. Moreover, a weak 
negative Pearson’s correlation coefficient (r) was shown (r = -0.37). This would 
suggest that relatively small changes in drug concentration anticipated during storage 
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would not be detected. Another approach attempted was to select evenly distributed 
areas for counting purposes but this approach also showed a high degree of innate 
subjectivity and inconsistency. 
 
Automated colony counting using programs such as Image J (V1.46i) and Cell 
profiler (V2.0) were also considered. A preliminary investigation on developing these 
platforms adequately for colony counting was time consuming and appeared, at the 
stage of development, not very promising. Furthermore, due to the large number of 
plates, counting and collating the colony formation data would be prohibitively time 
consuming even for a relatively small sample of plates or even wells. Attention was 
directed to determining viability using colorimetric methods. 
 
 
4.5.3 BT474 viability assessment using colorimetric methods 
 
Viability or counting cells using a colorimetric method removes the subjectivity 
encountered with the colony formation assay. Additionally, instrumentation and 
system software provide a manageable means to assess a large number of samples in 
terms of data collection, processing and analysis. Two approaches have been 
investigated. The first approach investigated was to release or re-solubilise the crystal 
violet (CV) from the fixed and stained colonies generated for the colony formation 
assay and make an absorbance measurement (Eichhorn et al. 2008). The second 
method utilised a commercial chromogenic enzyme reporter system which transforms 
a substrate to a formazan dye with its absorbance measured at 450 nm. The 
colorimetric determination of released stain was explored in both a 6 well and 96 well 
formats whereas the commercial enzyme reporter was only used for the 96 well 
microplates. This was due to the substrate reagent burden in the 6 well format and 
consequential cost incurred. The commercial reporter system selected was the Cell 
Counting Kit CCK8 (Sigma Aldrich) which is from a range of commercially available 
colorimetric-based assays. 
 
The concentration of the formazan dye and CV is normally directly proportional to 
the number of living cells. This condition is met if the cells are seeded consistently 
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and have uniform growth. Thus the first stage in method development requires the 
optimisation of a calibration protocol of adequate precision and sensitivity. 
 
 
4.5.3.1 Comparison of Crystal violet (CV) stain release method and CCK8 assay  
 
The calibration curves of absorbance as a function of cell number for CV and CCK8 
assay are presented from initial investigations (figure 6). A linear calibration infers 
that the cell numbers after the growth period relate to a consistent initial seeding and 
supports the view that the cell population as undergone uniform cell growth between 
wells for the CV (R2 = 0.9082) and CCK8 (R2 = 0.9854) experiments. The CCK8 
assay is performed first on the cells then they are fixed and stained. Following this the 
CV was released and absorbance measured. Thus the experiment is performed on the 
same population of cells and consequently the difference in the two methods may be 
exposed. One evident distinction between the two plots is the slope or gradient. The 
slope is indicative of the sensitivity of the calibration and it can be clearly seen that 
the CV assay has little sensitivity over the dynamic seeding range. 
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Figure 6 Cell seeding calibration in 96 well-plate format for re-solubilised CV stain 
and CCK8 formazan dye absorbance at 540 nm and 450 nm respectively as a function 
of cell number. Standard error of replicate analysis of wells is shown with inferential 
error bars (replicate wells = 8).  
 
 
 
Standard error of replicate wells for each calibration is shown with inferential error 
bars (replicate wells = 8 for each cell number). The inferential error bars further 
support an acceptable precision or consistency in the initial seeding and a subsequent 
uniform growth rate in each well. The R2 values obtained from the calibration exercise 
appear to be acceptable but are these values sufficiently close to unity to assert a 
linear relationship between cell number and absorbance within a reasonable level of 
uncertainty? R2 values above 0.995 or 0.999 have been reported (Harris 2003) as a 
suitable measure for the determination of  linearity for most purposes but to represent 
a truly linear fit for a data series the R2 value must be very close to unity (Harris 
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2003). An alternative and superior marker of linearity is a plot of the vertical 
deviation of the experimental data points from those calculated from the equation for 
the least-squares line (Harris 2003).  
 
In support of this view to assess linearity of the calibration more vigorously the ICH 
Harmonised Tripartite Guideline Validation of Analytical Procedures suggests data 
from a regression line may provide a mathematical estimation of linearity and with an 
analysis of the deviation of the actual data points from the regression line will be 
useful in evaluating linearity (ICH 2005). Vertical deviation for each data point was 
obtained from the difference in observed absorbance from the instrument response or 
readout and the absorbance calculated from the computed least-squares line (y observed 
– y calculated). The calculation of y for each x value of cell density involves using the 
linear regression equation obtained from the output from the Microsoft EXCEL 
(2003) regression analysis function.   
 
The cell number for each experimental data point was substituted for x in equation (1) 
to obtain each value of y for the straight lines of each calibration: 
 
 
y = mx + c equation (1) 
 
 
Crystal Violet regression analysis equation y = 1.0E-06x + 0.0725 
CCK8 regression analysis equation y = 2E-05x + 0.1696 
 
 
Where y = absorbance, m = slope and c = intercept on y axis, x = cell number, slope 
m from regression analysis of Crystal Violet linear plot = 1.0E-06 and slope m from 
regression analysis of CCK8 linear plot = 2E-05.  
 
Tables 1 and 2 show the vertical deviations for each data point of the crystal violet 
and CCK8 calibration respectively. This result is then plotted as a function of cell 
number to facilitate data judgement (figure 7).  
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Cell number 
 
y observed 
 
y calculated 
 
Vertical deviation 
(y observed – y calculated) 
20000 0.098 9.25E-02 0.0055 
16000 0.089 8.85E-02 0.0005 
10000 0.085 8.25E-02 0.0025 
8000 0.085 8.05E-02 0.0045 
6000 0.076 7.85E-02 -0.0025 
4000 0.073 7.65E-02 -0.0035 
3000 0.078 7.55E-02 0.0025 
1000 0.074 7.35E-02 0.0005 
400 0.075 7.29E-02 0.0021 
200 0.073 7.27E-02 0.0003 
 
 
Table 1 Showing results of the vertical deviation calculation for each cell number for 
crystal violet calibration. Values of vertical deviation are small in magnitude 
indicating closeness of experimentally determined y values compared to the y values 
calculated from that obtained from the linear regression analysis. 
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Cell number 
 
y observed 
 
y calculated 
 
Vertical deviation 
(y observed – y calculated) 
20000 0.487 0.5696 -0.0826 
16000 0.397 0.4896 -0.0926 
10000 0.326 0.3696 -0.0436 
8000 0.284 0.3296 -0.0456 
6000 0.246 0.2896 -0.0436 
4000 0.221 0.2496 -0.0286 
3000 0.2 0.2296 -0.0296 
1000 0.196 0.1896 0.0064 
400 0.186 0.1776 0.0084 
200 0.184 0.1736 0.0104 
 
 
Table 2 Showing results of the vertical deviation calculation for each cell number for 
CCK8 calibration. Values of vertical deviation are small in magnitude indicating 
closeness of experimentally determined values of y compared to the y values 
calculated from that obtained from the linear regression analysis. 
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Figure 7 Plot of vertical deviation (y observed – y calculated) of observed y data point 
values from calculated y values of the least-squares line y = m x + c. Data points 
represent the difference between experimental and calculated values of absorbance for 
each cell number for the CCK8 and CV calibration. 
 
 
 
Visualisation of the deviation of the observed data from data calculated from the 
regression analysis (figure 5) facilitates the identification of systematic differences, 
which may be present in the data set, and therefore establish if there is any significant 
departure from linearity.  Nonlinearity is detected if the vertical deviation of data 
points form a pattern, i.e., clustering of negative or positive points in different areas. 
In contrast linearity is evidenced by a random spread of points around the datum line 
of zero deviation. 
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Values of vertical deviation for the CV calibration are small in magnitude indicating 
closeness of experimentally determined values of y compared to the y values 
calculated from that obtained from the linear regression analysis. However, the 
vertical deviations tend to positive values, i.e., y observed is larger than predicted. 
Nevertheless the data is relatively centred on the datum. This result is consistent with 
the apparent low sensitivity of the CV system. In contrast on examination of the 
vertical deviation plot for the CCK8 calibration a pattern is evident. The data set tends 
to increasingly negative value with increase in cell number, i.e., y observed is smaller 
than predicted. This represents a deviation from linearity albeit of low magnitude and 
appears at first not consistent with the R2 value obtained for CCK8 of 0.9854 
compared to that for CV of 0.9082. This difference can be explained by the sensitivity 
or slope of the each assay. The CCK8 plot shows an absorbance difference over the 
calibration range of 0.303 units. This gives more capacity for systematic or random 
error to manifest itself. Conversely, the small slope of the CV calibration gives an 
absorbance difference of 0.025 units over the seeding range and therefore any error 
may be masked.  
 
The CV assay with its low sensitivity appeared to offer little scope for development 
into an acceptable assay. The CCK8 assay was selected for further development.  
 
 
4.5.3.2 Development of  CCK8 assay  
 
Two parameters were identified to be developed and optimised; a suitable seeding 
density for testing the Trastuzumab and improvement of instrument response or 
absorbance. Although it must be considered that an absorbance approaching the limit 
of the instrument represents very little light entering the detector. This is the case with 
absorbance readings at the top of the instrument working range (~3 units) and 
consequently this would increase measurement error.  
 
Considering the working range of the instrument a series of seeding densities were 
investigated adding the CCK8 reagent immediately after seeding. This identified a 
seeding of 10,000 cells per well as producing an absorbance of 1.8 read at 20 hours 
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comparable to early seeding calibration work. Figure 8 shows the relationship 
between absorbance and reading time for two seeding plates from a single cell stock. 
At 20 hours the absorbance is starting to level out. The two seeding experiments show 
low variation.  
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Figure 8 Graph showing absorbance as a function of read time. Seeding density 
10,000 cells per well. Standard error of replicate analysis of wells is shown with 
inferential error bars (replicate wells = 16).  
 
 
The absorbance values obtained from these seeding experiments sit well inside the 
working range of the instrument. Therefore there was sufficient potential capacity to 
increase the instrument response.  
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The concentration of the formazan dye generated in the assay is related to the ability 
of the cells to turn over the substrate and the number of cells present. Therefore if the 
CCK8 is added after the cells have multiplied an increase in absorbance would be 
expected. This was found to be the case as after a 4 day growth period the absorbance 
had reached a value of 3.32 and 3.53 for two seeding experiments for the 20 hour read 
(figure 9). This amplification step was subsequently used for all CCK8 calibrations 
and assays. This enabled the seeding range of the calibration to use the maximum 
working absorbance. In addition the projected cell number from the initial seeding for 
an assay maximises the sensitivity and decreases variation by utilising the absorbance 
working range available. Furthermore, the degree of difference in absorbance between 
killed cells and those proliferating freely will become increasingly pronounced with 
growth time. 
 
 
 
 
Figure 9 Graph showing absorbance as a function of read time after a 4 day growth 
period. Other details as for figure 8. 
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4.5.3.3 Optimised CCK8 assay 
 
Following the development work seeding experiments were performed to assess the 
improvements in the assay. The calibration curve of absorbance as a function of cell 
number was linear (R2 = 0.997 6) for both micro-plates (figure 10). The agreement of 
R2 values shows a high degree of inter-plate precision. Furthermore, the calibration set 
infer that the cell numbers after the growth period relate to a consistent initial seeding 
and supports the view that the cell population as undergone uniform cell growth 
between wells and plates.  
 
0
0.5
1
1.5
2
2.5
3
3.5
4
0 50000 100000 150000 200000 250000 300000 350000
Cell number
A
b
s
o
r
b
a
n
c
e
 (
4
5
0
 n
m
)
Cell seeding plate 1
Cell seeding plate 2
Linear (Cell seeding plate 1)
Linear (Cell seeding plate 2)
 
Figure 10 Representative biological assay calibration plot showing the relationship 
between projected BT474 cell number after a 4 day uninhibited growth period and 
absorbance at 450 nm. Duplicate calibration plots are shown originating from a single 
cell culture stock solution (number of independently performed experiments: n = 1). 
Standard error of replicate analysis of wells is shown with inferential error bars 
(replicate wells = 16). 
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Analysis of vertical deviation of the y data for the calibration set is shown in tables 3 
and 4. The data presented is also shown graphically in figure 11. 
 
 
 
 
 
Cell number 
 
y observed 
 
y calculated 
 
Vertical deviation 
(y observed – y calculated) 
0 0.391625 0.4714 -0.07978 
32000 0.818 0.799027 0.018973 
96000 1.499375 1.454281 0.045094 
160000 2.147875 2.109535 0.03834 
256000 3.151438 3.092416 0.059021 
320000 3.665727 3.74767 -0.08194 
 
 
Table 3 Showing results of the vertical deviation calculation for each cell number for 
calibration 1. Values of vertical deviation are small in magnitude indicating closeness 
of experimentally determined values of y compared to the y values calculated from 
that obtained from the linear regression analysis. 
 
 
 
  
141 
 
 
Cell number 
 
y observed 
 
y calculated 
 
Vertical deviation 
(y observed – y calculated) 
0 0.38825 0.4443 -0.05605 
32000 0.832438 0.766545 0.065893 
96000 1.466375 1.411034 0.055341 
160000 1.990438 2.055524 -0.06509 
256000 2.974563 3.022258 -0.0477 
320000 3.714182 3.666748 0.047434 
 
 
Table 4 Showing results of the vertical deviation calculation for each cell number for 
the calibration 2. Values of vertical deviation are small in magnitude indicating 
closeness of experimentally determined values of y compared to the y values 
calculated from that obtained from the linear regression analysis. 
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Figure 11 Plot of vertical deviation (y observed – y calculated) of observed y data point 
values from calculated values of y of the least-squares line y = m x + c. Data points 
represent the difference between experimental and calculated values of absorbance. 
 
 
 
Vertical deviations from plate 1 data have a slight positive bias which is almost 
mirrored by the negative deviations for plate 2 and covers the working range of the 
assay (~90% to ~50% viable cells). Looking at the vertical deviations collectively for 
the complete calibration set and considering the magnitude of the individual 
deviations it can be concluded that the calibration is adequately linear. Moreover the 
distribution is indicative of the high degree of sensitivity of the assay. 
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4.5.3.4 The stability indicating capability of CCK8 assay 
 
A colony formation assay was performed with stressed and not stressed Trastuzumab 
(0.1 mg/mL) to determine an appropriate dose for the assay. Stressed and not stressed 
samples were diluted to 0.5, 1, 2 and 100 nM and tested by a colony formation assay. 
After fixing and staining the colonies showed no apparent difference in colony size 
between stressed and not stressed samples for the 1, 2 and 100 nM concentrations.  At 
these concentrations the quantity of active drug may have saturated the HER2 
receptors (Watts 2012). In contrast the 0.5 nM concentration gave an observable 
decrease in colony size. This identified a well dosing drug concentration of 0.5 nM to 
be optimal; showing the greatest differentiation in colony size between stressed and 
unstressed drug at a stressing time of 15 minutes in a water bath heated to 75 oC. 
Therefore the optimal dose should allow loss of activity to be detectable and 
measurable with the CCK8 assay.  
 
Heating for 20 minutes decreased the potency to approximately 25% of fresh 
Trastuzumab as determined by the CCK8 assay. This work is expanded on in Chapter 
5: forced degradation studies of Trastuzumab.  
 
 
Sources of Error 
 
Cell counting is an important possible source of error and will propagate through 
subsequent assay steps. This may occur if the sample from the flask is 
unrepresentative of the cell population concentration and could be due to clumping of 
cells or insufficient mixing. The use of a haemocytometer may add further errors. The 
total volume of the counting chamber should represent a random sample. This is only 
the case if the single cells are in suspension. The error contributed by pipetting and 
sampling can be as high as 55% and for chamber and counting error 45% (Freund et 
al. 1964). This was for the same person counting duplicate plates of sperm cells. 
Additionally, pipetting may cause cell damage and impact on viability. This will 
decrease the expected cell number. Frothing of media can be a problem when 
pipetting, giving liquid and cell transfer error. These errors will decrease assay 
performance. 
  
144 
 
4.6  CONCLUSIONS 
  
Following assessment the CCK8 system was adopted as the best method to determine 
viability within a 96 micro-plate format due to its sensitivity and repeatability as 
shown in the seeding calibration data set (figure 8) 
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CHAPTER 5 
 
 
5 FORCED DEGRADATION STUDIES OF TRASTUZUMAB  
 
5.1 INTRODUCTION 
 
A forced degradation study normally entails subjecting a drug (drug substance, 
product or placebo) to extreme chemical and environmental conditions to determine 
the extent of degradation, to try to identify decomposition products, mechanism or 
mechanisms involved, and thus establish a stability indicating profile and fitness of 
the analytical method employed (Blessy et al. 2014). The degradation species formed 
in a forced degradation experiment are referred to as potential breakdown products 
which could be present under normal conditions but they may or may not represent 
the true degradation products and degradation mechanism encountered under different 
storage conditions over time (Blessy et al. 2014). 
 
One of the main approaches to degradation studies is to thermally stress the product 
by heating to accelerate decomposition (European Medicines Agency 2003). 
However, whilst this produces breakdown products in distinct chemical entities with 
small molecule drugs, for proteins this is inappropriate and will lead to fully 
denatured protein precipitate (Barnes 2012). This approach is a legacy from 
conventional chemical drug stability testing (European Medicines Agency 2003). The 
requirement to perform this test more reflects the lack of any guidance for testing 
stability of biological drugs which is yet to be addressed by the regulatory authorities 
than a scientific basis for this test (Allwood & Wilkinson 2013). Shown below is an 
overview of conditions which have been used for forced degradation of traditional 
drug products and drug substances (figure 1). 
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Figure 1: Forced degradation conditions used to test drug product and drug 
substance. Chart adapted from a Power Point presentation by Rhami Dharati entitled 
Forced Degradation concerning regulatory affairs (2007). 
 
 
In addition, a forced degradation study may validate the analytical procedures applied 
to the in-use shelf-life extension studies and inform on product integrity and 
degradation mechanism following accidental exposure to detrimental conditions; such 
as temperature excursions during transportation or storage (European Medicines 
Agency 2003). Current regulatory documents concerning forced degradation offer 
general guidance  and are aimed at the development and manufacture of new drugs 
(European Medicines Agency 2003). Furthermore, the Tripartite Guideline provides a 
basis for condition selection but may not be appropriate for biologics (European 
Medicines Agency 2003; Allwood & Wilkinson 2013). The ICH Topic Q5C 
Biological Products document states that study conditions selection should be on a 
case-by-case basis (European Medicines Agency 2006).  
 
However, it has been stated that stability testing of a new drug should include the 
effect of temperature, humidity, oxidation, photolysis and pH dependant hydrolysis 
depending on the drug product and drug substance (European Medicines Agency 
2003). Taking this information into account an approach to a proposed forced 
degradation study can be developed that is sufficiently appropriate to clinically 
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relevant conditions and appropriate for the Trastuzumab shelf-life extension study. 
The experimental approach adopted and its rationale is presented in the following 
section. 
 
The potential stresses likely to be encountered within a clinical setting are associated 
with mishandling of the drug during reconstitution, storage and administration (Liu et 
al. 2011). The stresses encountered represent a complex combination of shear and 
interfacial stresses involved during dissolution, mixing and transfer to infusion bag 
(Pabari et al. 2013). The drug may also experience temperature excursions during 
transportation or if inadvertently left out in the ward or due to refrigerator malfunction 
in the pharmacy (Bardin et al. 2011). Therefore these stresses can be broadly 
classified into mechanical and thermal stresses respectively.  
 
Thermal stresses are more likely to be encountered as the formulation is relatively 
sufficiently robust to the range of handling by trained staff (Bardin et al. 2011). This 
view is consistent with the recommendations by the ICH to include effects of 
temperature during the development and manufacture of new drugs (European 
Medicines Agency 2003). The models selected to represent thermal stresses were 
heating in a water bath at 75oC for a range of times (5, 10, 15 and 20 minutes) and 
storage in ambient conditions for 4 days. The former conditions are clearly not 
particularly realistic but do give the opportunity to investigate degradation products 
which may have a mechanistically limited relationship to that of an aged sample 
within an in-use temperature study. Furthermore, the range of times selected for 
thermal stressing will affect the degree of unfolding and therefore form a series of 
aggregation profiles which may provide mechanistic information.  
 
In contrast, the latter experimental conditions present a more realistic scenario where 
a 0.1 mg/ml sample was stored for 4 days in the laboratory approximate the 
conditions encountered on a hospital ward. Furthermore, the low concentration, which 
is not clinically relevant, may accelerate any degradation under these conditions and 
be more representative of the appropriate mechanism encountered during an 
accidental temperature excursion (Barnes 2012). The excipients will be at a relatively 
low concentration and will be less effective in stabilising the proteins’ native state by 
preferential hydration through surface tension effects (Rowe 2001). This choice of 
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infusion concentration is supported by the reported stability of a 0.4 mg/mL 
concentration infusion after exposure to 170oC by Pabari et al. (2011). Subsequently, 
it was reported by Paul et al. (2013) that Trastuzumab infusion stability was retained 
until degradation was detected after 2 years of storage at 20 oC. Additionally, the 
authors stated that 96 hours at 60 oC was required to allow the detection of instability. 
The infusion concentrations investigated were 0.8 mg/mL and 2.4 mg/mL. Therefore 
the 0.1 mg/mL infusion may be more susceptible to degradation than the higher 
concentration infusions. 
 
It is expected that heat stressing at 75 oC, due to the experimental temperature being 
in the region of the transition temperature (Tm) of the unfolding reaction or melting 
point of the protein (Matheus et al. 2006), will involve initiation of aggregation by an 
atypical increase in the population of less stable conformations leading to initial 
intermediates in a 50% unfolded state as compared to normal storage temperature 
(Wang 1999). The Tm of a protein is indicative of its thermal resistance (Wang 1999; 
Wang et al. 2010). However, there is no specific relationship between Tm and protein 
stability as determined thermodynamically by the free energy changes between folded 
and unfolded states (Dill et al. 1989; Wang 1999). 
 
Unfolded species may recruit native monomers and possibly propagate aggregation in 
a similar fashion to that encountered during aging under normal kinetically controlled 
conditions considerably below the Tm (Vermeer & Norde 2000). This may be even 
more the case when the stress is removed and when the aggregation process is likely 
to continue after critical nucleation driven by mass action involving the native 
antibody population (Vermeer & Norde 2000; Wang et al. 2010). Therefore SE-LC 
characterisation of the aggregate species within the sample immediately after stressing 
and after a period of storage under conventional storage conditions along with 
ambient exposure may give insight into any post stressing aggregation and associated 
mechanism or mechanisms encountered after an accidental temperature excursion. 
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5.2 Materials and Methods 
 
Forced degradation at elevated temperature 
 
Initial experiments involved exposing Trastuzumab at a concentration of 0.1 mg/ml to 
heat in a water bath for 5, 10 and 15 minutes at 75 oC to 79 oC in the region of the 
transition temperature (Tm) of the unfolding reaction or melting point of the protein. 
The stressed sample and unstressed control were diluted in the range of 0.5, 1, 2 and 
100 nM mirroring the concentrations used for the CCK8 cellular assay in the shelf-life 
study. A colony formation assay using the standard seeding density of 10 000 
cells/well was performed to assess changes in proliferation and to identify the 
optimum drug concentration and stressing time for subsequent CCK8 proliferation 
assay. Degradation was confirmed by size exclusion chromatography showing an 
increase in higher order aggregates and concomitant decrease in monomer or active 
drug molecule as compared to an unstressed control sample. The wavelength of 220 
nm was selected for optimum sensitivity in measuring the changes in low abundance 
products. Measurements were also made at 280 nm to confirm the products were 
protein in origin. Degradation was compared for each stress time point and a 
comparison made between chromatograms of stressed Trastuzumab which was 
analysed immediately with stressed Trastuzumab which had been stored under 
refrigeration (5-8 oC) for 4 days before analysis by size exclusion chromatography. 
 
The thermal degradation experiment was repeated using the optimum conditions and 
with an increased heating time of 20 minutes to further ensure sufficient degradation. 
A CCK8 assay was performed using the standard seeding density of 10,000 cells per 
well in a 96 well micro-plate. Replicates for drug treated wells were 28 wells and 32 
replicate for no-drug addition wells. The absorbance was read at 1 hour 2 hours and 4 
hours incubation following addition of CCK8 reagent. A seeding calibration was 
performed using a series of cell densities; 100,000, 80,000, 50,000, 30,000, 10,000 
and 0 cells per well with 16 replicates per cell density. The highest useable 
absorbance readings for the calibration of cell number as a function of absorbance at 
450 nm was obtained after 2 hour incubation. After this time absorbance is at the limit 
of the instrument and for the higher seeding densities at the top of the calibration 
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range absorbance was not measurable and gave an overflow result rather than a 
numerical readout of absorbance.  
 
 
Degradation under ambient conditions 
 
A 0.1 mg/mL sample of Trastuzumab was stored, maintaining aseptic conditions, for 
4 days under ambient conditions and degradation was assessed by size exclusion 
liquid chromatography (SE-LC). 
 
 
5.2.1 Size exclusion liquid chromatography (SE-LC) 
 
Size exclusion liquid chromatography was performed using a Dionex MAb Pac 
SEC1TM (Dionex; a Fisher Scientific company) size exclusion column with a packing 
particle size of 5 μm with a 300 Angstrom (0.03 μm) pore size. The column is 
specifically designed for the quantitative separation of monoclonal antibodies and the 
aggregates. A Shimadzu LC-10 system operating a Lab Solutions Chromatography 
system with Windows XP was used to perform the analysis. The mobile phase was 
300 mM sodium chloride in a 50 mM disodium hydrogen phosphate adjusted to pH 
6.8. The elution rate was 0.2 mL/minute with dual wave length UV detection at 280 
nm and 220 nm. Analysis was performed in triplicate. 
 
 
5.2.2 Attenuated Total Reflectance Fourier Transform Infra-red (ATR-FT-IR) 
Spectroscopy and protein secondary structure determination 
 
Spectra were acquired for stressed and standard Trastuzumab. Changes in the Amide I 
band, which is indicative of changes in secondary structure of the protein, may be 
detected by amide I band spectra overlay of each sample. Acquisition parameters 
were as follows; 256 scans for each spectrum was found to give good spectra at a 
standard resolution of 4 cm-1 and scan range of 4,000 cm-1 to 450 cm-1 wave numbers. 
Water vapour background subtraction and ATR correction were carried out by the on-
board Spectrum One functions. The sample (20 μL) was introduced into the recess 
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within which the germanium crystal is housed ensuring full surface coverage of 
crystal. The crystal was cleaned between samples with ten washings of demineralised 
water and with three washings of HPLC grade acetonitrile (Fisher Scientific). Blank 
spectra were collected to show that the crystal was clean prior to the sample being 
loaded.  Spectra were converted and exported as ASCII files for further processing in 
Microsoft EXCEL (2003). The corresponding blank spectra were subtracted from the 
sample spectra and normalised to 1,850 cm-1; the baseline wave number adjacent to 
the amide I envelope and graphed as Microsoft EXCEL (2003) charts. This enabled 
the direct comparison of the amide I region by spectrum overlay of all sample spectra. 
 
 
5.3 Results and Discussion 
 
Thermal degradation 
 
Biological Activity of Trastuzumab reconstituted and diluted to 0.1 mg/mL 
 
The colony formation assay gave an observable decrease in colony formation 
efficiency and identified a well dosing drug concentration of 0.5 nM to be optimal; 
showing the greatest differentiation in colony size between stressed and unstressed 
Trastuzumab at a stressing time of over 15 minutes in a water bath heated to 75 oC. 
Changes in colony size between stressed and unstressed drug were noticeable by the 
naked eye but can be seen more clearly by microscopic examination (figure 2).  
 
Figure 1A shows increased colony size of the BT474 cell line indicating increased 
cellular proliferation when exposed to thermally stressed Trastuzumab as compared to 
figure 1B showing the colony formation resulting from treatment with the freshly 
prepared Trastuzumab which shows smaller colonies and therefore decreased 
proliferation. This observation is consistent with Trastuzumab being fully active and 
that after heating to 75 oC for over 15 minutes the efficacy has decreased as compared 
to the untreated control. 
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(A) 
 
(B)  
 
 
 
Figure 2. Micrographs of BT474 colony formation: with (A) Trastuzumab that was 
thermally stressed at 75oC and (B) Trastuzumab that was not stressed as a control. 
Micrograph of crystal violet stained BT474 colonies (Magnification x100 with height 
at 750 μm for both micrographs) 
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The plot of absorbance at 450 nm versus cell number was linear (R2 = 0.9776) (figure 
3) thus confirming the cells were proliferating at the same rate for each initial seeding 
density and inferring similar behaviour with the cells used in the assay. This was a 
reasonable assumption as the cells came from the same flask with a low passage 
number and therefore generation. 
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Figure 3. Calibration plot showing absorbance measured at 450 nm versus initial cell 
count for BT474 at low passage number. R2 = 0.9776 for the data series. Standard 
error bars shown. 
 
 
 
Figure 4 shows the effect of thermal stress on the 0.1 mg/mL Trastuzumab infusion. 
The absorbance readings obtained were after 2 hours of incubation with the CCK8 
reagent. The mean absorbance readings decreased in the order of no drug, stressed 
and unstressed Trastuzumab with the mean absorbance values of 1.907 (0.403, n = 
32), 1.792 (0.206, n = 28) and 1.443 (0.320, n = 28) units respectively with standard 
deviation and number of readings (n) in brackets. However, the standard deviations 
appear too great for the result to be significant. This variability may be due to 
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inconsistent seeding of wells, although the seeding calibration performed in parallel 
with the assay was satisfactory.  
 
 
 
Figure 4 Plot showing the effect of thermally stressed Trastuzumab (0.1 mg/mL) on 
cellular viability as measured by CCK 8 absorbance at 450 nm after 2 hours 
incubation with reagent. Results show absorbance for the conditions: no drug, stressed 
drug and unstressed drug. Descriptive statistics shown as standard deviation error 
bars. 
 
 
 
After a further 2 hours incubation the difference between stressed drug and unstressed 
drug has become apparent: 3.120 (0.350) and 2.309 (0.289) absorbance units 
respectively. The absorbance for uninhibited growth of the cells was 3.158 (0.453). In 
figure 5 the absorbance for the stressed drug is approaching the reading for the 
uninhibited cells. In contrast the difference between the aforementioned absorbance 
readings and unstressed drug is greater. This is consistent with a decreased viability 
for the cells treated with the unaltered Trastuzumab compared to untreated and 
stressed drug. A t-Student test comparing the stressed and not stressed drug data sets 
gave p < 0.001 with a significance threshold of p = 0.050. The p value provides 
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evidence against there being no difference in cell absorbance between the fully active 
drug and stressed drug measurements. 
 
 
 
Figure 5 Plot showing the effect of thermally stressed Trastuzumab on cellular 
viability as measured by CCK 8 absorbance at 450 nm after 4 hours incubation. 
Standard deviation error bars shown. 
 
 
 
Physicochemical Stability of Trastuzumab reconstituted and diluted to 0.1 
mg/mL 
 
SE-LC results 
 
Trastuzumab as manufactured inherently contains a small amount of its dimeric form 
along with the active monomer (Philo & Arakawa 2009). Monitoring the formulation 
for changes in the monomer, dimer and appearance of other aggregate species enable 
the assessment of the stability or condition of the drug. Size exclusion 
chromatography (SEC) shows the monomer eluting at a retention time of 12 minutes 
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and the dimer at a retention time of about 10 minutes. The elution time of 12 minutes 
is consistent with the monomer but the dimer identity is unconfirmed.  
 
Figure 6 shows that after thermal stress the dimer peak increases in intensity and 
higher molecular weight species, which imply the formation of aggregates, begin to 
form with concomitant decrease in monomer peak area and height which is off scale. 
The generation of higher order aggregates is consistent with drug degradation. 
 
 
 
 
Figure 6. Size exclusion chromatogram of Trastuzumab at 0.1 mg/ml concentration 
thermally stressed at 75 oC for 20 minutes compared to fresh Trastuzumab at 0.1 
mg/ml. A broad range of higher order aggregates form and an apparent increase in 
dimer on stressing which is evident left of the monomer peak which is off scale at a 
12 minutes retention time (blue trace).  
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When Trastuzumab was stressed for 10 minutes and then analysed after a 4 day period 
by SEC the distribution of higher molecular weight species had changed compared to 
the aggregate profile of a stressed sample analysed immediately (figure 7). A shift to 
higher molecular species and a continued loss of monomer had occurred after the 
stress was removed and during storage under refrigeration. This observation supports 
the view that aggregation involves the native monomer in its propagation after the 
process is initiated. In contrast for a 15 minute heat stress experiment with SEC 
analysis after 4 days the monomer has decreased considerably more and the higher 
order aggregate peaks are hardly visible after 4 days (red trace) (figure 8). The dimer 
is not resolved possibly due to very low levels of monomer. This is consistent with the 
reversible dimer being in equilibrium with the monomer. Conversely immediate 
analysis after 15 minutes of heat stress produces the typical broad aggregate profile. 
 
 
 
 
 
Figure 7 Size exclusion chromatogram of Trastuzumab at 0.1 mg/ml concentration 
thermally stressed at 75 oC for 10 minutes and analysed immediately (blue trace) and 
Trastuzumab at 0.1 mg/ml concentration thermally stressed at 75 oC for 10 minutes 
and analysed after 4 days. Monomer has decreased and higher order aggregates have 
increased after 4 days. 
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Figure 8. Size exclusion chromatogram of Trastuzumab standard at 0.1mg/ml 
concentration (blue trace) and Trastuzumab at 0.1 mg/ml concentration thermally 
stressed at 75oC for 15 minutes and analysed after 4 days (red trace). 
 
 
 
These results broadly correlate with the cellular assay data. The Trastuzumab 
monomer peak decreased as the higher order aggregates increased after storage under 
refrigeration (5–8 oC) for the 10 minute heat-stressed sample. In contrast Trastuzumab 
that was heat-stressed for 15 minutes and analysed by SEC after 4 days revealed 
further monomer loss. Nevertheless, higher order aggregate peaks were barely visible 
with the dimer peak also absent. Moreover these peaks were detected when the 
analysis was performed immediately. These observations are consistent with the view 
that aggregation continued after the thermal-stress was removed and aggregate species 
became too large to be detected by SE-LC. This may explain, at least in part, why in a 
USP forced degradation study for their proposed Trastuzumab validation document, 
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that the degree of aggregation was not proportionate to the decrease in potency 
observed (USP 2013). Additionally, in the USP validation report SE-LC analysis was 
only performed on unstressed Trastuzumab and on Trastuzumab after 60 minutes of 
heating (USP 2013). 
 
 
Degradation under ambient conditions 
The 0.1 mg/ml sample of Herceptin stored for 4 days under ambient conditions 
(aseptic conditions maintained) showed a similar aggregate profile to the unstressed 
drug by size exclusion liquid chromatography (SE-LC) (figure 9). 
 
 
 
Figure 9 Size exclusion chromatogram for ambient storage of 0.1 mg/mL infusion 
sample compared to fresh Trastuzumab standard. 
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IR results 
 
The ATR corrected infra-red spectra (figure 10) show no apparent difference between 
stressed and freshly prepared Trastuzumab. This observation suggests there has been 
no major change in the protein at the secondary structural level and is consistent with 
the aggregation process mainly recruiting native monomers. 
 
 
 
 
Figure 10. Attenuated Total Reflectance (ATR) Fourier Transform Infra-red spectrum 
of fresh standard of Trastuzumab at 0.1mg/ml and Trastuzumab at 0.1 mg/ml 
concentration stressed 75 oC for 20 minutes. Spectra were water vapour subtracted, air 
background corrected, ATR corrected and normalised to 1,850 cm-1. Spectra are 
virtually coincidental for heat-stressed and freshly prepared Trastuzumab. 
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5.4 Conclusions 
 
The difference between colony size in stressed and unstressed drug treated wells was 
apparent (figure 2). The CCK8 assay showed variability (figure 4), although an 
acceptable seeding calibration was obtained (figure 3). The difference in mean 
absorbance between stressed and unstressed drug became more apparent after 4 hours 
incubation before absorbance measurement (figure 5). 
 
The SE-LC analysis of stressed Trastuzumab infusion showed an increase in the 
number and size of peaks at retention times (~10 minutes) immediately before the 
monomer (12 minutes) (figure 6). At retention times greater than 20 minutes small 
peaks were evident (figure 6). The appearance of these peaks was accompanied by a 
decrease in the monomer peak (figure 7). Further loss of monomer peak was shown 
after the 10 minute heat stress experiment on storage (figure 7). In addition, the peak 
system adjacent to the monomer shifted to shorter retention times (figure 6). A heat 
stressing time of 15 minute with SE-LC analysis after 4 days gave a further decrease 
in the monomer peak, however peaks at retention times < 12 minutes are hardly 
visible (figure 8). Storage under ambient conditions show no significant changes of 
the chromatogram (figure 8). The infra-red spectra show no apparent changes between 
stressed and freshly prepared Trastuzumab (figure 10). 
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CHAPTER 6 
 
 
6. USE OF CELLULAR ASSAY TO DETERMINE TRASTUZUMAB 
STABILITY 
 
 
6.1 INTRODUCTION 
 
The manufacturers state that Trastuzumab reconstituted with sterile water for injection 
is physically and chemically stable for 48 hours at 2 oC to 8 oC and on further dilution 
for infusion, in 0.9% sodium chloride solution, may be stored up to 24 hours at 
temperatures not exceeding 30 oC (European Agency for the Evaluation of Medicinal 
Products (EMEA) 2010). In contrast the multi-dose form of Trastuzumab which is 
available outside Europe has a designated shelf-life of 28 days if reconstituted with 
bacteriostatic water containing benzyl alcohol as a preservative (European Agency for 
the Evaluation of Medicinal Products (EMEA) 2005b). This implies that the 
manufacture’s stability limit is determined on a microbiological basis rather than 
physicochemical stability.  
 
If physicochemical stability and functional activity can be shown beyond the current 
limit, even for a few days, wastage will be decreased. Thus offering the potential to 
utilise none administered infusions or partially used vials. In addition it will allow for 
a more efficient drug compounding in the form of dose banding for patient ready 
preparations. It has been stated that efficient dose banding has a clear requirement for 
longer shelf-life stability of 28 to 84 days for infusions (Bardin et al. 2011). 
 
However, there is a lack of stability data for Trastuzumab to support an extended in-
use shelf-life; in particular functional activity is overlooked in the relatively small 
number of studies that address in-use stability (Kaiser & Kramer 2011; Paul et al. 
2013; Pabari et al. 2013). Biological assessment is an important aspect of assigning a 
shelf-life because it is a direct way of determining functional activity and supports 
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physicochemical stability data. This has been recognised in the NHS document 
guidance for deriving and assessment of stability of biopharmaceuticals which post-
dates this study whilst sharing common principles (Barnes 2012).  
 
It is important to consider the correct mode of action when selecting a biological 
assay. The mode of action of the drug must reflect its pharmaceutical action. 
Biological assessment may take the form of a binding assay for an enzyme or 
inhibitor. Whereas for more complex biological drugs, where binding to a receptor is 
followed by a cellular cascade with an extra-cellular response, there is a need to 
consider the complete mechanism of action. This may be multimodal which 
sometimes requires more than one cellular assay to fully assess the efficacy of the 
drug. 
 
The drug concentrations selected should reflect clinical dosing at high and low 
concentrations. Thus if stability is found at high and low concentrations it may be 
possible to interpolate to intermediate concentrations (Barnes 2012). In this study 
Trastuzumab concentrations of 0.5 mg/mL and 6 mg/mL were selected. An additional 
concentration of 0.1 mg/mL was selected as this may enhance instability with the 
potential to study degradation products. There is a predisposition for lower 
concentrations of biologic drugs to be less stable. This may be the result of the 
dilution of excipients or decreased drug-drug interaction providing increased 
opportunity for adsorption on surfaces (Barnes 2012).  
 
A study period of 119 days was chosen with test points at day 0, 7, 14, 28, 35, 43 and 
119. The final test point at 119 days provides an increase in assurance of the 43 day 
data. 
 
This chapter will now show the data of the cellular assay. 
 
 
 
 
 
 
  
164 
 
6.2 MATERIALS AND METHODS 
 
6.2.1 Test materials 
 
6.2.1.1 Reference Trastuzumab (Herceptin® Roche) 
 
The reference Trastuzumab was the same batch supplied for the development work 
(chapter 4 Development of Cellular Assay Methods and Materials section 4.2 page 
94). 
 
The lyophilised Trastuzumab was reconstituted as described in Chapter 2 Methods 
and Materials section 2.2.1 page 51.  
 
 
6.2.1.2 Infusion bag samples 
 
The infusion bags were prepared aseptically according to the manufacturer’s 
instructions which are described in the summary of product characteristics (SPC) 
(European Agency for the Evaluation of Medicinal Products (EMEA) 2010). 
Concentrations of 0.1, 0.5 and 6 mg/ml in 0.9% sodium chloride solution for infusion 
in intravenous (IV) Polyolefin infusion bags (Freeflex®) (50 ml) were prepared by 
Clatterbridge Centre for Oncology, Clatterbridge Hospital. All concentrations were 
made within acceptable tolerance for patient dosage. 
 
 
6.2.2 Drug storage conditions and sampling protocol 
 
The reconstituted and diluted samples were stored under refrigeration between 2 oC 
and 8 oC. Biological testing was carried out at each time point. 
 
Samples were taken from the infusion bags by removing 1ml of the contents in 
duplicate with a 2 part syringe (Luer and Luer lock with no silicone) (B Braun) under 
aseptic conditions. 
 
  
165 
 
Each sample was serially diluted in the complete cell culture media RPMI 1640, 
which was used to maintain the cells prior to the assay, to a nominal concentration of 
1 μMolar before further serial dilution to the appropriate concentration range used in 
the assay (1 pM to 100 nM). The reference Trastuzumab was diluted in tissue culture 
media in an equivalent manner to the samples. 
 
 
6.2.3 Biological testing with the BT474 cell-line 
 
The BT474 breast tumour (human ductal tissue (epithelial) carcinoma) cell line from 
ATTC (HTB-20; lot: 58471910) was selected for the testing of Trastuzumab because 
these cancer cells have an overabundance of the specific receptor which is the 
therapeutic target (HER2) on the cells’ surface and is indicative of the cancer type for 
which Trastuzumab has been designed to treat. 
 
 
6.2.3.1 Maintenance of cells 
 
BT474 cells were maintained as described in Chapter 4 Method Development of 
Cellular Assay Methods and Materials section 4.2.2.2 page 116. 
 
 
6.2.3.2 Seeding  BT474 cells for biological testing 
 
Cells were seeded at 10,000 cells per well in a 96 well micro-plate according to the 
protocol described in Chapter 4 Method Development of Cellular Assay Methods and 
Materials section 4.2.2.4 page 116. 
 
The wells were inspected to assess the quality of seeding and health of cells using an 
inverted microscope (Nikon Eclipse T100 binocular phase contrast microscope fitted 
with Digital Sight DS Fi1 imaging system). Plates with an even and uninterrupted 
distribution of cells over the growth surface of the wells were selected for assay. The 
seeding method was validated by calibration in the development work and during the 
study. 
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6.2.3.3 Determination of BT474 Cell viability after addition of Trastuzumab 
using Cell Counting Kit CCK8 
 
The BT474 cell-line growth media was exchanged for either fresh media (200 μl) for 
the zero drug control (negative control) i.e. cells and media, reference Trastuzumab 
(positive control) which was freshly reconstituted and diluted in media (200 μl) or test 
Trastuzumab which had been removed from the stored infusion bag at the appropriate 
time point and diluted in media (200 μl). The detail of the procedure was described in 
Chapter 4 Method Development of Cellular Assay Methods and Materials section 
4.2.3 page 119. 
 
Each sample of drug in media was added using replicate (n = 8) wells to the 96 well 
micro-plate including reference standards (n = 8) and controls (n = 8) for each plate. 
Additional control plates with untreated wells (n = 32) were produced. The micro-
plates were then returned to the humidified incubator at 37oC, 5% CO2 (Sanyo NC0-
19AIC (UV)). The cells were then incubated for 4 days to allow for growth of BT474 
colonies. This time period allowed the degree of difference in cell growth between 
untreated and treated wells to be amplified.  
 
Testing with the cellular reporter substrate CCK8 (Sigma Aldrich) was according to 
standard protocol documented in Chapter 4 Method Development of Cellular Assay 
Methods and Materials. The absorbance was then read at 450 nm using a Biotek 
micro-plate reader (Biotek Epoch, operating on Gen 5 Software, version 1.10.8) after 
1, 2, 3, 4 and 20 hours incubation.  
 
A seeding calibration was performed at each test time point in duplicate with replicate 
wells (n = 16) for each seeding density. The purpose of this was to determine the 
relationship between cell density and absorbance after the 4 day test period. The final 
projected cell densities (0 to 320,000 cells per well) of the calibration encompass the 
cell density range at the assay end-point to enable the determination of relative cell 
numbers within the wells which had a drug addition or none.  
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6.2.4 Colony Formation Assay 
 
After the biological assay had been performed all microplate colonies were fixed and 
stained as a permanent record of cellular proliferation and provided an opportunity to 
assess if the colonies had remained evenly distributed and no cells had been lost 
before the micro-plates were read. This enabled the rejection of absorbance data from 
unsatisfactory populated wells. Fixing and staining preserves the cells in a form close 
to their original structure and facilitates further examination and assessment of colony 
numbers by unaided counting or instrumental-software based methods. 
 
The colonies were fixed and stained as described in Chapter 4 Development of 
Cellular Assay Methods and Materials section 4.2.2.5 page 117. 
 
 
 
6.3 QUALITY ASSURANCE AND QUALITY CONTROL 
 
A standard reference solution of Trastuzumab was prepared using consistent dilutions 
at each time point. The standard reference determines the relative accuracy of 
subsequent measurements of test infusion samples. The additional control plates 
where the wells had no drug addition allow the demonstration of the uninhibited 
growth of the cells from the initial seeding for the assay. Furthermore, the control 
plates and the calibration plates enable the confirmation that the cells used from the 
stock culture were seeded and growing consistently and suggest that any differences 
between experimental cells and control cells should have originated from the drug 
addition of stored or standard Trastuzumab.  The data from the assay and calibration 
were exported using Microsoft Excel 2003 for further analysis including uncertainty 
of data and inter-plate precision. 
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6.4 STUDY LIMITATIONS 
 
Biological activity or potency of Trastuzumab, as determined by the CCK cell 
viability assay, during the storage period will be reported and discussed. Before this 
can be achieved appropriately it is provident to consider vigorously the nature of the 
experiment being performed and a justification of the approach to the analysis of the 
experimental results. The results for each time point cannot be compared collectively 
due to the inherent variation in cell growth at each time point. Furthermore, due to a 
single stock culture being used the multiple assays performed at each time point can 
only be considered as a single experiment with replicate cell cultures, i.e., n = 1 and 
therefore error bars or statistics are shown to report only on the consistency of seeding 
between wells of the single experiment (Cumming et al. 2007). Moreover, these errors 
do not inform on the reproducibility of the differences between experimental wells 
and control wells (Cumming et al. 2007). However, the comparison to freshly 
prepared standard concentrations does enable a direct comparison of aged drug 
performance or efficacy to the corresponding concentration of Trastuzumab at time 
zero at each time point of the study. Although, interpretation of the results should be 
exercised with great care due to the limited data points and concentration range used 
for measurement.  
 
 
6.5 RESULTS AND DISCUSSION 
 
6.5.1 Determination of cell viability as an indicator of potency of stored 
Trastuzumab 
 
6.5.1.1 Assessment of biological activity day 0, 7, 14 and 28 
 
Earlier data for days 0, 7, 14 and 28, using the concentration range 1 pM to 100 pM, 
showed a deficiency in the required sensitivity for assessing confidently changes in 
efficacy. This inferred that the dose-response had changed from that determined 
during pre-study validation and the concentration-absorbance response curve had 
been displaced to a higher concentration range. This resulted in the concentrations 
initially selected for the assay now coinciding within a plateau region of the curve, 
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i.e., a region insensitive to changes in concentration of the active drug or changes in 
potency. Figure 1 shows a typical response of the BT474 cells to Trastuzumab 
concentrations over a 0 to 700 pM range with the red double headed arrows showing 
the concentration range extension. The schematic also shows the shift in response 
from the linear portion of the curve (position 1) to the plateau section of low 
sensitivity (position 2) encountered with the early time points. To overcome this loss 
in satisfactory response to assess changes in efficacy the concentration range was 
extended from the 1 to 100 pM range up to 1 nM for days 35 and 43. For the final 
time point of day 119 a concentration range of 1 nM, 2 nM, 10 nM and 100 nM was 
selected. At these test points 1 nM and 2 nM was the concentration of maximum 
response of the drug as the response for these concentrations as they lay on the linear 
and steep portion of the dose response curve. In this region of the dose-response curve 
a small change in biological activity, such as a loss in potency or decrease in 
concentration of active Trastuzumab, will manifest itself in a relatively large change 
in absorbance. Therefore, changes in absorbance at 1 nM and 2 nM were selected to 
report efficacy as a percentage relative to fresh drug prepared and tested at each test 
point, i.e., 1nM for days 35 and 43 and with both 1nM and 2nM for day 119 for the 
final time point. 
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Figure 1 Schematic showing typical dose-response curve of BT474 cells over a 0 to 
700 pM range. Also, the shift in response from the linear portion of the curve 
(position 1) to the plateau section of low sensitivity (position 2) found initially in the 
early time points when a Trastuzumab concentration range of 1 pM to 100 pM was 
used. The red double headed arrows show the concentration range eventually 
extending beyond 700 pM to 100 nM. 
 
 
6.5.1.2 Assessment of biological activity day 35, 43 and 119 
 
To characterise changes in efficacy at day 35 a concentration range of 1 pM to 1 nM 
was selected. The concentration range (1 pM to 100 pM) employed for the earlier 
time points (days 0, 7, 14 and 28) was found to be insensitive to changes in 
Trastuzumab concentration. Difference in absorbance at 1 nM (1000 pM) was used to 
assess any changes in Trastuzumab activity of the stored infusion bags at days 35 and 
43. At the final test point of the study day 119 efficacy was determined at both 1 and 
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2 nM. The data set for the whole study shows no loss of efficacy over the period of 
119 days.  
 
Efficacy was reported as a percentage difference in absorbance between reference 
Trastuzumab, reconstituted and further diluted at the test point, and the stored 
Trastuzumab infusions (European Medicines Agency 2006). If there is no change in 
efficacy between the freshly prepared standard and the stored infusion then the result 
for the test infusion would be 100%. Conversely, a result of less than 100% would be 
indicative of an apparent loss of biological activity. However, a number of test 
samples showed an apparent increase in cell suppression or greater potency than the 
freshly prepared Trastuzumab (tables 1 and 2). For example the 0.5 mg/mL infusion 
recorded 153% cell growth suppression on day 35 compared to freshly prepared drug 
tested at the same time. The concentrations of 1 nM and 2 nM used to measure 
efficacy at the final time point define the sensitive portion of the dose-response curve 
and therefore a small change in active drug concentration within this region should 
give a large change in absorbance and facilitate detection of any changes in potency 
(USP 2013). However, this responsive region would also be expected to amplify any 
errors in the experiment such as variation in the cellular response or discrepancy of 
the original concentration in the infusion bag (Barnes 2012). This view is supported 
by the difference in measurement when 1 nM and 2 nM concentrations are used. The 
second measurement of potency was generally closer to the reference Trastuzumab.  
 
The data for the clinically relevant concentrations of 0.5 mg/mL and 6 mg/mL have 
been collated and graphed for each concentration for each time point (figures 2 and 
3). For each concentration two bags and two plates have been combined giving 16 
replicates for each concentration. Efficacy at the assigned concentration for individual 
plates (replicates = 8) is also presented in table 1 for comparison of assay performance 
between duplicate plates A and B. Table 2 summarises the results obtained from the 
complete data sets for each concentration where replicates = 16 for each assay 
concentration. 
 
The results for the 0.1 mg/mL infusion bags and the 21 mg/mL vial concentrate stored 
in the original vial are discussed separately. The results for day 119 will be presented. 
For the 0.1 mg/mL concentration data from four bags and two plates have been 
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combined giving 32 replicates for each assay concentration. The results for the 21 
mg/mL vial concentrate have 4 replicates for each assay concentration. Rejection of 
data from wells that showed unsuccessful seeding and subsequent growth decreased 
the number of replicates available for analysis of the concentrate. 
 
 
6.5.1.3 Day 35 
 
Figure 2 shows a typical response of absorbance as a function of Trastuzumab 
concentration. The data presented in this graph is from two infusion bags of 0.5 
mg/mL concentration. The relationship between dose and response is clear for both 
reference and test Trastuzumab. As the Trastuzumab concentration increased cell 
numbers became lower as evidenced by the lower absorbance; which was consistent 
with the view that cell growth had been suppressed or cell viability decreased as the 
dose increased. This trend is observed for both reference and stored infusions.  The 
0.5 mg/mL test infusion gave a 153% increase in activity at the 1 nM (1000 pM) 
assay concentration. The 6 mg/mL infusion test sample showed a similar response to 
drug dose (figure 3). This sample gave a 123% apparent potency increase at 1 nM 
(1000 pM). 
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Figure 2 A plot of absorbance as a function of drug dose is shown for combined data 
for stored (day 35) infusion bags (replicates = 16) at a concentration of 0.5 mg/mL. 
Inferential error shown as standard error. The response is typical showing a decrease 
in absorbance with increase in Trastuzumab concentration. 
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Figure 3 A plot of absorbance as a function of drug dose is shown for combined data 
for stored (day 35) infusion bags (replicates = 16) at a concentration of 6 mg/mL. 
Inferential error shown as standard error. The response is typical showing a decrease 
in absorbance with increase in Trastuzumab concentration. 
 
 
 
6.5.1.4 Day 43 
 
A comparable response to day 35 was found at day 43. The dose-response for the 
combined infusion bag data for each concentration of 0.5 mg/mL and 6 mg/mL stored 
test samples are shown in Figures 4 and 5 respectively. The percentage difference 
between sample and reference for 0.5 mg/mL and 6 mg/mL infusions were 87% and 
103% correspondingly. This represents a decrease and increase in cell suppression 
respectively for the test samples. 
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Figure 4 A plot of absorbance as a function of drug dose is shown for combined data 
for stored (day 43) infusion bags (replicates = 16) at a concentration of 0.5 mg/mL. 
Inferential error shown as standard error. The response is typical showing a decrease 
in absorbance with increase in Trastuzumab concentration. 
 
 
 
 
 
  
176 
 
0
0.5
1
1.5
2
2.5
3
0 200 400 600 800 1000 1200
Concentration of drug / pM
A
s
o
rb
a
n
c
e
 a
t 
4
5
0
n
m
Trastuzumab 6mg/ml infusion stored 43 days
Reference Trastuzumab 21mg/ml concentrate reconstituted
day 43
 
 
Figure 5 A plot of absorbance as a function of drug dose is shown for combined data 
for stored (day 43) infusion bags 1 and 2 for plate A and B (replicates = 16) at a 
concentration of 6 mg/mL. The response is typical showing a decrease in absorbance 
with increase in Trastuzumab concentration. 
 
 
 
6.5.1.5 Day 119 
 
At the final time point the concentration range for the assay was extended to 100 nM. 
Efficacy for the 0.5 mg/mL and 6 mg/mL infusion bags was determined at both 1 nM 
and 2 nM and showed greater cell suppression than the reference Trastuzumab.  The 
0.5 mg/mL test infusions recorded 149% at 1 nM and 114% at 2 nM. Whereas the 6 
mg/ml test infusions recorded 136% at 1 nM and 123% at 2 nM. In all cases the 1 - 2 
nM concentration range gave the maximum response for both reference and test 
Trastuzumab.  After these concentrations the dose-response becomes limiting as the 
end point of biological response has been attained and the response levels out into a 
plateau region. Therefore this region also represents an additional concentration 
insensitive section of the dose-response profile mirroring the response at the lower 
concentration limit. After the response at the 1 - 2 nM concentration region of the 
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response plot the absorbance changes very little with increase in drug concentration as 
the response has maximised after the 2 nM and remains relatively insensitive to dose 
up to the 100 nM concentration. It can be seen that the experimental dose-response 
profile over the extended range (1, 2, 10 and 100 nM) (figures 6 and 7), even with a 
limited number of experimental data points, is suggestive of the theoretical dose-
response shown in figure 1. 
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Figure 6 A plot of absorbance as a function of drug dose is shown for combined data 
for stored (day 119) infusion bags (replicates = 16) at a concentration of 0.5 mg/mL. 
Inferential error shown as standard error. The response is typical showing a decrease 
in absorbance with increase in Trastuzumab concentration. Cell suppression: 149% at 
1 nM and 114% at 2 nM. 
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Figure 7 A plot of absorbance as a function of drug dose is shown for combined data 
for stored (day 119) infusion bags (replicates = 16) at a concentration of 6 mg/mL. 
Inferential error shown as standard error. The response is typical showing a decrease 
in absorbance with increase in Trastuzumab concentration. Cell suppression: 136% at 
1 nM and 123% at 2 nM. 
 
 
 
6.5.1.6 Summary of biological activity results 
 
The results of biological activity expressed as percentage difference in absorbance 
between sample and reference show overall no loss in potency over 119 days (table 1 
and 2). Results for the duplicate plates show some variation in response within a 
single time-point. In addition, response varies more between time-point which is 
consistent with the use of a different stock or population of cells. The difference 
between the nominal and actual concentration of the infusion was also considered as a 
possible source of error. However, this is not clear in this case because on 
examination of the data presented in table 1 and 2 there is no consistent or systematic 
variation for all time points or between plates which would originate from sampling 
from the same bag at each test point. The day 43 time point records results relatively 
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close to 100% while the results for the other time points vary between 114% and 
153% (table 2). 
 
Variations are most likely due to the range of responses an individual cell can initiate 
on the addition of drug. This view is supported by the growth characteristics of the 
uninhibited BT474 cells. The calibrations for each test point showed good linearity 
and repeatability and therefore indicates uniform growth of that particular stock of 
cells used in the experiment. Therefore if an extensive number of controls without 
drug are used to define maximum viability or cell number, and set to 100%, the 
relative cell numbers as a percentage can be assigned to the assay concentrations with 
the aid of the calibration and expressed as percentage of viable cells. This approach of 
normalising the data was adopted for the final time point of day 119 and is discussed 
in the following section 6.5.1.7 page 181. 
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Time 
Point 
(Day) 
 
 
0.5 mg/mL IV bags 
 
 
6 mg/mL IV bags 
 
% difference in absorbance (viability) 
between sample and reference for 
microplates A and B (replicates = 8) 
 
% difference in absorbance (viability)  
between sample and reference for 
microplates A and B (replicates = 8) 
 
Measurement 
Concentration 
1 nM 
Measurement 
Concentration 
2 nM 
Measurement 
Concentration  
1 nM 
Measurement 
Concentration  
2 nM 
 Plate A Plate B Plate A Plate B Plate A Plate B Plate A Plate B 
35 121 155 - - 101 142 - - 
   - -   - - 
43 79 94 - - 103 102 - - 
         
119 157 141 134 94 151 120 121 124 
 
Table 1 Biological activity of stored infusions for Plates A and B (bags 1 and 2 
combined giving replicates = 8 for each plate): Absorbance reported at a drug dose of 
1 nM for day 35 and 43 and at 1 nM and 2 nM drug concentration for day 119. Assay 
performed in duplicate (plates A and B). A percentage score below 100% represents 
an increase in absorbance (more cells) and hence an apparent decrease in drug activity 
for test sample compared to reference drug standard. Conversely, a percentage score 
greater than 100% represents an apparent increase in drug activity for test sample 
compared to freshly prepared drug. 
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Time 
Point 
(Day) 
 
 
0.5 mg/mL IV bags 
 
 
6 mg/mL IV bags 
 
% difference in absorbance (viability) 
between sample and reference from 
combined data (plates A and B with 
replicates = 16) 
 
 % difference in absorbance (viability)  
between sample and reference from 
combined data (plates A and B with 
replicates = 16) 
 
Measurement 
Concentration 
1 nM 
Measurement 
Concentration 
2 nM 
Measurement 
Concentration  
1 nM 
Measurement 
Concentration  
2 nM 
35 153 - 123 - 
     
43 87 - 103 - 
     
119 149 114 136 123 
 
Table 2 Biological activity of stored infusions using pooled data (combined data for 
bags and plates A and B: replicates = 16): Absorbance reported at a drug dose of 1 
nM for day 35 and 43 and at 1 nM and 2 nM drug concentration for day 119. A 
percentage score of 100% represents no change in absorbance and hence an apparent 
no change in drug activity for test sample compared to freshly prepared standard. 
 
 
 
6.5.1.7 Percentage viability of BT474 cell count (normalised to base cell 
viability without drug) 
 
In addition to the above treatment of the data for day 119 the biological response was 
normalised to uninhibited cell growth represented by the extensive controls of zero 
drug (replicates = 46) used at the final test point. The normalised percentage viability 
at 1 nM and 2 nM of both standard and test sample can then be directly related to 
unrestrained cell proliferation experienced by the cells without drug addition, i.e., 
100%. This approach may give a more reliable indicator of potency changes by 
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assessing the relative response of reference and test samples compared directly to a 
zero drug response. Furthermore, the use of many controls may facilitate a more 
accurate datum line for uninhibited biological activity of the cells upon which to base 
the analysis on.  
 
The dose-response profile expressed as a relative percentage viability for both 0.5 
mg/mL and 6 mg/mL stored infusions is similar to the absorbance-concentration plots. 
Figure 8 shows the relative percentage viability dose-response profile for the 
0.5mg/ml infusion test sample.  
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Figure 8 Plot showing normalised dose-response. 0.5 mg/mL infusion test sample and 
reference Trastuzumab expressed as percentage viability of maximum uninhibited cell 
viability (no drug) set to 100%. 
 
 
 
The difference between standard and test sample is best seen on a reduced scale plot 
for both 0.5 mg/mL and 6 mg/mL stored infusions (figure 9 and 10). The percentage 
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viability at 1 and 2 nM for reference and test samples are shown in tables 3 and 4. The 
test samples show an apparent decrease in viability or increase in potency. 
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Figure 9 Plot showing normalised dose-response with reduced scale (0 – 10 nM). 0.5 
mg/mL infusion test sample and reference Trastuzumab expressed as percentage 
viability of maximum uninhibited cell viability (no drug) set to 100%. The percentage 
viability can be seen at 1 and 2 nM for reference and test sample: reference 87% and 
57%, test sample 60% and 52% respectively. 
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Figure 10 Plot showing normalised dose-response with reduced scale (0 – 10 nM). 6 
mg/mL infusion test sample and reference Trastuzumab expressed as percentage 
viability of maximum uninhibited cell viability (no drug) set to 100%. The percentage 
viability can be seen at 1 and 2 nM for reference and test sample: reference 87% and 
57%, test sample 68% and 56% respectively. 
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Trastuzumab 
concentration / 
nM 
 
 
% Viable Cells 
Reference / 
control 
 
 
% Viable Cells 
0.5 mg/mL 
infusion 
 
 
% difference 
(Reference - 
Test) 
 
0 100  
1 87 60 27 
2 57 52 5 
10 53 
 
100 45 
 
 
Table 3 Normalised percentage cell viability is shown for 0.5 mg/mL test infusion 
sample and compared to reference viability at point of measurement (1 and 2 nM). 
Percentage difference is shown in the last column. A positive percentage difference 
indicates an apparent increase in potency. 
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Trastuzumab 
concentration / 
nM 
 
 
% Viable Cells 
Reference / 
control 
 
% Viable Cells 
6 mg/mL 
infusion 
 
 
% difference 
(Reference - 
Test) 
 
0 100  
1 87 68 19 
2 57 56 1 
10 53 
 
100 45 
 
 
Table 4 Normalised percentage cell viability is shown for 6 mg/mL test infusion 
sample and compared to reference viability at point of measurement (1 and 2 nM). 
Percentage difference is shown in the last column. A positive percentage difference 
indicates an apparent increase in potency. 
 
 
 
6.5.1.8 Stability of 0.1 mg/ml infusion bags and 21 mg/ml vial concentrate 
 
A comparison of Trastuzumab at 0.1 mg/mL and the 21 mg/mL reconstituted 
concentrate in the original vial over the study period may provide insight into the 
stability at extremes of concentration which bracket the therapeutic range of 
concentration. 
 
The manufacturers indicate a shelf life of up to 28 days post reconstitution of 
Trastuzumab when reconstituted with bacteriostatic water for injection (BWFI) 
containing benzyl alcohol (1.1%) in its original container in accordance with the 
United States Pharmacopoeial Convention (USP). This is indicative of acceptable 
stability with a preservative present which may actually decrease physical stability 
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(Philo & Arakawa 2009; Kaiser & Kramer 2011). This suggests a better physical and 
similar microbiological stability should be shown under aseptic conditions when 
reconstituted with sterile water for injection as is the practise in Europe. Moreover, 
this may support stability of 28 days in solutions more dilute than the concentrate as 
aggregate formation is less likely to occur at lower concentration (Shire et al. 2004). 
This may be supported by Kaiser and Kramer in their 28 day study where infusion 
concentrations 0.4 and 4.0 mg/mL showed no signs of physical instability (Kaiser & 
Kramer 2011). 
 
In contrast, in this study visible particulates were found after 7 days with the 0.1 
mg/mL infusion. In the Kaiser and Kramer study (Kaiser & Kramer 2011) the lowest 
concentration investigated was 0.4 mg/mL. This is consistent with the view that at a 
lower limit of concentration, i.e., below 0.4 mg/mL, the formulation becomes more 
susceptible to aggregation (Barnes 2012). The biological assay did not reflect the loss 
of active drug by showing a decrease in potency (figure 11 and table 5). The 
normalised cell viability difference was 21% and 2% at 1 and 2 nM respectively; 
showing an apparent increase in potency. This may imply that the assay has not 
detected these changes due to an error in the actual concentration of the test sample 
prior to dilution or is masked by systematic error in the performance of the assay. 
There is a relatively large positive difference (21%) or decrease in viability at 1 nM of 
the test sample compared to the reference which may infer a greater concentration for 
the 0.1 mg/mL infusion. This in part would explain the observed apparent increase in 
potency. Values of a similar magnitude at 1 nM were found with the rest of the 
infusion test concentrations whilst the concentrate in the original vial recorded a 5% 
increase in apparent potency at 1nM with a small decrease at 2 nM of -3% compared 
to reference drug (table 6). This observation when considered with the consistent 
preparation of all test samples, using identical dilution steps, infers that the source of 
error may originate in the formulation of the infusion bags and variation of biological 
response. 
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Figure 11 Plot showing normalised dose-response with reduced scale (0 – 10 nM). 
0.1 mg/mL infusion test sample and reference Trastuzumab expressed as percentage 
viability of maximum uninhibited cell viability (no drug) set to 100%. The percentage 
viability can be seen at 1 and 2 nM for reference and test sample: reference 87% and 
57%, test sample 66% and 55% respectively. Replicates = 32. 
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Figure 12 Plot showing normalised dose-response with reduced scale (0 – 10 nM). 21 
mg/mL concentrate test sample from original vial and reference Trastuzumab 
expressed as percentage viability of maximum uninhibited cell viability (no drug) set 
to 100%. The percentage viability can be seen at 1 and 2 nM for reference and test 
sample: reference 87% and 82%, test sample 66% and 60% respectively. Replicates = 
4. 
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Trastuzumab 
concentration / 
nM 
 
 
% Viable Cells 
Reference / 
control 
 
 
% Viable Cells 
0.1 mg/mL 
infusion 
 
 
% difference 
(Reference - 
Test) 
 
0 100  
1 87 66 21 
2 57 55 2 
10 53 
 
100 45 
 
Table 5 Normalised percentage cell viability is shown for 0.1 mg/mL test infusion 
sample and compared to reference viability at point of measurement (1 and 2 nM). 
Percentage difference is shown in the last column. A positives value indicates an 
apparent increase in potency at 1 and 2 nM. 
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Trastuzumab 
concentration / 
nM 
 
 
% Viable Cells 
Reference / 
control 
 
 
% Viable Cells 
21 mg/mL 
infusion 
 
 
% difference 
(Reference - 
Test) 
 
0 100  
1 87 82 5 
2 57 60 -3 
10 53 
 
100 45 
 
Table 6 Normalised percentage cell viability is shown for 21 mg/mL test infusion 
sample and compared to reference viability at point of measurement (1 and 2 nM). 
Percentage difference is shown in the last column. A negative value at 2 nM indicates 
an apparent decrease in potency. 
 
 
 
6.5.1.9 Summary of normalised biological activity results for day 119 
 
Table 7 shows a summary of the results for each concentration of infusion and the 
original vial concentrate. Values are relatively consistent between infusion samples 
with viability difference at 1 nM recording a higher value than at 2 nM which 
indicates an apparent increase in active concentration or potency. In contrast the 
concentrate stored in original vial mirrored this behaviour but showed only a 
relatively small increase in activity at 1 nM with a small decrease in activity at 2 nM. 
These observations are consistent with the view that the 1 nM and 2 nM 
concentrations cover the region of maximum dose response for all samples. 
 
The apparent increase in efficacy with time could be related to dimer content; due to 
increased binding compared to the monomer (Wolff et al. 1993). This has been 
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reported as giving a 10 times increase in potency with thioether bonded dimers (Wolff 
et al. 1993). Furthermore, it has been reported that antibody dimers formed by 
introducing a thioether linkage become potent anti-tumour agents (Ghetie et al. 1997). 
 
 
 
 
 
Trastuzumab 
concentration / 
nM 
 
% difference in viability (Reference - Test) 
Day 119 
 
 
0.1 mg/mL 
 
 
0.5 mg/mL 
 
 
6 mg/mL 
 
 
21 mg/mL 
 
 
1 
 
 
21 
 
 
27 
 
 
19 
 
 
5 
 
 
2 
 
2 
 
5 
 
1 
 
 
-3 
 
 
 
Table 7 Summary of normalised biological activity results for day 119. The table 
shows % viability difference at 1 nM and 2 nM assay concentrations for test infusions 
and concentrate stored in original vial compared to reference drug reconstituted and 
tested in parallel. Values are relatively consistent between infusion samples with 
activity at 1 nM recording a higher value. In contrast the concentrate stored in original 
vial showed a smaller increase in potency at 1 nM and a small decrease in potency at 
2 nM. A t-Student test with a significance threshold of < 0.05 showed no significant 
difference between day 119 infusions and fresh drug: p = 0.46 for the 0.5 mg/mL 
concentration at 1 nM and p = 0.62 at 2nM, for the 6 mg/mL infusions p = 0.71 and 
0.22 for the 1 nM and 2 nM respectively. 
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A biological assay is the most direct way to assess functional stability and thus 
became an important aspect of developing a strategy for studying the stability of 
Trastuzumab infusions.  
 
There was no loss in biological activity of Trastuzumab indicating an acceptable 
functional stability during storage. The in-use stability studies which were compared 
to this study did not employ a biological assay. However Pabari et al. (2011) used a 
biological assay, in addition to physicochemical methods, to assess the effect on 
functional activity of various processing stresses. Pabari et al. (2011) showed that 
activity of Trastuzumab did not significantly change after sonication, freeze-thawing, 
lyophilisation, spray-drying and encapsulation. These results suggest that the 
Trastuzumab molecule can retain its biological activity, as determined by a cellular 
assay, under manufacturing and in-use conditions.  
 
Paul et al. (2012) report that a direct cytotoxicity assay showed that Rituximab 
remained fully efficacious for 6 months at 4 oC. However, direct cytotoxicity is the 
incorrect mechanism that Rituximab exerts its effect in vivo. The results are presented 
as IC50, IC25 and area under the curve. It has been stated that using the data in this 
way would lack the necessary sensitivity over a long period of time (Watts 2012).  
Furthermore, small changes such as 5% would not be detected due to variation in 
data: IC50 time 0 = 137.2 +- 28.18 µg/mL versus time = 6 months 125.8_+- 36.5 
µg/mL. 
 
The biological activity of Pertuzumab, Rituximab and Infliximab was assessed at the 
limit of their SPC shelf-life, typically one or two days (Parry et al. 2014). The authors 
report greater or equal biological activity and fewer aggregates than freshly prepared 
infusions.  Trastuzumab was also assessed and showed increase in functional activity 
at the concentrations tested. A Trastuzumab infusion at a concentration of 3.15 
mg/mL showed just under a 5% increase in biological activity at the SPC shelf-life 
limit (Parry et al. 2014). These results may, at least in part, show agreement with this 
study. 
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Sources of error 
 
A primary source of error was the cell counting and seeding process which has been 
discussed in chapter 4. However, satisfactory calibration data and control data may 
provide assurance that the cells are growing uniformly. Some error may originate with 
the variation in cell response to the drug. The cellular response should be shown in 
variation of cell numbers and therefore absorbance read out. If this is the case, the 
amplification step used in the CCK8 assay may magnify this error. High cell density 
may result in higher background signal which will contribute to instrumental 
inaccuracy (Bohn 2015). This error is mitigated by optimisation of cell density. 
Additionally variation may be between wells (Lundholt et al. 2003). Cells in the outer 
wells may react differently to the cells in the inner wells, showing uneven growth 
known as the edge effect (Lundholt et al. 2003). This may be due to a temperature 
differential when the plates are incubated (Bohn 2015). 
 
 
6.6 CONCLUSIONS 
 
The biological activity data for the whole study shows no loss of efficacy over the 
period of 119 days for all infusion bag concentrations. However, visible particulates 
were found after 7 days with the 0.1 mg/mL infusion. Although this concentration is 
below therapeutic relevant concentrations it does highlight the need to consider 
physicochemical stability data together with biological potency to provide a more 
complete profile of stability. The performance of the stored concentrate in the original 
vial compared to the reference sample, which originates from freshly reconstituted 
concentrate, displayed a similar dose-response profile to the infusion samples and 
recorded relatively small percentage differences in viability relative to the reference 
Trastuzumab. The similarities of the dose-response profiles suggest that this 
behaviour originates from cellular response rather than sample preparation.  In 
contrast the infusion bag samples showed a larger deviation from the reference drug. 
This implies that the differences between the infusion and the reference may be in part 
an artefact of bag preparation. 
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CHAPTER 7 
 
 
7. GENERAL DISCUSSION AND CONCLUSION 
 
7.1 Introduction 
 
There is an established body of published literature relevant to the in-use stability of 
injectable drugs that are defined as small molecules. Publications such as the Hand 
book on Injectables provide guidance in the form of summaries of this information 
regarding clinical use of parenteral medication (American Society of Health-System 
Pharmacists 2014). Additionally the Infostab website publishes an international 
database (Stabilis) of compatibilities and stabilities of injectable drugs (Infostab 
2014). 
 
The approach to conducting stability studies is documented to an extent but is 
generally confined to that applicable for the manufacturing of new drug substances 
and drug products (European Medicines Agency 2003). Furthermore, only limited 
reference is made to biologically-derived drugs known as biologics (European 
Medicines Agency 2006).  
 
Biologic drugs require an unique approach to stability that takes into consideration 
their complex and labile protein nature where conventional testing such as accelerated 
testing may not be suitable (European Medicines Agency 2006). Without doubt, this 
necessitates a more thorough understanding of potential degradation pathways and of 
their mode of action than that for small molecule medications. Furthermore, 
application of suitable methodology and adequate assessment of criteria are essential 
to enable published data to be of value (Barnes 2012). These requirements have 
exacerbated the absence of in-use knowledge of biologics. Therefore there is a need 
for appropriate stability data for biologics including monoclonal antibodies such as 
Trastuzumab. Thus it is the aim of this study to some extent address this gap in 
knowledge for Trastuzumab once reconstituted and further diluted for use. 
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It is a common fact that manufacturers of parenteral drugs only disclose a limited 
amount of stability information which is relevant once the drug is reconstituted for 
use. This may take the form of statement, within the summary of product 
characteristics, limiting the use of a prepared infusion to 24 hours. This reflects 
stability from a microbiological perspective. Moreover, the manufacturer is not 
concerned with in-use stability and therefore may not possess pertinent data for the 
hospital pharmacist. Alternatively, if stability testing has been performed there may 
be a reluctance to disclose this information. This situation requires that studies must 
be performed to meet the need for in-use stability data. This is beginning to change 
although often published data is of limited value due to the use of inappropriate drug 
concentrations and inadequate number or selection of stability criteria investigated. 
More specifically, with Trastuzumab there have been some recent publications which 
have not included biological testing of potency (Paul et al. 2013; Pabari et al. 2013). 
These studies are therefore incomplete as they lack important information concerning 
stability in relation to the mode of drug action.  
 
In July 2013 a reference procedure in the form of a USP summary validation report 
for Trastuzumab had been developed (USP 2013). At the time of writing this 
document is not yet an official USP document. The study described here precedes 
these publications but has some shared common aims with the USP principle 
requirements. A consensus is now evolving as to which tests should be included in a 
stability study for a biologic drug. A comparison of the findings of this study with 
other protein-based drugs and further studies on Trastuzumab are presented below.  
 
This study was in agreement with other studies showing long-term stability of in-use 
marketed protein-based drugs beyond that stated in the summary of product 
characteristics. Long-term stability has been defined as an acceptable stability for a 
minimum of 2 weeks (Vigneron et al. 2014). 
 
Paul et al. (2012 (a)) showed that re-packaged Bevacizumab in 1 mL syringes at a 
concentration of  25 mg/mL was stable at 4°C for 3 months. Although long term 
stability was reported no determination of biological activity was attempted. In 
contrast the choice of techniques used for physical stability was acceptable, although 
only data for time points 0 and 90 days are reported. SE-LC showed a similar 
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monomer and aggregate profile found in the Trastuzumab study. However, detection 
was at a single wavelength of 280 nm and not the sensitive dual method used in this 
study.  A later study on Bevacizumab also showed continued stability on re-packaged 
drug for a period of 6 months at 5°C  (Khalili et al. 2015). Determination of biological 
activity was included in this study, using a biochemical assay in the form of a binding 
assay. The binding of immobilised vascular endothelial growth factor (VEGF) to 
Bevacizumab was determined by surface plasmon resonance (SPR) (Huber & Mueller 
2006). VEGF is the therapeutic target of Bevacizumab (European Agency for the 
Evaluation of Medicinal Products (EMEA) 2005a). This form of binding assay is 
more sensitive than an ELISA (Barnes 2012), although structural changes remote 
from the binding site are unlikely to be detected (Barnes 2012). It is more usual, as in 
this study, to use a cell-based assay to measure a biological end-point or action 
(Weinberg et al. 2005). SDS-PAGE and SE-LC analysis showed no changes in the 
presence of higher molecular weight species or degradants between time zero and 6 
months. In contrast, in the Trastuzumab studies, including this study, aggregates were 
not detected by SDS-PAGE (Kaiser & Kramer 2011; Pabari et al. 2013). These results 
are consistent with reported silicone oil contamination from re-packaging into 
syringes which has been associated with increased levels of aggregates (Liu et al. 
2011). 
 
Rituximab was reported has showing a 6 months stability at 4°C (Paul et al. 2012). A 
cell-based assay was used employing a XTT colorimetric test and Raji cells 
expressing the CD20 receptor therapeutic target (Glennie et al. 2007). However, the 
direct cytotoxicity effect measured was not clinically relevant (Watts 2012). Paul et 
al. (2012) report that physical and chemical attributes remained unchanged. 
Rituximab showed only one peak by SE-LC with detection at 280 nm. The absence of 
higher molecular weight species is supported by the result of Hernández-Jiménez et 
al. (2016). Injecting undiluted samples, to prevent masking of results, they found no 
evidence of aggregates using a more sensitive UV detection of 214 nm. 
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The key findings of this study and the results of the other studies support the 
hypothesis: Trastuzumab is sufficiently robust to remain unaltered following 
reconstitution or dilution to clinically relevant concentrations when stored in 
appropriate containers under controlled normal conditions of storage. However, 
regarding the cellular assay CCK8 it must be stated that it is in the developing stages 
and the results are preliminary. Further experiments will be required before the 
usefulness of the CCK8 assay can be relied on. 
 
Furthermore, Trastuzumab has been reported to be resistant to a range of processing 
stresses which supports an acceptable stability under the considerably less demanding 
conditions of pharmacy storage. 
 
 
 
7.2 Future work 
 
This study employed a relatively small number of techniques compared to the USP 
validation document. Whilst more techniques may garner more information the 
question should be which techniques are appropriate for an in-use stability study. For 
example the USP document has a significant number of methods for identification of 
Trastuzumab and assessing process related degradation or side-products resulting 
from oxidation and deamination reactions. These processes are more probable during 
manufacturing and therefore the associated methods may not be appropriate for an in-
use stability study.  
 
Pharmacists would generally attempt to decrease headspace in an IV bag to decrease 
contact with air. This may decrease oxygen absorption but more importantly may help 
to decrease protein adsorbing at the interface and undergoing a conformational change 
and aggregation. In fact, the unavoidable presence of dissolved oxygen in the infusion 
has not caused oxidation in the studies discussed. However, for home healthcare 
patients the transportation of infusions may expose the drug to stresses not normally 
found in a hospital and therefore requires more testing. This further highlights the 
difference between what is often the manufacturer’s perspective and that of end-user. 
However, Genentech have recently presented a colorimetric assay for assessing 
transportation stress and the potential damage to a biologic drug in an IV bag at the 
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speciality cancer congress ECOP 2014 in Krakow. This represents a significant and 
unprecedented engagement by the manufacturing community into problems 
encountered by end-user. 
 
The NHS guidance document suggests a suitable range of techniques covering 
physical and chemical aspects of in-use stability. However biological assessment, 
specific to the pharmaceutical effect of the drug, must always be included as it is 
central to the NHS stability criteria guidance and a complete stability assessment. 
Biological assessment may be best served utilising some of the newer cell-based and 
biochemical approaches which have become available. However, the selection of 
biological techniques ultimately depends on the drug and its mode of action. 
 
Cell proliferation or viability assays assess the direct effect on the cancer cells but 
there are other functions involved in vivo. Another functional aspect of biologic drug 
action is the interaction with the immune system. In particular monoclonal antibody-
based drugs may utilise antibody-dependent cellular cytotoxicity (ADCC) in their 
mechanism of action. The bound antibody mediates with the immune system via 
natural killer effector cells with the end point being cell lysis. 
 
The ADCC function has been applied to a limited extent as a basis for a cell-based 
assay that utilised natural killer cells which are a component of the peripheral blood 
mononuclear cells (PBMC) (Timonen 1981). The assay is complex to perform and 
shows a high degree of variability which has led to the development of a ADCC-gene 
reporter alternative (Parekh et al. 2012). An engineered Jurkat cell-line was used for 
the effector cell and a luciferase reporter end-point generating a bioluminescence 
read-out. For read-out the antibody must be bound to the target cell and Fc receptor on 
the Jurkat cell (Parekh et al. 2012). The ADCC-gene assay has recently being 
developed into a kit format by Promega (2014).  
 
Though often used for assessment of functionality of antibodies ELISA has recently 
been applied to assess higher order structure to aid biologic drug development (Wang 
et al. 2013). In this case the antibody itself is subjected to antibody interrogation by a 
panel of antibodies which report on its 3-dimensional structure or higher order 
structure. Polyclonal antibodies raised to the linear peptide sequence of the 
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monoclonal antibody interrogate the 3-dimensional structure of the therapeutic 
protein. A polyclonal antihuman antibody-biotin conjugate completes the sandwich 
ELISA. A streptavidin-HRP (horse radish peroxidase) conjugate detects the complex 
through the turnover of a TMB substrate read-out. If hidden epitopes are exposed, as 
little as 0.1%,  due to structural change this will show itself in the ELISA read out 
(Wang et al. 2013). 
 
The antibody array read-out would allow the determination of small structural 
changes between fresh and aged drug during storage. The ELISA kit-format (Array 
Bridge Inc.) has the ability to identify local changes in the molecule and the 
proportion of molecular population that has undergone these changes (Wang et al. 
2013). In contrast physicochemical techniques are not as sensitive at detecting 
localised change in higher order structure and report on the average response (Wang 
et al. 2013). 
 
The NHS (UK) shelf-life study showed that the secondary structure of Trastuzumab 
did not change and is indicative of a robust structure. ATR-FT-IR provided no 
evidence of change and equally circular dichroism (CD) in another study (Pabari et al. 
2013). Thus it may be appropriate for techniques which probe secondary structure to 
be omitted from a study. Moreover, if other physicochemical techniques have been 
previously shown to give no evidence of change in a molecule during a study it may 
be provident not to include such tests in future studies. 
 
The omission of redundant tests would allow other methods which provide pertinent 
stability information to take their place within a study design. One such technique 
would be glycan profiling using normal phase chromatography. Changes in glycan 
content have a profound effect on biological activity. This chemical change in the 
molecule can be correlated with the biological assay to provide structure-function 
information on changes in the glycan profile. The glycan profile may also influence 
the charge heterogeneity of the protein molecule and can have an important effect on 
stability and efficacy. Charge heterogeneity may be assessed by cation exchange 
chromatography. This technique has become more widely adopted and should be 
considered to be included in a future study. 
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Lastly, with the introduction of Trastuzumab for subcutaneous delivery by the NHS 
less Trastuzumab will be prepared in IV bags. However, the principles and approach 
developed in this study are applicable to monoclonal antibody drugs in general 
including Rituximab and Bevacizumab  (Paul et al. 2012 (a); Paul et al. 2012 (b)). 
Studies have been published on these two important drugs, however as with 
Trastuzumab, there is either an absence of biological assessment or the assay selected 
is testing a none-clinically relevant effect. Thus highlighting a need for research into a 
better understanding of the important area of pharmaceutical action. 
 
 
7.3 Conclusion 
 
In conclusion it was found that Trastuzumab is a relatively robust molecule under 
storage conditions likely to be encountered in a hospital pharmacy. The outcome of 
this was the shelf-life of Trastuzumab was recommended to be extended to 28 days 
for Trastuzumab stored in polyolefin IV bags at concentrations between 0.5 mg/mL 
and 6 mg/mL with 0.9% saline at 2 oC to 8 oC. However, infusions with 
concentrations below 0.5 mg/mL are not recommended for storage. 
 
The extension of the shelf-life of Trastuzumab infusions has enabled Clatterbridge 
Hospital to better utilise Trastuzumab drug resources by treating more patients and 
providing a substantial health economic benefit. 
 
The potential of using the CCK8 assay as part of a shelf-life stability study has been 
explored. However, further work is required before its usefulness can be depended on. 
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APPENDIX: INFRA-RED SPECTRA 
 
 
 
 
CHAPTER 2 
 
ATR-FT-IR conditions unless stated otherwise in figure. 
Scan range of 4,000 cm-1 to 450 cm-1 wave numbers 256 continuous scans at a 
resolution of 4 cm-1 and with an accuracy of +/- 0.1 cm-1 at 1,600 cm-1. Spectrum 
normalised to wavenumber 1,850 cm-1 and background, water vapour and ATR 
corrected. 
 
 
 
 
 
Figure 1 ATR-FT-IR spectrum from 2,000 cm-1 to 1,000 cm-1 of germanium crystal 
ATR in air i.e. no sample.  
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Figure 2 ATR-FT-IR spectrum of reconstituted Trastuzumab 21 mg/mL from two 
vials (red and blue plots).  
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Figure 3 ATR-FT-IR representative spectra of reconstituted Trastuzumab 21 mg/mL 
from two vials (red and blue plots) showing Amide I region (1,800 cm-1 to 1,500 cm-1 
wave numbers).  
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Figure 4 ATR-FT-IR difference spectrum of reconstituted Trastuzumab (heat-stressed 
and not heat-stressed) at 0.1 mg/mL concentration. Showing region 2,000 cm-1 to 
1,000 cm-1 wave numbers.  
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Figure 5 ATR-FT-IR spectra of reconstituted Trastuzumab at 0.1 mg/mL, 0.5 mg/mL, 
15 mg/mL and 21 mg/mL showing Amide I region (1,800 cm-1 to 1,500 cm-1 wave 
numbers).  
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CHAPTER 3 
 
Difference Spectra  
0.1 mg/mL Infusion bags 
 
Spectrum from time point 0 was subtracted from the spectrum acquired at different 
time points for day 7 (black), 42 (red) and 119 (green). 
 
 
 
 
Figure 6 Infusion bag 1 
 
 
  
224 
 
 
 
Figure 7 Infusion bag 2 
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Figure 8 Infusion bag 3 
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Figure 9 Infusion bag 4 
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0.5 mg/mL infusion bags 
 
 
Figure 10 Infusion bag 1 
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Figure 11 Infusion bag 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
229 
 
6 mg/mL infusion bags 
 
 
 
Figure 12 Infusion bag 1 
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Figure 13 Infusion bag 2 
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CHAPTER 5 
 
 
 
 
 
Figure 14 Fresh standard of Trastuzumab at 0.1mg/ml and Trastuzumab at 0.1 mg/ml 
concentration stressed 75 oC for 20 minutes.  
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Figure 15 Fresh standard of Trastuzumab at 0.1mg/ml and Trastuzumab at 0.1 mg/ml 
concentration stressed 75 oC for 20 minutes. Amide I region (1,800 cm-1 to 1,500 cm-1 
wave numbers) shown.  
 
 
  
 
